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Abstract 
Diabetes is characterized by absolute or relative deficiency of insulin secretion by 
β-cells. Currently, there are no non-invasive diagnostic tools for assessing β-cell mass 
and function in situ. This thesis aims to develop and implement MRI techniques to 
image the β-cell in vivo. Calcium ion (Ca2+) entry occurs during insulin secretion and 
the manganese ion (Mn2+) has been used as a Ca2+ surrogate to study Ca2+ transport in 
β-cells. Mn2+ is also a positive T1 contrast agent and imaging [Mn2+] changes with 
manganese-enhanced MRI (MEMRI) may be used to monitor Ca2+ influx during 
insulin secretion. I hypothesize activated β-cells take up more manganese than resting 
cells after manganese chloride (MnCl2) administration; therefore, the 
glucose-stimulated pancreas may show higher signal intensity (SI) than the 
non-stimulated pancreas by T1-weighted MRI.  
 
Being thin and diffuse, the mouse pancreas is difficult to image. It was found to be best 
delineated by magnetization prepared rapid gradient echo (MP-RAGE) MRI. However, 
MP-RAGE is not conventionally used for quantitative studies and the relationship 
between MP-RAGE data and [Mn2+] have to be determined. First, an in vitro study was 
performed and showed a positive correlation between the effective R1 (R1-effective) 
values and [Mn2+]. Then, SI profiles and R1-effective values at increasing Mn2+ doses 
were obtained in the pancreas. Additionally, there was a linear correlation between 
tissue [Mn2+] by inductively-coupled plasma atomic emission spectrometry and 
R1-effective by MP-RAGE. The results showed that the MP-RAGE sequence can be 
used in a semi-quantitative manner. 
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Subsequently, the methodology was applied to image the pancreas in vivo, with and 
without glucose challenge, in healthy and streptozotocin-induced diabetic mouse 
models. It revealed a statistically greater signal in the glucose-stimulated pancreas 
compared to control in healthy mice but not in diabetic mice. Further, Mn2+ infusion 
appeared to have minimal effects on blood glucose levels and islet morphology. Muscle 
glucose uptake is also a Ca2+-regulated process and therefore MEMRI was applied in 
the muscle. Results showed increased manganese uptake in glucose-stimulated muscle, 
suggesting MEMRI may be used for monitoring muscle glucose uptake. 
 
This thesis demonstrates an in vivo methodology to detect enhanced Mn2+ influx in the 
activated pancreas and skeletal muscle, opening up opportunities for assessing β-cell 
and skeletal muscle function during normal and abnormal glucose homeostasis.  
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1 Introduction 
1.1 Brief overview 
Assessment of the β-cell by non-invasive methods is important for the research and 
development of novel therapies for diabetes. β-cells are the major cell type in islets of 
Langerhans. However, islets constitute only 1-2 % of the pancreatic mass and are 
distributed throughout the pancreas. Further, it is difficult to distinguish β-cells from 
surrounding non-β-cells within the islets by current imaging modalities. Therefore, 
β-cell imaging represents a challenge and there is a need to introduce targeted imaging 
agents to highlight the β-cell for imaging.  
 
Glucose is the main stimulator for β-cell insulin secretion. An increase in blood glucose 
e.g. following feeding leads to uptake of glucose by β-cells via the glucose 
transporter-2 (GLUT-2) (Unger, 1991). Increased glucose metabolism elevates the 
cytoplasmic adenosine triphosphate (ATP) to adenosine diphosphate (ADP) ratio, 
closing ATP-sensitive potassium (KATP) channels by the binding of ATP to the β-cell 
KATP channel subunits, and causing cellular depolarization. Depolarization induces 
calcium influx through voltage-gated calcium channels (VGCCs) which leads to 
exocytosis of insulin granules in the β-cell. There is a positive correlation between 
glucose-stimulated insulin secretion and an increase in intracellular calcium ion 
concentration ([Ca2+]i).  
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The manganese ion (Mn2+) is a T1 contrast agent in MRI and can act as a surrogate of 
the calcium ion (Ca2+), and thus can be used to monitor Ca2+ fluxes across the cell 
membrane. Manganese-enhanced MRI (MEMRI) has been used to image Ca2+-related 
cellular activity in neurons and myocardium. As exocytosis of insulin granules from 
β-cells is triggered by cellular Ca2+ influx, MEMRI may be used to image β-cell 
function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33
1.2 Pancreas 
The pancreas is a lobulated glandular organ located between the stomach, duodenum, 
large intestine, left kidney and spleen. In humans, the pancreas is a solid retroperitoneal 
organ divided into 3 parts: head, body and tail with no distinct margin between the parts. 
It is generally considered that the head of the pancreas is located between the 
duodenum and superior mesenteric vein whereas the rest of the pancreas is equally 
divided into the body and tail (distal part) (Suda et al., 2006). The gross anatomy of the 
rodent pancreas differs from that of the human (Figure 1-1). In rodent, the pancreas is a 
rather thin, membrane-like, diffuse organ (Case, 2006). It is divided into three parts: 
duodenal, biliary and gastrosplenic portions (Kara, 2005). The biliary portion is the 
central part of the pancreas located between the biliopancreatic duct and descending 
duodenum. The duodenal pancreas is the part of the pancreas extending into the 
duodenal ligament. The gastrosplenic pancreas is the left part of the pancreas extending 
along the dorsal part of the stomach towards the splenic hilum. The gastrosplenic 
portion is the biggest and thickest portion of the rodent pancreas.   
 
The pancreas consists of two types of tissues: the endocrine (islets of Langerhans) and 
exocrine tissues (Figure 1-2). The exocrine pancreas gives rise to the vast majority of 
the pancreatic mass and comprises primarily of acinar cells which secrete digestive 
enzymes such as lipases, proteases and nucleases into the pancreatic ductal system. The 
endocrine pancreas or the islets of Langerhans are small nests of cells (100-500 µm in 
size) scattered throughout the pancreas (Medarova and Moore, 2009; Quesada et al., 
2008). Pancreatic islets makes up only 1-2 % of the total pancreas mass (Figure 1-2) 
and each islet consists of 1000-3000 cells (Quesada et al., 2008).  
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Figure 1-1. Illustration of the human and rodent pancreas.  
 
 
Figure 1-2. Gross anatomy of the mouse pancreas, distribution of islets and architecture 
of the mouse islet.  
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1.3 The islets of Langerhans 
There are four major cell types in the islets of Langerhans: α-cells, β-cell, δ-cells and 
pancreatic polypeptide (PP) cells secreting glucagon, insulin, somatostatin and 
pancreatic polypeptide, respectively. The islet architecture in rodent and human are 
markedly different. Mouse β-cells are located in the core and non-β-cells in the 
perimeter (Figure 1-2) whereas human α-, β- and δ-cells are distributed throughout the 
islet (Brissova et al., 2005). 
 
The islets of Langerhans make up only 1-2 % of the total pancreatic mass but obtain 10 
% of the total pancreatic blood flow (Jansson and Hellerstrom, 1983). Indeed, the islet 
perfusion is disproportionately greater than its relative volume in the pancreas. Within a 
mouse islet, the patterns of islet flow are either from periphery to inner core to perfuse 
the β-cell first or from one side to another to perfuse islet cells regardless of cell type 
(Nyman et al., 2008). Thus, the β-cell either has the priority or equal priority to the rest 
of the other islet cell types. Glucose is the major regulator of β-cell function, although 
the effect of glucose on β-cell or islet perfusion remains unclear. An increase in the 
pancreatic blood flow by 25 % was demonstrated while islet blood flow increased by 80 
% at 25 min after intraperitoneal (i.p.) glucose injection in rats by using a 
non-radioactive microsphere technique, (Jansson and Hellerstrom, 1983). However, 
when glucose was given intravenously, pancreatic blood flow was unaffected by 
glucose while islet blood flow doubled (Jansson, 1988).  
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1.3.1 The β-cell  
The β-cell is the predominant cell type in the islet, making up 60-80 % of all islets 
(Edlund, 2002;Mu et al., 2006) and there are around 2000 β-cells in each islet (Meier et 
al., 2006). β-cells produce insulin following stimulation, e.g. by glucose. The major 
function of insulin is to lower glucose levels in response to hyperglycaemia i.e. by 
facilitating glucose uptake into peripheral tissues and inhibiting hepatic glucose 
production. Regulation of blood glucose levels requires adequate numbers and good 
quality β-cells to sense the blood glucose concentrations appropriately, and hence the 
concept of the functional β-cell mass. Loss of pancreatic β-cell mass and function plays 
an important role in the pathogenesis of diabetes.  
 
1.3.1.1 Insulin 
Insulin is the major hormone regulator of glucose metabolism whereas glucose is the 
primary regulator of insulin synthesis and exocytosis. Insulin was first discovered by 
Frederick Banting, Charles Best and John James Rickard Macleod in 1921. Since then, 
injection of insulin has been used for the treatment of diabetes. To acknowledge their 
breakthrough achievement in the field of diabetes, the Nobel Prize in Physiology or 
Medicine was awarded to Banting and Macleod in 1923. Insulin is synthesized 
exclusively by the β-cell and stored in secretory granules in the resting state. Upon 
stimulation by e.g. hyperglycaemia, the insulin secretory granule is transported to the 
β-cell surface and insulin released by exocytosis. Insulin synthesis and exocytosis is 
primarily regulated by glucose, although also regulated by the complex interplay 
between glucose metabolism and a variety of factors such as nutrients, incretin, neural 
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innervation and antocrine-paracrine signalling (Berggren and Leibiger, 2006). Insulin 
secretion is pulsatile with major pulses which occurr every 1.5-2 h and the most 
significant pulses after food intake (Polonsky et al., 1988). A circadian rhythm of 
insulin secretion has also been reported (Boden et al., 1996; Polonsky et al., 1988).  
 
1.3.1.2 Calcium signalling 
Ca2+ signalling plays a major role in both normal cellular function and pathological 
processes in most cell types. Such signalling requires an increase of cytoplasmic Ca2+ in 
response to different stimuli and is coupled to a wide variety of cellular responses 
including exocytosis, contraction, metabolism, transcription, fertilization and 
proliferation (Berridge et al., 2003). It is well-known that the redistribution of Ca2+ 
stores from cellular organelles and cellular influx of extracellular Ca2+ contribute to the 
elevation in [Ca2+]i. Ca2+-storing organelles include the endoplasmic reticulum, 
mitochondria, Golgi apparatus, endosomes, lysosomes and secretory vesicles (Rizzuto 
and Pozzan, 2006). Since the internal stores have a limited capacity, cellular entry of 
Ca2+ drives most Ca2+-dependent cellular events (Parekh, 2006).  
 
Entry of Ca2+ can be either excitation-dependent or excitation-independent. Neurons, 
muscle cells, and neuroendocrine cells are electrically excitable cells (Dolphin, 2006). 
Ca2+ enters across the plasma membrane via VGCCs which open when these cells are 
depolarized. The remaining cell types such as epithelial, endothelial and blood cells, are 
electrically non-excitable and Ca2+ entry pathways are activated by inositol 
triphosphate receptors (Berridge, 2005; Putney, 2001). Calcium-sensitive fluorescent 
indicators can be used to measure [Ca2+]i and monitor Ca2+-signalling pathways in 
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whole cells, optically. Intracellular electrodes or patch-clamp techniques can also be 
used to record cellular electrical activity (Petersen et al., 2005). 
 
It is difficult to distinguish whether an increase in cytoplasmic Ca2+ derives from 
release of internal stores or from Ca2+ influx across the plasma membrane. One method 
for observation of  Ca2+ influx is to employ Ca2+ surrogates such as the Mn2+ or barium 
ion (Ba2+) and then to monitor their intracellular accumulation during cellular 
activation. Mn2+ is the most commonly used ion for studying Ca2+ influxes since Mn2+ 
can pass through many subtypes of Ca2+ channels in the plasma membrane (Hsiao and 
Payne, 1998). Further, it is not normally present in cells and can bind Fura-2, a 
fluorescent Ca2+ indicator, to quench fluorescence. Therefore, Ca2+ entry can be 
estimated by measuring Mn2+-induced quenching of Fura-2 fluorescence in the 
presence of extracellular Mn2+. Owing to the ability of Mn2+ to act as a surrogate for 
Ca2+, combined with the paramagnetic property of Mn2+, MEMRI can be used as a 
novel route to map Ca2+–related cellular activities.  
 
The pancreatic β-cell is an electrically excitable cell in which Ca2+ signalling plays a 
critical role in insulin secretion (Rorsman, 1997). Hyperglycaemia induces increased 
β-cell uptake of glucose and subsequent glucose metabolism leads to a rise in the 
cytoplasmic ATP/ADP ratio. This causes closure of KATP channels in the plasma 
membrane and so the β-cell undergoes depolarization, which leads to opening of 
VGCCs and the influx of extracellular Ca2+. The increase in [Ca2+]i triggers exocytosis 
of the insulin-containing granules. The stimulation of β-cells with glucose induces a 
biphasic insulin secretion in vivo. It is of great interest that the mouse islets in vitro 
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display a similar first-phase insulin secretion but not the second-phase (Nunemaker et 
al., 2006). Therefore, there is a need for non-invasive observation of pancreatic β-cell 
in vivo to assess β-cell mass and function.  
 
1.3.2 The α-cell  
The α-cell is the second most abundant cell type in the pancreatic islet and constitutes 
15-20 % of islet cells (Gopel et al., 2000). It secretes glucagon in response to 
hypoglycaemia and is a counter-regulatory hormone of insulin. Glucagon induces liver 
glycogenolysis and gluconeogenesis which results in an increase in the blood glucose 
level (Quesada et al., 2008). Pancreatic α-cells are electrically-excitable cells equipped 
with Ca2+-channels and Ca2+ entry induces glucagon secretion by α-cells (Gromada et 
al., 1997; Quesada et al., 2008).  
 
1.3.3 The δ-cell  
The δ-cell secretes somatostatin in response to glucose stimulation and the mechanism 
of glucose sensing is similar to that in β-cells (Kanno et al., 2002), although, little is 
known about this process. It is suggested that the release of somatostatin by δ-cells is 
also Ca2+-dependent and associated with an increase in [Ca2+]i (Bermudez-Silva et al., 
2009; Braun et al., 2009).  
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1.4 Diabetes 
1.4.1 Aetiology   
Diabetes is a group of metabolic disorders characterized by high blood glucose levels. 
It is estimated that expenditure on diabetes is around £9 billion/year or 10 % of the NHS 
budget in the UK (Diabetes UK, 2009) and $US 116 billion in the US (American 
Diabetes Association, 2007). The actual costs due to diabetes exceed direct health 
expenditure as there are indirect costs such as income loss and reduced life quality. 
Therefore, it is vital to explore both the prevention and cure for diabetes. There are two 
common types of diabetes: type 1 and type 2 diabetes. 
 
1.4.1.1 Type 1 diabetes 
Type 1 diabetes accounts for 10-15 % of patients with diabetes. It is caused by β-cell 
destruction, leading to a reduction in β-cell mass and absolute deficiency of insulin 
secretion. When 80 % of the insulin production capacity is lost, hyperglycaemia 
develops. Thus, diabetes can only be diagnosed when β-cell mass lose exceeds a critical 
threshold i.e. when 90 % of the β-cell mass has been destroyed (Martinic and von 
Herrath, 2008). By such time, anti-diabetic interventions will only alleviate symptoms 
and not cure diabetes.  
 
β-cell destruction is caused by an  autoimmune response associated with a recruitment 
of antibodies to islet cell cytoplasm, insulin, glutamic acid decarboxylase, tyrosine 
phosphatases IA-2 and IA-2β in the vast majority of type 1 diabetes patients (Atkinson 
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and Eisenbarth, 2001). This immune-mediated form of diabetes is classified as type 1A 
diabetes according to the report of American Diabetes Association (American Diabetes 
Association, 2003). This form of diabetes is associated with multiple genetic and 
environmental factors and the individual is also prone to other autoimmune diseases. 
Type 1B diabetes (idiopathic type 1 diabetes) is characterized by β-cell destruction 
without the presence of autoimmune antibodies and is inheritable (Pinero-Pilona and 
Raskin, 2001), although its aetiology remains unclear.  
 
1.4.1.2 Type 2 diabetes 
Type 2 diabetes affects 85-90 % of people with diabetes and is the most common type 
of diabetes. In health, the pancreatic β-cell secretes insulin in response to elevated 
blood glucose to maintain glucose homeostasis by facilitating glucose uptake in 
skeletal muscle and adipose tissue, and decreasing hepatic glucose production. 
Whenever normal amounts of insulin produce a less than normal biologic response, 
insulin resistance occurs (Kahn, 1978). Insulin resistance can arise from either genetic 
factors or can be acquired. With the aggravation of insulin resistance, β-cells increase 
insulin secretion to adapt to the increased insulin demands. Failure to compensate for 
insulin resistance is fundamental to the pathogenesis of type 2 diabetes. Therefore, 
insulin levels in type 2 diabetes patients can be elevated, normal, or high; depending on 
the stage of the disease. Thus, the resulting hyperglycaemia in type 2 diabetes is a 
consequence of relative rather than absolute insulin deficiency.  
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Type 2 diabetes is a heterogeneous disorder characterized by disorders of insulin 
secretion and action. Many factors such as age, obesity and physical inactivity 
contribute to it.  Progression from insulin resistance to the onset of diabetes may take 
10-20 years (Codario, 2005; Hawkins and Rossetti, 2005) or may never happen 
(Lebovitz, 1999). Insulin resistance appears to progress to type 2 diabetes only if β-cell 
function is inadequate to compensate for the insulin resistance.  
 
1.4.2 Current diagnostic methods 
The diagnosis of diabetes is based on the clinical symptoms and laboratory tests. 
Current laboratory tests include measurements of blood glucose, insulin, connecting 
peptide (C-peptide) and hemoglobin A1C (HbA1C). 
 
1.4.2.1 Blood glucose measurement 
1.4.2.1.1 In man 
The most common method for diagnosing diabetes is the fasting plasma glucose test. It 
reflects the ability of β-cells to lower blood glucose. The plasma glucose test reflects 
β-cell activity to some extent and is an indirect marker of β-cell function, although a 
relatively late marker of diabetes. Fasting plasma glucose levels are measured after 
overnight (usually 8 h) fast.  
 
Another way of assessing β-cell function is the glucose tolerance test which measures 
the glucose clearance rate from the blood after a glucose load. In humans, it is routinely 
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performed after oral ingestion of 75 g of glucose and blood glucose is measured 2 h 
after dosing. The 2006 World Health Organization (WHO) recommendation report 
outlined a clear definition for both abnormal blood levels and glucose tolerance test 
(Table 1-1) (World Health Organization 2006).  
 
Diabetes 
Fasting plasma glucose   
or  2 h plasma glucose*   
 
≥ 7.0 mM (126 mg/dL) 
≥ 11.1 mM (200 mg/dL) 
Impaired glucose tolerance (IGT) 
Fasting plasma glucose    
and 2 h plasma glucose*  
  
 
< 7.0 mM (126 mg/dL)  
≥ 7.8 and < 11.1 mM (140 and 200 
mg/dL) 
Impaired fasting glucose (IFG) 
Fasting plasma glucose     
and (if measured) 
2 h plasma glucose* 
 
6.1 – 6.9 mM (110 - 125 mg/dL) 
 
< 7.8 mM (140 mg/dL) 
Table 1-1. WHO recommendations for human diabetes. *Venous plasma glucose 2 h 
after ingestion of 75g oral glucose load.  
 
1.4.2.1.2 In mice 
Unlike in humans, there are no such clear description of glucose levels for both the 
fasting plasma glucose and glucose tolerance tests in diabetic mouse models. A review 
article shows diabetes was indicated by non-fasting blood glucose levels > 200 mg/dL 
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in 3 %, > 250 mg/dL in 18 %, > 300 mg/dL in 27 %, > 350 mg/dL in 37 %, > 400 mg/dL 
in 37 %  and > 450 mg/dL in 32 % of reports (Melzi et al., 2007).   
 
In mice, there are two common forms of glucose tolerance tests: the oral glucose 
tolerance test and the intraperitoneal (i.p.) glucose tolerance test. In mice, the glucose 
tolerance test is routinely performed following an overnight fast to achieve baseline 
blood glucose level. Then, mice are challenged with an i.p or intravenous (i.v.) glucose 
load: blood glucose levels are measured prior to glucose administration and at 15, 30, 
60 and 120 min after glucose administration. An abnormal glucose tolerance test is 
normally diagnosed by comparison with a control group. Glucose doses from 0.5 to 3 
g/kg body weight and the most common dose being 2 g/kg body weight have been used 
for the glucose tolerance test (Andrikopoulos et al., 2008).  
 
1.4.2.2 Blood insulin measurement 
The insulin precursor is a single-chain protein containing the B chain and A chain of 
insulin linked through a C-peptide segment (Steiner, 1969). The insulin precursor is 
then converted into insulin, a two-chain peptide consisting of A and B chains, by the 
loss of C-peptide (Steiner et al., 1967). Measurement of peripheral insulin levels serve 
as a gold standard for assessing β-cell secretory activity (Cavaghan and Polonsky, 
2005). However, 50 % of insulin is removed during first-pass metabolism by the liver 
(Polonsky et al., 1983) making insulin measurement an ineffective indicator for β-cell 
function.  
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1.4.2.3 Blood levels of connecting peptide  
C-peptide is a by-product of insulin production (see above), secreted by β-cells in 
equimolar quantities with insulin. Unlike insulin, C-peptide is not removed by the liver 
during first-pass metabolism and thus, is a more reliable marker of functional β-cell 
mass and a useful measurement to distinguish type 1 from type 2 diabetes (Marques et 
al., 2004; Vinik, 2004).  
 
1.4.2.4 Blood levels of hemoglobin A1C 
HbA1C is formed by the irreversible binding of glucose molecules to the N-terminal of 
β-chains of haemoglobin A (Bunn et al., 1976). It is slowly formed during the 120-day 
life span of an erythrocyte such that it reflects an average glucose level over the 
preceding 6-8 weeks (Cooppan, 2005). The HbA1C test provides an indicator for 
long-term glucose control and complications in diabetic patients rather than as a 
measurement of β-cell function.  
 
1.4.3 Treatment   
In clinical practice, patients with type 1 diabetes (absolute insulin deficiency) are 
treated with exogeneous insulin, pancreas or islet transplantation. The treatment 
strategies for type 2 diabetes are far more complex, including diet control, exercise, 
administration of blood glucose lowering drugs, and/or insulin. Lowering of blood 
glucose can be achieved by increasing insulin secretion, lowering insulin resistance or 
enhancing glucose disposal and production. For example, sulfonylureas bind 
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sulfonylurea receptor subunits of β-cell KATP channels, causing closure of KATP 
channels, cellular depolarization and Ca2+ entry with the increase in intracellular Ca2+ 
stimulating insulin secretion (Edwards and Weston, 1993). On the other hand, 
metformin exerts its anti-diabetic effect through increasing glucose disposal and 
decreasing hepatic glucose output (Bailey and Turner, 1996). The mechanism of 
thiazolidinediones to treat diabetes is incompletely understood but appears to work 
through binding to nuclear receptors, peroxisome proliferator-activated receptor-γ 
(PPARγ) (Pittas and Greenberg, 2002). PPARγ is involved in glucose and lipid 
metabolism and its activation leads to increased uptake of fatty acids and lipogenesis in 
adipose tissue which in turn lower levels of circulating fatty acids and lower insulin 
resistance (Ovalle and Fernando, 2002). 
 
1.4.4 Experimental models of diabetes   
1.4.4.1 In vivo models 
1.4.4.1.1 Type 1 diabetes 
Type 1 diabetes is characterized by the destruction of insulin-secreting β-cells 
secondary to autoimmune reaction or to other unknown aetiologies. Animal models of 
type 1 diabetes can be generated by destruction of β-cells by chemicals, e.g. 
streptozotocin (STZ) or induction of autoimmune responses.  
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Streptozotocin (STZ)-induced diabetic mice 
STZ is a β-cell-specific mycotoxin produced by Streptomyces achromogenes vas. 
streptozoticus and possesses antineoplastic, antibiotic, diabetogenic and mutagenic 
activities (Reusser, 1971). STZ has been a well-established method of inducing β-cell 
necrosis resulting in a deficiency of insulin secretion and generating an appropriate 
model to study type 1 diabetes (Wang and Gleichmann, 1998). However, the 
mechanism why β-cells are selectively sensitive to STZ is not fully understood (Konrad 
et al., 2001).   
 
The pancreas of STZ-induced diabetic mouse shows peri-islet lymphocyte and 
macrophage infiltration, permeating islets of Langerhans with islet distortion and β-cell 
necrosis by histological examination (Like and Rossini, 1976). The same study also 
shows smaller size and degranulation of the surviving β-cells but normal appearing α- 
and δ-cells. Among the commonly used mouse strains, non-obese diabetic mice (NOD 
mice) and C57BL/6 mice are both susceptible to STZ-induced diabetes (Gonzalez et al., 
2003). STZ can be given as a single high dose (150-200 mg/kg) or as multiple low 
doses (40-50 mg/kg in 5 consecutive days) via i.v. or i.p. routes. A single STZ injection 
causes β-cell necrosis within 4 h after dosing and achieves hyperglycaemia rapidly, 
whereas multiple dosing induces gradual elevation of blood glucose with a maximal 
reached during 10-25 days after the last injection (Like and Rossini, 1976).  
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Non-obese diabetic (NOD) mice 
Non-obese diabetic (NOD) mice are genetically susceptible to autoimmune disease 
(Aoki et al., 2005) and is a useful model to study the mechanisms of β-cell destruction. 
They can spontaneously develop insulitis and diabetes but not all progress from 
insulitis to diabetes. Insulitis in NOD mice is characterized by mononuclear infiltration 
predominantly of CD4+ T lymphocytes, but CD8+ T lymphocytes, B lymphocytes, and 
macrophage/dendritic cells are also found (Mathew and Leiter, 2005). The incidence of 
spontaneous diabetes in NOD mice is 60 % to 80 % in females and only 20 % to 30 % in 
males (Anderson and Bluestone, 2005).  
 
1.4.4.1.2 Type 2 diabetes 
Type 2 diabetes is a heterogeneous and multifactorial disease associated with both 
insulin resistance and impaired insulin secretion. Several attempts have been made to 
develop mouse models of type 2 diabetes, including by dietary and genetic 
manipulation.  
 
Diet-induced type 2 diabetes models 
A high fat diet has been shown to induce diabetes and obesity in various rodent strains 
(Collins et al., 2004). The C57BL/6 mouse is commonly used in type 2 diabetes studies, 
because it is genetically disposed to develop obesity, hyperglycaemia, 
hyperinsulinemia and insulin resistance, parallelling the progression of human type 2 
diabetes (Seldin et al., 1994). Insulin resistance and visceral fat accumulation develop 
after being fed a high fat diet containing 40-60 % of calories for 8-16 weeks (Reuter, 
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2007). Further, the increase in body fat deposition is consistent with the concomitant 
development of insulin resistance and hyperglycaemia (Black et al., 1998).  
 
Genetically manipulated models 
Although type 2 diabetes is a polygenic disorder, monogenic mouse models of diabetes 
are still valuable as they can provide information about the mechanisms in the 
pathophysiology of diabetes. Insulin resistance in type 2 diabetes can be achieved by 
manipulating a number of genes, including those encoding the insulin receptor, 
GLUT-4, IRS1-4 and Akt present in a number of tissues (LeRoith and Gavrilova, 
2006). Mouse models of obesity, such as the db/db and ob/ob mice, are associated with 
type 2 diabetes. The db/db mouse has a point mutation in the leptin receptor gene, 
displaying hyperglycemia and hyperlipidemia (Matveyenko and Butler, 2006). The 
ob/ob mouse, on the other hand, has a point mutation in the leptin gene and also 
displays hyperglycaemia and hyperlipidemia (Matveyenko and Butler, 2006). In 
response to hyperglycaemia, there is an increase in islet size and number in the ob/ob 
mouse resulting in enhanced insulin secretion compensating for the insulin resistance 
(Bock et al., 2003). In the db/db mouse, there is a transient increase in insulin secretion 
followed by a decrease in β-cell mass due to islet necrosis (Shafrir et al., 1999).  
 
The limitation of using rodent type 2 diabetes models is that they do not show similar 
islet pathology to that in humans, such as production of islet amyloid (Cefalu, 2006). 
Another important difference is the capacity of rodent islets to proliferate compared to 
human islets (Parnaud et al., 2008). Although rodent models fail to reproduce all 
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aspects of human type 2 diabetes, they are still of great value, in mimicking certain 
pathophysiological aspects of human type 2 diabetes.  
 
1.4.4.2 In vitro models 
1.4.4.2.1 Isolated islets  
Isolation of islets from the rodent pancreas was first described by Lacy and 
Kostianovsky  and most subsequent islet isolation procedures designed have been 
based on this pioneering work (Lacy and Kostianovsky, 1967). Briefly, the animal is 
anesthetized and the pancreas perfused with Hanks buffer through the common bile 
duct. Then, the pancreas is removed, cut into small pieces and digested with 
collagenase. Islets are isolated from this tissue preparation by sedimentation or 
centrifugation. During the isolation process, islets are exposed to a variety of cellular 
stresses, e.g. disruption of cell-matrix relationship and  loss of peri-islet basement 
membrane, leading to islet damage (Rosenberg et al., 1999; Wang et al., 1999). 
Prolonged islet culture has been shown to reduce responsiveness to glucose stimulation 
and maintenance of islets in culture has remained a challenge (Gaber et al., 2001).  
 
1.4.4.2.2 Cultured β-cell lines 
Common β-cell lines, such as RIN lines, HIT lines, βTC lines, MIN lines, βHC lines 
and NIT-1 line, are derived mainly from insulinomas and preneoplastic islet cells in 
rodents (Ulrich et al., 2002). Therefore, results derived from β-cell lines may need to be 
confirmed in primary cultured islets since differences may exist between normal and 
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transformed cells. Most of the β-cell lines secrete insulin in response to glucose 
stimulation (Hohmeier and Newgard, 2004) and are appropriate models for studying 
the mechanism of glucose-stimulated insulin secretion. However, transformed β-cell 
lines can cause a decreased insulin response after prolonged culture (Ulrich et al., 
2002).   
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1.5 Insulin target tissues 
Blood glucose levels remain in a narrow range between 4 and 7 mM under 
physiological conditions and this tight regulation is determined by a balance between 
glucose production by the liver and glucose disposal by peripheral tissues which are 
mediated by insulin production by β-cells (Ruderman et al., 2005). Target tissues for 
insulin action include the liver, skeletal muscle and adipose tissue. Glucose is 
membrane-impermeable and its transport across cell membrane requires the glucose 
transportor (GLUT) family. There are five GLUT proteins, GLUT-1, 2, 3, 4, and 5, 
which differ in their properties and tissue distributions. GLUT-2 occurs primarily in the 
liver, pancreatic β-cell, intestine and kidney, whereas GLUT-4 is located primarily in 
heart, skeletal muscle and adipose tissue (Shepherd and Kahn, 1999). Increased blood 
glucose levels leads to increased glucose uptake in β-cells through GLUT-2. The rise in 
intracellular glucose stimulates insulin-gene transcription in the β-cell as well as 
increased glycolysis leading to insulin secretion (Efrat et al., 1991).  
 
1.5.1 Skeletal muscle  
Skeletal muscle is the major glucose-utilizing organ responsible for 75 % of 
insulin-dependent glucose uptake following an exogeneous glucose load (Saltiel and 
Kahn, 2001). Skeletal muscle glucose disposal in vivo is regulated by glucose delivery 
to muscle cells, GLUTs and intracellular glucose metabolism (Rose and Richter, 2005). 
Glucose supply to muscle cells is dependent on skeletal muscle perfusion and blood 
glucose levels. Muscle blood flow increases during exercise and is known to increase in 
a linear manner in response to muscle workload (Andersen and Saltin, 1985). 
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Therefore, muscle contracture is a potent stimulator of muscle glucose uptake. During 
exercise, muscle contracture causes depletion of muscle glycogen stores and increased 
ATP demand, leading to the activation of adenosine monophosphate-activated protein 
kinase (AMPK) (Bergeron et al., 1999). Glucose uptake by skeletal muscle can be 
totally insulin-independent via the activation of AMPK following exercise (Holloszy, 
2005).  
 
Glucose uptake into the skeletal muscle cell is mediated by GLUT-4 in the cell 
membrane. GLUT-4 is stored in intracellular vesicles which translocates to the plasma 
membrane in response to elevated insulin level. The role of insulin in skeletal muscle is 
to increase skeletal muscle perfusion (Baron and Clark, 1997) as well as initiate 
GLUT-4 translocation. Similar to the other exocytotic processes in neurons and 
pancreatic β-cells, exocytosis of GLUT-4 is mediated by increased [Ca2+]i (Schudt et 
al., 1976; Westfall and Sayeed, 1990).  
 
In summary, glucose uptake by skeletal muscle is regulated by insulin-mediated and 
contraction-mediated glucose transport pathways. Both pathways involve an increase 
in cytosolic Ca2+ with an influx of extracellular Ca2+ due to insulin-mediated glucose 
uptake, and from intracellular Ca2+ stores for the contraction-mediated pathway 
(Lanner et al., 2008). As insulin can induce a net Ca2+ influx and Mn2+ can quench 
fura-2 fluorescence (a fluorescent Ca2+ indicator) and has been used to detect Ca2+ 
influx in response to insulin activation in skeletal muscle (Lanner et al., 2006), MEMRI 
may be used to image insulin-mediated glucose transport processes in vivo in skeletal 
muscle.  
 54
1.5.2 Liver 
The liver is a major site of glucose production which is inhibited by insulin and 
stimulated by glucagon. Both insulin- and glucagon-mediated processes induce Ca2+ 
influx into hepatocytes in vitro (Applegate et al., 1997; Barritt et al., 2008; Benzeroual 
et al., 2000). Glucagon binds to the glucagon receptor on the cell membrane of 
hepatocytes and an increase in intracellular Ca2+ is accompanied by this process (Hems 
and Whitton, 1980; Nathan and Cagliero, 2001; Xu and Xie, 2009). However, the role 
of Ca2+ in the suppression of hepatic glucose production by insulin is unclear. Although 
some studies suggest that insulin and glucagon both facilitate Ca2+ influx into 
hepatocytes (Applegate et al., 1997; Barritt et al., 2008; Benzeroual et al., 2000). Thus, 
Ca2+-regulated signalling pathways are complex, with numerous Ca2+ channels 
involved in a wide range of cellular functions (Barritt et al., 2008). Unlike in the 
pancreas (see 1.2) and skeletal muscle (see 1.5.1), the relationship between glucose 
uptake and hepatic blood perfusion is unclear (Bor et al., 1980; Pugliese et al., 1988).  
 
Mn2+ is metabolized in the liver. In addition, Mn2+ also plays an important role in the 
enzyme function in the liver. Mn2+ is known to be a constituent of mitochondrial 
MnSOD, liver arginase and liver pyruvate carboxylase; and an activator of  glutamine 
synthetase and alkaline phosphatase (Christianson and Cox, 1999; Greger, 1998; 
Hurley et al., 1959; Thunus and Lejeune, 1999). 
 
The liver plays a major role in the regulation of blood glucose levels by balancing 
uptake and production of glucose (Nordlie et al., 1999). Blood glucose is mainly 
derived from digested nutrients in the fed state and is maintained by hepatic glucose 
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production in the fasted state (Kruger et al., 2006). In the liver, glucose is produced via 
the pathways of gluconeogenesis and glycogenolysis. The rate of gluconeogenesis 
remains constant while the rate of glycogenolysis changes in different metabolic states 
in healthy human (Nuttall et al., 2008). In type 1 diabetes, the absolute insulin 
deficiency results in the lack of a suppressive effect on hepatic glucose production and 
a deficiency of peripheral glucose uptake (Kruger et al., 2006). However, relatively 
little is known about the role hepatic glucose production in patients with diabetes 
(Nuttall et al., 2008).  
 
1.5.3 Adipose tissue 
Adipose tissue is a metabolic and endocrine organ. It expresses receptors for insulin, 
glucagon, growth hormone, thyroid-stimulating hormone, glucagon-like peptide-1 and 
secretes proteins such as leptin, adiponectin, adipsin, tumor necrotic factor α, 
interleukin-6 (Kershaw and Flier, 2004). There are two types of adipose tissues in 
mammals: white adipose tissue (WAT) and brown adipose tissue (BAT). The white 
adipocyte contains a single large lipid droplet and a peripherally located nucleus 
whereas the brown adipocyte contains multilocular lipid droplets and a centrally 
located round nucleus (Hull, 1966). WAT is found subcutaneously, around visceral 
organs and in the bone marrow. BAT is lobulated, located in deep cervical regions 
including the interscapular, suprasclavicular and paravertebral regions.  WAT is the 
primary site of energy storage and plays a role in metabolic regulation and 
physiological hemeostasis (Trayhurn and Beattie, 2001). BAT is important in the 
regulation of energy expenditure (Cypess et al., 2009).   
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WAT and BAT also appear to have different origins with WAT being derived from 
stromal vascular fraction and BAT being obvious to have a similar lineage to skeletal 
muscle (Enerback, 2009). BAT in adults human was not thought to be present but 
recent Positron Emission Tomography (PET)-Computerized Tomography (CT) scan 
conducted in both lean and obese adult has provided compelling evidence of BAT 
(Cypess et al., 2009). 
 
In WAT, the role of Ca2+ influx in insulin-mediated glucose uptake remains unclear. 
Some studies suggest that intracellular Ca2+ is essential for insulin-mediated glucose 
transport and GLUT-4 translocation in isolated white adipocytes (Draznin et al., 1988; 
Pershadsingh et al., 1987; Worrall and Olefsky, 2002). Although other studies suggest 
that increased [Ca2+]i is not related to insulin-mediated glucose transport in isolated 
white adipocytes in vitro (Kelly et al., 1989; Khil et al., 1997). 
 
In isolated rat epididymal adipocytes, Mn2+ has been shown to be insulinomimetic by 
enhancing insulin binding (Baquer et al., 2003; Ueda et al., 1984) and Mn2+ deficiency 
can result in impaired glucose transport and defects in lipid metabolism (Baly et al., 
1990; Davis et al., 1990). It has been shown that Mn2+ treatment was able to reverse 
declining insulin sensitivity in diabetic rat model (Baquer et al., 2003). Therefore, it is 
possible that there is a link between exposure to Mn2+ and insulin resistance in the 
adipose tissue.  
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In BAT, the relationship between insulin and GLUT-4 mediated glucose seems similar 
to that in WAT (Cannon and Nedergaard, 2004) and the role of Ca2+ influx in 
insulin-mediated glucose uptake is still not fully established.    
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1.6 β-cell imaging 
Autopsy studies show there is a 90 % β-cell mass loss in type 1 diabetes and 0-65 % in 
type 2 diabetes (Matveyenko and Butler, 2008). It is essential to accurately image the 
β-cell mass before irreversible loss of β-cells leads to the symptoms of diabetes to 
provide an earlier therapeutic window and so, increase the likelihood of maintaining the 
β-cell mass. In spite of the rapid progress in biotechnology, there is no accurate and 
non-invasive diagnostic tool for assessing β-cell mass and function it situ. Currently, 
direct and reliable measurements for β-cells are limited to biopsy or autopsy studies. 
Therefore, there is a need to develop imaging techniques to image the β-cell anatomy, 
pathophysiology and metabolism in situ to improve understanding of diabetes. Current 
imaging technologies used for β-cell imaging include optical imaging, nuclear imaging 
and MRI (Saudek et al., 2008). These modalities all require the use of β-cell-specific 
imaging probes for the quantification of β-cell mass.  
 
Although the dominant cell type in the islet, the β-cell only comprises 1 % of the total 
pancreatic volume. Therefore, potential imaging technologies must have the ability to 
effectively identify β-cell signal intensity (SI) from that of the background pancreas. 
Two characteristics of an ideal β-cell imaging probe has been established: (1) a 1000:1 
β-cell labelling specificity with respect to exocrine cells (2) signal from bound probes 
in β-cells is significantly higher than that from unbound probes in extracellular spaces 
(Sweet et al., 2004).  
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1.6.1 Optical Imaging 
Optical imaging is an imaging method which uses visible or near infrared radiation. It 
has limited penetration and so is unable to visualize the pancreas unless the pancreas is 
surgically exposed. Thus, optical imaging methods cannot be readily translated to the 
clinic as compared to nuclear imaging and MRI. However, confocal microscopy, a 
high-resolution optical imaging technique, has been used to generate three-dimensional 
(3D) images from a selected tissue focal plane in vivo.  
 
Confocal fluorescent microscopy is capable of imaging fluorescently labelled cells or 
molecules (Balas, 2009). Operating in the ultraviolet range, it has the advantage of 
cellular to subcellular resolution. On the other hand, it has the drawbacks of low 
penetration depth (20-200 μm) and high background signal. Recently, a novel 
application of in vivo imaging of islet morphology, vascularization, cell function and 
cell survival  in vivo was reported using confocal laser scanning microscopy (Speier et 
al., 2008). The investigators transplanted green fluorescent protein (GFP)-expressing 
islets into the anterior chamber of the eye which was used as a natural body window to 
overcome the depth limitation of confocal microscopy. This technique allows 
non-invasive imaging of GFP-expressing islets over time. By administration of Texas 
red, a fluorescence dye via the tail vein, the islet vasculature could also be readily 
visualized.  
 
Optical projection tomography (OPT) is an approach for imaging of small specimens 
with 1-10 mm thickness (Holmberg and Ahlgren, 2008). It acquires nearly cellular level 
resolution (~ 15-20 μm), generating 3D morphology of a particular organ or 
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distribution of labelled cells (Holmberg and Ahlgren, 2008; Sharpe, 2004). Alanentalo 
et al. reported an OPT-based ex vivo 3D quantitative method to demonstrate the 
complex shape of mouse pancreas and visualize insulin-labelled islet distribution and 
volume in NOD mice (Alanentalo et al., 2007). This work also demonstrated a 
correlation between the total islet volume and onset of type 1 diabetes in a NOD mouse 
model. Transplanted islets has been detected in vivo by both MRI and fluorescence 
microscopy by labeling islets with superparamagnetic iron oxide (SPIO) nanoparticles 
and near-infrared fluorescent Cy5.5 dye (Medarova et al., 2005). 
 
1.6.2 Nuclear imaging 
Radionuclides undergo radioactive decay or disintegration with the emission of 
ionizing radiation in the form of α, β or γ rays. Often compounds are radiolabelled and 
allow visualization of pathophysiological processes (Imam, 2005). A gamma camera is 
used to detect waves or particles emitted by radiolabelled complexes in tissues to 
generate images after administration into the subject. The detected radioactive signals 
are then processed mathematically to create images to show the location as well as 
activity of the radiolabelled metabolite or radiopharmaceutical. Current nuclear 
imaging modalities include Single Photon Emission Computerized Tomography 
(SPECT) and PET. The disadvantages of nuclear imaging are poor spatial resolution 
and the use of ionizing radiation.  
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1.6.2.1 SPECT 
The most common radionuclides used in SPECT are technetium-99m, thallium-201, 
gallium-67, iodine-123, iodine-131 and samarium-153 which emit gamma rays during 
radioactive decay. SPECT cameras are designed to detect the single photons emitted by 
gamma-emitting radionuclides (Powsner and Powsner, 2006b). SPECT is less 
expensive than PET, although relatively less sensitive and of lower spatial resolution. 
By labelling β-cells with a radiolabeled IC2 antibody (a proposed β-cell–specific 
antibody), Moore et al showed a good correlation between β-cell mass and 
accumulation of radioligands in vivo using SPECT (Moore et al., 2001). 
 
1.6.2.2 PET 
Common radionuclides used in PET are carbon-11(11C), nitrogen-13, oxygen-15, 
fluorine-18 (18F). These radionuclides undergo positron decay, producing paired 
photons traveling away in opposite directions (Powsner and Powsner, 2006a). PET 
scanners are designed to detect these paired annihilation photons. Biological molecules 
are radiolabelled by replacement of nuclei with photon emitting nuclei e.g. 18F labeled 
fluorodeoxyglucose (18F-FDG). Specific receptors can be imaged by labeling of 
appropriate ligands, such as 11C labeled dihydrotetrabenazine (DTBZ) for the vesicular 
monoamine transporter-2 (VMAT2). Currently probes proposed to image β-cells are 
ligands targeted to VMAT2, antibodies to zinc transporter-8, and antibodies to β-cell 
surface proteins.  
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Monoamines, such as epinephrine, norepinephrine, dopamine, serotonin and histamine, 
are stored in secretory granules of neurons, endocrine and neuroendocrine cells. The 
role of VMATs is to transport and package monoamines from the cytoplasm into 
storage organelles. VMAT2 is located in islets, neurons and chromaffin cells of the 
adrenal medulla (Freeby et al., 2008). In the pancreas, VMAT2 is found to be expressed 
specifically in β-cells and not in exocrine cells by immunohistochemistry and in situ 
hybridization (Anlauf et al., 2003). Therefore, it has been proposed as a molecular 
target for β-cell imaging and measuring the uptake of radioactive ligands that 
selectively binds VMAT2 represents the insulin secretory capacity (Harris et al., 2008). 
DTBZ is a specific ligand which binds to VMAT2. Studies showed an excellent 
correlation between 11C-DTBZ uptake and the β-cell mass in animal models (Simpson 
et al., 2006; Souza et al., 2006). DTBZ can also be labeled with 18F to give 18F-labeled 
9-fluoropropyl-(+)-DTBZ which has been used for mapping the β-cell mass in rats 
(Kung et al., 2008). It is worth noting that a recent study showed that VMAT2 is 
expressed in both pancreatic β-cells and PP cells in human (Saisho et al., 2008) such 
that 11C-DTBZ uptake may not be wholly specific to β-cells (Malaisse et al., 2009).  
 
Zinc ion (Zn2+) is involved in a wide variety of physiological processes in many tissues. 
It is stored with insulin in the secretory granule and therefore important metal in the 
β-cell  (Hutton et al., 1983).  The distribution of Zn2+ is high in the β-cell (Clifford and 
MacDonald, 2000), but also in the brain (Que et al., 2008). Thus, radioactive Zn2+ may 
be used to label the insulin granules in the β-cell to assess insulin storage and secretion. 
However, insulin granules can be secreted from the β-cell and so lower accumulation of 
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radioactive zinc (Zn) may be more correlated to a decrease in the insulin store rather 
than a reduction in the β-cell mass (Schneider, 2008).   
 
1.6.3 MRI 
1.6.3.1 Introduction 
MRI is a popular medical imaging tool in clinical practice providing excellent soft 
tissue contrast by appropriate choice of the MRI sequence and parameter values. MRI 
is more attractive than other non-invasive imaging modalities, as it can be easily 
translated to the clinic and does not employ ionizing radiation, although MRI is usually 
more expensive and requires longer scan times. For preclinical research, small animal 
MRI affords spatial localization of morphological and functional changes in tissues 
which has become increasingly important (Pautler, 2004b). 
 
MRI exploits the phenomenon of nuclear magnetic resonance (NMR). NMR results 
from the introduction of charged nuclei into a magnetic field and their adoption of 
specific orientations. The simplest nucleus is the proton and water protons are the most 
abundant nuclei in biological tissues (McRobbie et al., 2007). Protons are randomly 
oriented in the absence of a magnetic field and adopt one of two orientations in the 
presence of magnetic field, either parallel with the magnetic field (spin up) or 
antiparallel (spin down).  As there is a slight excess of the spin up population, there is a 
net magnetization (M0) in the same direction as the applied magnetic field (the 
z-direction). Application of a radiofrequency pulse at the appropriate frequency will tip 
the magnetization away from the z-axis (Figure 1-3).  The magnetization, M, has both 
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an Mz and an Mxy component.  As M returns back to the equilibrium position, M0, the 
rate at which the Mz and Mxy components returns to the equilibrium position is termed 
longitudinal and transverse relaxation, respectively.(Hashemi et al., 2003b). The rate of 
longitudinal and transverse relaxation is given by the values of T1 and T2, respectively. 
By T1-weighted MRI, tissues with short T1 can be preferentially positively enhanced.  
Tissues with short T2 values can be preferentially negatively enhanced by T2-weighted 
MRI. 
 
 
Figure 1-3. The effect of radiofrequency pulse on the bulk magnetization M0.  
 
It is challenging to image rodent pancreas by in vivo MRI. Firstly, the pancreas is 
surrounded by organs of the gastrointestinal tract such as the stomach, duodenum, 
jejunum and colon such that physiological movements can give rise to image blurring. 
Secondly, the rodent pancreas is a diffuse organ and the voxel in each acquired slice 
may have a mixture of tissues which contribute to partial volume averaging. Therefore, 
slice thickness needs to be as thin as possible to avoid partial volume artefacts. Thirdly, 
 65
the pancreas is enclosed by solid organs including the liver, left kidney and spleen such 
that sufficient tissue contrast is needed between the pancreas and its surrounding organs 
to readily identify their boundaries. Taken together, the criteria for optimal pulse 
sequences for rodent pancreatic MRI are: short scan times to attenuate the motion 
artefacts, high spatial resolution to avoid partial volume averaging and high tissue 
contrast to delineate the pancreas. 
 
It is even more of a challenge to specifically image the β-cell mass and function. Firstly, 
the volume of the β-cell mass is only 1 % of the pancreas and is scattered throughout the 
whole pancreas. Secondly, the size of β-cells is smaller than the commonly used spatial 
resolution of MRI technology. Moreover, the signal from β-cells cannot be separated 
from other types of cells in the pancreas by MRI and so, β-cell-specific contrast agents 
are required to visualize only β-cells by MRI. 
 
1.6.3.2 Contrast agents 
MRI contrast agents are metal complexes such as Mn2+, iron (III) ion (Fe3+) and 
gadolinium ion (Gd3+) which alter T1 and T2 relaxation times, leading to an increase in 
the longitudinal and transverse relaxation rates (1/T1 and 1/T2) of the water protons, 
respectively, in tissue. The efficiency to enhance relaxation rates by the contrast agent 
is referred as the relaxivity (Eric  et al., 2008). The relaxivity of MRI contrast agents 
depends on the number of unpaired electrons. Mn2+ (electron configuration 3d5), Fe3+ 
(electron configuration 3d5) and Gd3+ (electron configuration 4f7) are all high spin 
number ions with 5, 5, and 7 unpaired electrons, respectively. They are paramagnetic in 
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which the unpaired electrons are aligned parallel with the applied magnetic field. The 
metal ions in MRI contrast agents can be toxic and its toxicity can be reduced by 
covalent binding, chelation, polymer conjugation, formation of inclusion complexes 
and liposome entrapment (Thunus and Lejeune, 1999).  
 
In MRI, the delineation of the area of interest in tissue depends on tissue contrast and 
imaging resolution (Kuo and Herlihy, 2006). MRI images are affected by a 
combination of spin density, longitudinal relaxation time T1 and transverse relaxation 
time T2 and other effects (De Graaf, 2007). Therefore, any difference in these properties 
can be used to enhance tissue contrast in MRI. MRI contrast agents can enhance the 
tissue contrast between diseased and normal tissues, indicate organ perfusion and 
evaluate blood flow-related changes in MR images by influencing the relaxation rates 
of water protons (Caravan et al., 1999). By serial assessment of contrast kinetics 
following administration of a contrast agent, dynamic contrast-enhanced MRI can 
provide insights into the integrity and perfusion of the tissue (Choyke et al., 2003), and 
has been clinically used for differential diagnosis of lesions with different 
hemodynamic characteristics. 
 
MRI contrast agents can be used as intravascular agents for imaging vascular structures 
such as Gd-based contrast agents, intracellular agents to image cellular activity such as 
Mn-based contrast agents, or labelling of biological molecules such as iron oxide-based 
contrast agents (Thunus and Lejeune, 1999).  
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1.6.3.2.1 Gd3+ 
Gd3+ is a toxic heavy metal and therefore chelated forms of Gd3+ are used for clinical 
application to reduce toxicity (Caravan et al., 1999; Westmeyer and Jasanoff, 2007). 
Gd3+-based contrast agents are by far the most commonly used MRI contrast agents 
with only rare and mild adverse reactions (Caravan et al., 1999). However, recent 
reports show there is a strong association between exposure to Gd3+-based contrast 
agents and  development of nephrogenic systemic fibrosis (Agarwal et al., 2009; 
Grobner and Prischl, 2007) and has the disadvantage of being non-biocompatible 
(Mohs and Lu, 2007). Gd3+-chelates are extracellular contrast agents as they distribute 
in the plasma and extracellular space. By pre-labelling isolated islets with 
gadolinium-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic 
acid] (GdHPDO3A), transplanted islets can be detected in vivo up to 65 days 
post-transplantation in mice (Biancone et al., 2007). However, GdHPDO3A is not a 
β-cell-specific contrast agent and this method cannot be applied to image native islets 
in vivo.  
 
1.6.3.2.2 Iron oxide nanoparticles 
Iron oxide-based contrast agents are iron oxide crystals coated with carbohydrates such 
as dextran or carboxydextran. Those that are > 50 nm in size are referred to as SPIO 
particles whereas those that are < 50 nm in size are ultrasmall superparamagnetic iron 
oxide (USPIO) particles (Erpelding et al., 2008). Iron oxide nanoparticles have a T2 
shortening effect and decrease SI in areas of accumulation on T2- or T2*-weighted MRI. 
This class of MRI contrast agent is biocompatible  (Bulte and Kraitchman, 2004) and 
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taken up by Kupffer cells in the normal reticuloendothelial system, primarily in the 
liver and thus are liver-specific MR contrast agents (Tanimoto and Kuribayashi, 2006). 
Transplanted islets have been pre-labelled with iron oxide nanoparticles prior to 
transplantation and have been successfully imaged in vivo by MRI (Evgenov et al., 
2006). The NOD mouse is a murine model of spontaneous type 1 diabetes characterized 
by lymphocytic infiltration in β-cells and β-cell destruction (Yang et al., 1997).  By 
labelling lymphocytes with SPIO, the labelled lymphocytes were found in the islet of 
diabetic NOD mouse ex vivo (Moore et al., 2002).  
 
By cell labelling techniques, iron oxide based contrast agents can be used to image 
transplanted islets or insulitis. However, iron oxide-labelled islets may be metabolised, 
released and phagocytosed, e.g. by macrophages. Islets grafted into the kidney capsule 
and macrophage in the kidney capsule can ingest magnetic nanoparticles (Hsiao et al., 
2008), contributing to the SI of islet graft. Therefore, this protocol is not applicable to 
image native islets, as it is not possible to selectively label native islets in vivo in such a 
way and the clinical application of this technology is limited. 
 
1.6.3.2.3 Mn2+ 
Manganese (Mn) is an essential cofactor and activating agent to many metalloenzymes 
in mammalian cells (Christianson, 1997). Mn2+ is a constituent of arginase and 
pyruvate carboxylase, whereas Mn2+ and Manganese (III) ion (Mn3+), are key 
components of manganese superoxide dismutase (MnSOD) (Keen et al., 2000). 
Therefore, both Mn2+ and Mn3+ are crucial in biological systems. In addition, free Mn2+ 
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is a MRI contrast agent, predominantly by shortening T1 relaxation time, giving rise to 
a positive signal by T1-weighted MRI.  
 
Mn may exist in plasma as Mn2+ and Mn3+ after exposure to MnCl2, as  Mn2+ can be 
oxidized to Mn3+ (Armstrong, 2008; Aschner et al., 2007). Mn2+ and Mn3+ are both 
paramagnetic ions (Schaefle and Sharp, 2005). Within plasma, Mn2+ remains as the free 
ion or binds to α2-macroglobulin (Harris and Chen, 1994), whereas Mn3+ binds to 
transferrin (Rabin et al., 1993).  It is known that Mn2+ is rapidly taken up by cells and 
quickly removed from blood after administration (Zheng et al., 2000). An in vitro study 
shows Mn concentrations are high in the liver, pancreas, kidney and adrenal gland, and 
low in the brain and spleen by inductively coupled plasma atomic emission 
spectrometry (ICP-AES) after i.v. injection of MnCl2 or MnDPDP (Ni et al., 1997). 
 
Despite its importance, little is known about Mn2+ transportation and accumulation in 
live organisms (Armstrong, 2008; Pittman, 2005). In the cells, Mn2+ is accumulated in 
the mitochondria and nuclei (Kalia et al., 2009). Mn2+ can be transported across the 
plasma membrane of a wide variety of cell types, such as hepatocytes, platelets, 
endothelial cells, neutrophils, and parotid acinar cells (Merritt et al., 1989; Mertz et al., 
1990). Mn has been demonstrated to transport via specific transporters, Ca2+ channels 
and endocytosis (Roth, 2006). 
 
Divalent metal transporter-1 (DMT1) is a proton-dependent transporter for a variety of 
divalent metal ions including Mn2+, Fe2+, Zn2+, Co2+, Cd2+, Cu2+, Ni2+ and Pb2+ 
(Gunshin et al., 1997) but not Ca2+ (Xu et al., 2004), and appears to be the major 
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mammalian Mn2+ transporter (Chua and Morgan 1997). Zrt-like, Irt-like protein has 
been shown to transport Zn2+, cadmium ion (Cd2+) and Mn2+ in vitro (He et al., 2006). 
In size, Mn2+ has an ionic radius similar to Ca2+ (Mn2+ = 97 pm, Ca2+ = 114 pm) 
(Shannon, 1976) and therefore, shares some transport pathways, such as VGCCs. Ionic 
radius is not always important for permeation across VGCCs, so is hydration index, 
such as with K+ channels. In terms of physical and chemical properties, Mn3+ is similar 
to Fe3+ and thus TfR which transports Fe3+ may also transport Mn3+ (Aschner and 
Gannon, 1994; Davidsson et al., 1989). 
 
Mn2+ is metabolized in the liver (Thunus and Lejeune, 1999) and its uptake by the liver 
has been reported to be a unidirectional process in vitro (Keen et al., 2000). The 
mechanisms of cellular Mn2+ influx remain unclear, as well as that of Mn2+ efflux 
(Madejczyk et al., 2009). After entering the liver, Mn2+ can either be excreted in the 
bile (Ni et al., 1997) or accumulate in the mitochondria (Gunter et al., 1975; Gunter et 
al., 1978).  
 
1.6.3.3 Manganese-enhanced MRI (MEMRI) 
The use of Mn2+ as a MRI contrast agent can be traced back to the earliest use of MRI 
(Lauterbur, 1973). Mn2+ can act as both an extracellular and intracellular MRI contrast 
agent as it can exist in the circulation and be transported across cell membranes. There 
is always a concern when using Mn2+ as a contrast agent since Mn2+ exposure may lead 
to respiratory distress, liver failure, cardiac toxicity and neurological disorders (Silva et 
al., 2004). Mangafodipir trisodium (MnDPDP) is a FDA-approved Mn2+-chelate 
derived from vitamin B6 to decrease toxicity of Mn2+ (Gallez et al., 1996; Regge et al., 
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2009). MnDPDP releases Mn2+ slowly from the chelate and several hours are required 
for clearance from the blood (Krombach et al., 2004). In contrast, manganese chloride 
(MnCl2) is toxic, but has the advantage of fast kinetics and is currently being used in 
pre-clinical experiments. MnDPDP has been used as a hepatobiliary contrast agent in 
clinical practice based on its greater affinity to hepatocytes (Elizondo et al., 1991; Lim 
et al., 1991). 
 
1.6.3.3.1 Brain 
Three major applications of MEMRI in the brain are to: detect cellular activity, trace 
neuronal tracts in visual or olfactory pathways and enhance tissue contrast after a 
systemic dose (Lee and Koretsky, 2004; Silva and Bock, 2008). Firstly, Mn2+ enters 
into cells through cell membrane VGCCs upon cell depolarisation (Koretsky and Silva, 
2004). When cells are activated, Ca2+ channels open followed by the Mn2+ influx. Thus, 
cells show greater Mn2+ uptake upon activation and this can be observed by 
T1-weighted MRI (Silva et al., 2004). MEMRI has been used to image neuronal 
activation in the hypothalamus (Kuo et al., 2007; Parkinson et al., 2009), 
photoreceptors (Berkowitz et al., 2009) and hippocampus (Hsu et al., 2007). Secondly, 
Mn2+ can move along neuronal pathways in an anterograde and retrograde direction 
after injection into specific brain regions and has been used to trace neuronal networks 
in animal models (Pautler, 2004a; Silva et al., 2008). Thirdly, increases in tissue 
contrast are detected on T1-weighted MRI following systemic MnCl2 infusion, aiding 
better delineation of brain structure (Lin and Koretsky, 1997).  
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1.6.3.3.2 Heart  
Both cellular Ca2+ influx and the release of intracellular Ca2+ store contribute to the 
activation of contraction in the heart (Bers and Perez-Reyes, 1999). MEMRI has been 
demonstrated to act as a potential tool for imaging cellular viability in the myocardium 
(Brurok et al., 1999) based on the close relationship between [Ca2+]i and cardiac 
contractility (Wendland, 2004). In viable myocardium, the SI increases during the 
MnCl2 infusion period, reaching peak enhancement by the end of infusion and remains 
so for a further 30 min in mice (Hu et al., 2001). Whereas in the infracted myocardium, 
Mn2+ accumulates during MnCl2 infusion, but washes out as quick as 3-5 min after the 
end of infusion (Hu et al., 2004). Moreover, the SI of the myocardium decreases in 
mice with Ca2+ channel blocker and increased with positive inotropic activation 
following MnCl2 infusion (Hu et al., 2001), indicating a relationship between Mn2+ 
uptake and cardiac inotropy.  
 
1.6.3.3.3 Pancreas 
Pancreatic β-cells are similar to neuronal cells in being electrically excitable cells 
having VGCCs (Catterall et al., 2005; Ko et al., 1997) and the exocytosis of insulin 
granules is Ca2+-dependent (Rorsman et al., 2000). Mn2+ has been used as a Ca2+ 
surrogate to study Ca2+ flux in islets in vitro (Rorsman et al., 1982; Rorsman and 
Hellman, 1983).  
 
During the course of this work, there were two articles in the field of MEMRI of β-cell 
mass published. An in vitro study shows that the SI in Mn2+-labelled islets increase by 
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200 % following glucose stimulation compared to that of non-stimulated islets by MRI 
(Gimi et al., 2006). A subsequent in vivo study showed that the normalized pancreatic 
SI is greater in the glucose-stimulated mice compared to control by MEMRI 
(Antkowiak et al., 2009).  
 
1.6.3.3.4 Lymphocyte 
Mn can be taken up by a wide variety of cell types and therefore may be used to label 
cells. Lymphocytes can be labelled by MnCl2 for up to 24 h, showing a dose-dependent 
relationship between changes in T1/T2 values and MnCl2 concentrations in vitro (Aoki 
et al., 2006). However, it is not clear whether the migration of Mn-labelling 
lymphocytes can be detected in vivo.  
 
1.6.3.4 Pulse sequences  
A pulse sequence is a sequence of radiofrequency pulses applied throughout the MRI 
experiment (Hashemi et al., 2003a). Mn2+ is a T1 contrast agent and therefore, 
T1-weighted MRI sequences are employed for performing MEMRI.   
 
1.6.3.4.1 Signal intensity (SI) 
The strength of the SI from a given tissue in MRI depends on intrinsic physical 
parameters of tissue, such as the proton density, T1 and T2, as well as the local magnetic 
field, field inhomogeneity and choice of imaging parameters (Suranyi et al., 2007). 
MRI contrast agents are often used to enhance the SI difference between different 
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tissues, or between normal and diseased tissues. After administration of a T1 contrast 
agent, the T1 value in the tissue where the contrast agent accumulates decreases, leading 
to an increase in tissue SI by T1-weighted MRI. The degree of increased SI depends on 
the local concentration of the contrast agent. Thus, the pharmacokinetics of the contrast 
agent in a tissue can be indirectly estimated by analysing the time course of SI changes 
in a serial set of MR images acquired before and after the administration of a contrast 
agent. For MEMRI, the signal enhancement can be measured by spin echo (SE) or 
gradient echo sequences. Only SE and 3D magnetization prepared rapid gradient echo 
(MP-RAGE) sequences (a gradient echo based sequence), are discussed here.  
 
Spin echo sequence 
The SE sequence is the most frequently used MRI pulse sequence. It is made up of a 
repeated series of 90° pulses to flip the spins into the x-y plane followed by one 180° 
pulse to eliminate the dephasing effects and generate an echo (Hashemi et al., 2003a). 
The echo time (TE) is the period between the 90° pulses and the echo whereas 
repetition time (TR) is the period between two 90° excitation pulses. To perform 
T1-weighted MRI, a value of TE less than 40 ms and a short TR value of less than 750 
ms are used whereas for T2-weighted MRI, long TE and long TR values are used 
(Westbrook et al., 2005).  
 
Magnetization-prepared rapid gradient echo (MP-RAGE) sequence 
MP-RAGE is a fast scanning technique which acquires high resolution, high contrast, 
T1-weighted images and is used in imaging structural details in the inner ear, skull base 
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and abdomen in clinical practice (McRobbie, 2007; Mugler and Brookeman, 1991). It 
acquires 3D image sets of the abdomen with minimal respiratory artefacts (Mugler and 
Brookeman, 1990a) and so we have proposed its use for mouse pancreatic imaging. The 
MP-RAGE sequence consists of three steps which constitute the inner loop of the 
sequence (Figure 1-4): a 180° pre-pulse for magnetization preparation, a repeated small 
flip angle (α) rapid gradient echo acquisition for data sampling, and a delay for 
magnetization recovery (Mugler and Brookeman, 1991). A whole MP-RAGE image is 
constructed by repeating the inner loop of the sequence until all k-space has been 
collected (Mugler and Brookeman, 1990b).  
 
 
Figure 1-4. Illustration of the MP-RAGE pulse sequence. The inner loop of the 
MP-RAGE sequence consists of: a 180° inversion pulse followed; a period of inversion 
time (TI) for magnetization preparation; repetitive small flip angle (α) for data 
acquisition; and a delay time (TD) for recovery of magnetization. The sequence is 
repeated to build up the whole imaging data matrix in the k-space. The period between 
repeated small flip angle pulses is the repetition time (TR). The overall repetition time 
(TR0) includes the TI, data acquisition and TD. Ky indicates the number of phase 
encoding steps in the inner loop.  
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In MRI, the centre of k-space determines the vast majority of signal in the image and 
encodes the bulk of image shape, whereas the periphery of k-space contains spatial 
information which encodes the delineation of fine structures but only weak image 
signal. Therefore, the time from the centre of inversion pre-pulse to the acquisition of 
k-space central line in the data acquisition segment controls the SI of different tissues in 
the MP-RAGE image (Laffon et al., 2001). There are several methods for filling 
k-space including centric, linear, radial, spiral and parallel ordering (Paschal and 
Morris, 2004). Centric and linear orderings are two of the most common k-space filling 
methods used in MP-RAGE sequence (Figure 1-5). With centric ordering, the image 
acquisition starts from the centre of k-space and then toward the top and bottom of 
k-space. With linear ordering, the image acquisition starts from top to bottom of 
k-space.  Since some signal recovery occurs during data sampling, the ordering to 
acquire k-space data can affect accuracy of SI and sharpness of the MP-RAGE image. 
With linear ordering, the periphery of k-space is acquired first and results in a better 
delineation of details of the image. Thus, image quality is superior with linear than with 
centric phase encoding (Mugler and Brookeman, 1991). On the other hand, with centric 
ordering, the centre of k-space is acquired first and acquired SI is less likely to be 
affected by the repeated small flip angles. 
 
The image contrast (or SI difference) between two adjacent tissues allows us to 
delineate the tissue boundary. In MP-RAGE, the inversion preparation pulse is applied 
to enhance image contrast. Then, a series of small flip angle rapid gradient echo pulses 
are applied for data collection. MP-RAGE sequence is less susceptible to motion 
artefacts as it uses very short TR such that the data sampling period (TR × Ky) is 
relatively short. It needs to be noted that the repeated gradient echo pulses can result in 
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some signal recovery occurring during data sampling period such that small flip angles 
are chosen to minimize the effect (Holsinger and Riederer, 1990). Thus, flip angle also 
plays an important role in image contrast for the tissues of interest (Mugler and 
Brookeman, 1990). The overall repetition time (TR0) is used to allow recovery of 
longitudinal magnetization and prevent saturation effects in MP-RAGE sequence 
(Jivan et al., 1997). 
 
 
Figure 1-5. Illustration of MP-RAGE sequence with linear and centric k-space filling. 
The dotted box indicates the inversion time (TI). The grey bars indicate the delay time 
(TD). The numbers indicate the lines of k-space.  
 
1.6.3.4.2 T1 measurement 
Changes in SI provide a better temporal resolution of Mn2+ accumulation compared to 
changes in T1 values as the former takes less scan time. However, the MRI SI obtained 
from the tissue is influenced by experimental conditions, such as imaging parameters 
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and local magnetic field (Suranyi et al., 2007). Therefore, measurement of T1 provides 
a more robust method for determining tissue character. T1 measurement can be 
performed by using saturation recovery and inversion recovery (IR) methods. In 
addition, the MP-RAGE method may also be employed to provide a T1 value and is 
discussed (see below).  
 
Inversion recovery method 
The IR sequence consists of a 180° pulse to flip the bulk magnetization antiparallel to 
the static magnetic field, followed by a 90° pulse after a time TI. In IR sequences, 
recovery of longitudinal magnetization occurs within the time TR, before the next 
excitation pulse. The time for recovery of 95 % of the longitudinal magnetization is 
approximately 3 × T1 with about full recovery (99 %) for 5 × T1. The IR method is the 
gold standard for T1 measurement. The IR sequence is performed over a range of TI 
values and fitting the SI at different TIs to equation below (Gowland and Stevenson, 
2003):  
 
SI (TI) = A – B × 1/ TTIe−  -----------------  Equation 1 
When TR is  >> 5T1, the equation 1 can be simplified to equation 2. 
SI (TI) = A × (1-2 1/ TTIe− ) -----------------  Equation 2 
SI (TI) is signal intensity collected at TI 
A and B are constants 
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MRI images are magnitude images and so SI is always positive (magnitude data). 
However, polarity-restored data are needed for fitting the signal recovery curve to 
estimate the T1 value. Therefore, the polarity of the modulus data acquired by inversion 
recovery sequences needs to be restored before fitting to the signal recovery curve 
(Figure 1-6). The point at which SI is equal to zero is defined as the null point and the 
inversion time at the point is denoted as TInull. TInull is ~ 0.693 × T1. When MRI contrast 
agents are used, there is a positive correlation between the degree of contrast 
concentration and the SI obtained by T1-weighted sequences at TI ≥ TInull.   
 
       
0 1 2 3 4 5
0
Polarity-restored data
Magnitude data
TI / T1
Si
gn
al
 in
te
ns
ity
 
Figure 1-6. Magnitude and polarity-restored data obtained by the inversion recovery 
sequence. 
 
Saturation recovery method 
To measure T1 by saturation recovery, the sequence comprises of a repeated series of 
90° pulses to flip the magnetization into the x-y plane followed by a period of time (TR) 
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to allow recovery of the longitudinal magnetization. The saturation recovery method is 
performed over a range of TR values and fitting the obtained SI at different TRs to the 
equation SI (TR) = A× (1- 1/TTRe− ) to calculate T1 values. 
 
Magnetization prepared rapid gradient echo method 
The equations to fit the MP-RAGE SI data to the signal recovery curve for estimation of 
T1 values are complex (Deichmann et al., 2000; Jivan et al., 1997; Kingsley, 1999; 
Wright et al., 2008). However, the complex equations for fitting MP-RAGE data can be 
approximated to the same as the IR equation for T1 measurement when low flip angle 
and the overall image-repetition time (TR0) > 5 T1 are employed (Jivan et al., 1997). In 
appreciation of the approximation made for the calculation of the T1 value from 
MP-RAGE data, the T1 calculated is named T1-effective.   
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1.7 Analysis of tissue manganese (Mn) 
Each element consists of electrons, neutrons and protons. Protons and neutrons are 
found in the nucleus and electrons are located around the nucleus. Following excitation, 
atoms and molecules absorb and emit electromagnetic radiation at characteristic 
wavelengths (spectral lines). Atomic absorption spectrometry (AAS) is used to 
determine elemental composition by measuring the characteristic absorption of 
radiation passing through a sample (Atkins and De Paula, 2006a). Conversely, emission 
spectrometry techniques, such as x-ray fluorescence spectrometry (XRF, see section 
1.7.1), inductively coupled plasma atomic emission spectrometry (ICP-AES, see 1.7.2) 
and laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) 
measures the characteristic radiation emitted by a sample following excitation (Atkins 
and De Paula, 2006b).  Emission spectrometry has a lower detection limit of detection 
than AAA, but is more costly (Hill et al., 2002). These analytical methods measure the 
total Mn levels in samples and do not distinguish between the different oxidation states 
of Mn (Barceloux, 1999). In addition, it is worth noting that cross contamination during 
sample preparation and handling may be an error source during analysis of 
Mn-containing biological samples (Bolann et al., 2007). 
 
1.7.1 X-ray fluorescence (XRF)  
X-ray is a type of electromagnetic wave with extremely short wavelength. After an 
external excitation by x-ray, an electron is ejected from the inner shell of the atom, 
creating a vacancy. The vacancy is then filled by an electron from outer shell which 
loses energy corresponding to the difference in the energy levels involved. The energy 
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can be released in the form of an x-ray or transferred to another electron. XRF is based 
on measuring the fluorescence emitted from the elements in a sample following 
irradiation by x-rays (Pyle, 1996). While each element reveals its unique x-ray 
spectrum during this process, the acquired x-ray spectrum can be used to identify the 
unknown elements in a sample. It is a non-destructive analytical method and has been 
used to measure lead in bone in vivo (Todd and Chettle, 1994).   
 
1.7.2 Inductively coupled plasma atomic emission spectroscopy 
(ICP-AES)  
ICP-AES has been used to measure the metal content in biological samples (Frame and 
Uzgiris, 1998; Zhang et al., 2004). ICP-AES analysis is performed in solution samples 
and biological samples are usually digested with acids to get the metal into solutions. 
The resultant solution is then aerolised and atomised and exposed to high energy 
plasma with production of charged ions (Jarvis and Jarvis, 1992). The sample is excited 
by plasma, ionised gas, leading to electrons transiting to a higher energy state. As the 
electrons return to their previous low energy level, they emit electromagnetic radiation 
at a characteristic set of wavelengths. The wavelength of the emitted radiation depends 
on the difference between the excited energy level and the ground state. As each 
element has a unique set of energy levels, each element has a characteristic set of 
spectral lines. Finally, the optical signals emitted from the elements pass to a light 
detector and signals within the selected range of wavelengths are converted into 
electrical signals.  
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Spectral line overlap is a problem by ICP-AES. To avoid spectral interference, an 
analytical line is chosen to avoid overlapping by another element in the sample. Thus, 
the specific wavelengths in the spectrum indicate the elemental composition in a 
sample and the magnitude of the spectral signal provides the concentrations of the 
observed elements. The typical wavelength line used for Mn measurement is 257.610 
nm. The sensitivity of ICP-AES method is insufficient for extremely low elemental 
levels and very small sample sizes (Frame and Uzgirisb, 1998).  
 
1.7.3 Laser ablation inductively coupled plasma mass spectroscopy 
(LA-ICP-MS) 
Laser radiation may cause ablation, vaporization and excitation of solid samples and 
therefore a sample preparation method for elemental analysis (Arrowsmith, 1987). 
LA-ICP-MS uses a laser beam to scan and vaporize solid samples to the vapour phase 
for mass spectroscopy analysis. The scanning technique makes LA-ICP-MS a method 
for mapping the spatial distribution of elements with micron-level resolution (Becker, 
2002). Working with solution samples, it is easy to obtain suitable calibration and 
internal standardization for elemental analytic techniques (Arrowsmith, 1987). 
Therefore, the disadvantage of LA-ICP-MS method is the lack of internal standards and 
therefore it is difficult to obtain quantitative information (Arrowsmith, 1987; Becker, 
2002).  
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1.8 Hypothesis and aim 
The overall aim of this project is to develop and implement MRI techniques to assess 
location, quantity and function of β-cells in vivo. Specific hypotheses and aims for 
individual studies are listed below.  
 
1.8.1 Mouse pancreatic MRI 
The mouse pancreas is a thin and membrane-like organ spreading throughout the upper 
abdomen. Therefore, delineating and imaging the mouse pancreas in vivo by MRI is 
challenging.  
• To gain experience in discerning the pancreas from surrounding organs by MRI 
with the aid of gross anatomy knowledge 
• To explore and optimize MRI methodology for pancreatic imaging in viv. 
 
1.8.2 Validation of the quantitative MP-RAGE method in vitro 
The MP-RAGE sequence is suitable for in vivo pancreatic imaging as it provides 
improved tissue contrast and is less susceptible to motion. However, MP-RAGE MRI is 
not well-established for quantitative MRI assessment. Therefore, the ability of 
MP-RAGE MRI as a quantitative measurement tool for [Mn2+] was tested in this 
section.  
• To establish the dose-dependent relationship between MnCl2 concentration and 
T1/R1 values as measured by MP-RAGE MRI 
• To test the agreement between T1 values assessed by IR-SE and MP-RAGE 
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1.8.3 Pharmacokinetics of MnCl2 in vivo 
The purpose of this study was to assess dose-dependent tissue Mn2+ accumulation in 
vivo by MRI.  
• To establish the dose-dependent relationship between infused MnCl2 dose and 
tissue [Mn2+] by MP-RAGE MRI  
• To validate the MRI results by ICP-AES, non-MRI method,  
• To establish the tissue Mn2+ washout over time 
 
1.8.4 Glucose challenge experiments in vivo 
Mn2+ can act as a surrogate of Ca2+ as well as being a positive T1 contrast agent. These 
properties make MEMRI a quantitative method for assessing Ca2+-related cellular 
activities in excitable cells such as neurons and myocardiocytes. Glucose-stimulation 
of β-cells leads to an intracellular influx of Ca2+ and insulin secretion. Therefore, the 
glucose-stimulated β-cells activity may be detected by MEMRI. Here, the ability of 
MEMRI as an in vivo method to assess β-cell function was tested. 
• To assess activation of the functional β-cell mass in response to glucose 
stimulation in healthy mice by MEMRI 
• To identify a reduction of the functional β-cell mass in a diabetic mouse model 
by MEMRI 
• To correlate the Mn distribution measured by non-MRI methods, LA-ICP-MS 
and XRF, with islet distribution assessed histologically 
• To assess the effects of Mn2+ and STZ on pancreatic islets by histology and 
immunohistochemistry 
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• To apply MEMRI techniques to image Ca2+ in other insulin-target organs  
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2 Materials and methods  
2.1 Materials 
2.1.1 Animals 
Male C57BL/6 mice weighted 30g were obtained from Harlan UK (Bicester, Oxon, 
UK). Animal studies were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 (UK) under project licence numbers 70/6532 and 70/6656. All 
mice were housed in individually ventilated cages with 12 h of light and dark cycled 
(light on at 7 am and off at 7 pm) and with free access to standard chow (RM3, Special 
Diets Services Ltd, Essex, UK) and drinking water unless otherwise stated.  Shortage of 
animal supply occurred during this work and thus C57BL/6 mice weighted 23 g were 
ordered for the experiments after the pilot studies.  
 
2.1.2 Reagents 
Isoflurane was purchased from Baxter Healthcare Ltd. (Norfolk, UK). Glucose solution 
(50 % w/v) was obtained from Hameln Pharmaceuticals Ltd (Gloucester, UK). Sterile 
water was purchased from B. Braun Melsungen AG (Melsungen, Germany). Histoclear 
was purchased from Raymond A Lamb (East Sussex, UK). Absolute ethanol was 
obtained from Fisher Scientific Ltd. (Leicestershire, UK). Aristar nitric acid and 
concentrated Aristar perichloric acid were purchased from BDH (Poole, Dorset, UK).  
 
The following reagents were obtained from Sigma-Aldrich Co Ltd (Poole, Dorset, 
UK): molecular biology grade 1 M manganese chloride solution (manganese chloride 
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tetrahydrate, MnCl2.4H2O), streptozotocin powder (STZ, C8H15N3O7), 10 % neutral 
buffered formalin, hematoxylin  and eosin Y (H&E). (Note: STZ and formalin are 
carcinogens according to the Material Safety Data Sheet and were handled in a 
chemical fume hood.) 
 
The following reagents were obtained from Dako (Ely, Cambridgeshire, UK) for 
immunohistochemistry staining: guinea pig anti-insulin antibody (Dako A0561), 
biotinylated anti-goat/mouse/rabbit immunoglobulin (Dako E0453), streptavidin-biotin 
complex conjugated with horseradish peroxidase (Dako K0377), diaminobenzidine 
(DAB) substrate chromogen solution (Dako K4011), rabbit anti-glucagon antibody 
(Dako A0565) and biotinylated sheep anti-rabbit/goat/mouse immunoglobulin (Dako 
E0453).  
 
2.2 Equipment 
2.2.1 MRI equipment 
All MRI experiments were performed on a 4.7T VMRIS scanner (Varian Inc., Palo 
Alto, USA) and equipped with an actively shielded gradient coil (Magnex Scientific, 
Oxford, UK) with a maximal gradient strength of 40 G/cm and a rise time of 200 ms 
based at the Biological Imaging Centre (Clinical Sciences Centre, Imperial College 
London, UK). For MRI, a quadrature volume coil (35mm internal diameter, Magnetic 
Resonance Laboratories, Oxford, UK) was used. A plastic bed (home-built) was used to 
hold the animal, physiological monitoring equipment and infusion apparatus.  
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2.2.2 Physiological monitoring 
Physiological parameters, respiration and rectal temperature, were monitored using 
Model 1025 Monitoring and Gating System (Small Animal Instruments, Inc., NY, 
USA) during scanning. Body core temperature was maintained using warm air with an 
automated temperature control system integrated with the physiological monitoring 
equipment.  
 
2.2.3 Animal dosing 
1 mL syringes and 27G needles were obtained from Becton Dickinson SA (Madrid, 
Spain; Drogheda, Ireland). 27G butterfly needles and 24G plastic catheters were 
purchased from Hospira Inc. (Sligo, Ireland; Donegal Town, Ireland). Polyethylene 
tubing (inner diameter = 0.38 mm, outer diameter = 1.09 mm) was obtained from 
Portex Ltd (Kent, UK). For i.v. infusions, a PHD 2000 Syringe Pump (Harvard 
Apparatus, Holliston, MA, USA) was used and positioned outside the magnet. A 2.5 m 
long polyethylene tube was used to connect the syringe at the syringe pump to the 
butterfly needle implanted in the tail of the animal. For bolus i.p. injection of glucose or 
vehicle solutions during scanning, a 2 m long polyethylene tube was used to connect the 
i.p. catheter implanted in the peritoneal cavity of animals with the syringe located 
outside the magnet bore.   
 
 90
2.2.4 Blood glucose measurement 
The MediSense Optium Xceed Blood Glucose Meter (MediSense, Abbott 
Laboratories, Ireland) with Optium Plus test strips (Abbott Diabetes Care, Maidenhead, 
UK) was used to measure blood glucose concentrations.  
 
2.2.5 Analysis of manganese 
All the samples for analysis of Mn were prepared in the Biological Imaging Centre 
(Clinical Sciences Centre). Bulk tissue Mn analysis was performed by ICP-AES using 
SPECTRO CIROS VISION ICP spectrometer (SPECTRO Analytical Instruments, 
Inc., MA, USA) at the Centre for Analytic Sciences of Sheffield University in 
collaboration with Prof. Cameron McLeod. LA-ICP-MS was performed by using an 
HP-4500 (Agilent Technologies, Manchester, UK) inductively coupled plasma 
quadrupole mass spectrometer coupled to an Nd:YAG laser ablation system (UP-266 
Macro LA system, New Wave Research, Huntingdon, UK). XRF was performed on a 
Fluo X-ray fluorescence microprobe beamline at the ANKA synchrotron radiation 
facility (Karlsruhe, Germany) by Dr Po-Wah So. A 4 μm SPEX SamplePrep 
aluminium film was obtained from Ultralene® (New Jersey, U.S.A.) for XRF study.  
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2.3 Methods 
2.3.1 Gross anatomy of the mouse pancreas 
Pancreatic imaging in mice is challenging since the organ is a diffuse, but not a 
well-defined solid organ. Therefore, it is important to gain some experience in the 
anatomical features of the mouse pancreas prior to the MRI experiments. Examination 
of the pancreas through dissection of mouse cadavers may assist discemment of the 
mouse pancreas from the surrounding organs in MR images. Therefore, the gross 
anatomy of the mouse pancreas was correlated with MRI data. 
 
A male C57BL/6 mouse (~ 30 g) was fasted overnight (~ 18 h) by removal of food at 5 
pm prior to the day of scanning, but had free access to drinking water. The animal was 
killed by neck dislocation after the overnight fast and the abdominal cavity exposed. 
The anatomical relationship of the pancreas was examined and the photographs of the 
whole mouse were taken. 
 
2.3.2 Optimization of MRI 
2.3.2.1 Introduction 
The optimal pulse sequences for rodent pancreatic MRI are: short scan time to avoid 
motion artefacts, use of thin imaging slices to avoid partial volume averaging and high 
tissue contrast to visualize the pancreas from the surrounding tissues (see 1.6.3.1). 
Here, images were acquired with SE and MP-RAGE MRI sequences. The former is the 
most commonly used MRI pulse sequence and the latter is a 3D T1-weighted gradient 
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echo sequence, commonly used for abdominal imaging (Mugler and Brookeman, 
1990b). To minimize the effect of circadian variations in insulin secretion, all 
experiments were performed in the early light phase of the diurnal cycle. 
 
2.3.2.2 Spin echo 
2.3.2.2.1 Mouse cadaver imaging 
Male C57BL/6 mouse was fasted overnight (~ 18 h) by removal of food at 5 pm prior to 
the day of scanning but had free access to drinking water (n = 1, 21.6 g). The animal 
was killed by neck dislocation after the overnight fast and then placed in a plastic bed in 
a supine position with the mouse at the centre of the RF coil for MRI. MR images were 
performed with a standard SE sequence with different values of TR and TE. Imaging 
parameters were as follows: TR = 200, 300, 400, 500, 600, 700, 800, 900, 1000 and 
1200 ms; TE = 15, 20 and 30 ms; matrix size = 256 × 128; field of view (FOV) = 100 × 
50 mm, average = 2, 10 slices, 1 mm thickness and 0.5 mm gap.  
 
Regions of interest (ROIs) were manually placed by the same experienced operator in 
the splenic portion of the pancreas (the thickest part of the mouse pancreas), left renal 
cortex, left liver, left thigh muscle, spleen, myocardium, interscapular and epididymal 
fat (Figure 2-1). Each ROI was carefully selected in the centre of the organ to avoid 
partial volume effects and large vessels. ROIs for each organ were of the same size and 
location throughout the experiment within the same animal, but varied between 
individual animals. Areas of ROIs were ~ 2mm2 in the spleen, kidney and BAT; ~ 
3mm2 in the pancreas, WAT and heart; ~ 5mm2 in the liver and muscle. Analysis of 
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ROI was carried out using Image J software (Image J 1.3.1, NIH, USA). Differences in 
SI between the pancreas and its adjacent organs – the liver, left kidney and spleen, were 
calculated. It is worth noting that the ROIs were selected from a part but not the entirety 
of an organ of interest, and a non-experienced operator is likely to have difficulties in 
placing ROIs in the pancreas and adipose tissue.  
 
                 
Figure 2-1. Coronal MP-RAGE MRI images showing placement of regions of interest 
in the heart (H), left kidney (K), left liver (L), left thigh muscle (M), gastrosplenic 
portion of the pancreas (P), spleen (S), epididymal fat pad (white adipose tissue, WAT) 
and interscapular fat pad (brown adipose tissue, BAT) in a C57BL/6 mouse after 36 
min after the start of MnCl2 infusion (2 mM, 0.1 mL, 0.2 mL/h). 
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2.3.2.2.2 Anesthetized mice imaging 
Physiological motion resulting from respiration, the beating heart, and bowel peristalsis 
during abdominal MR scan can cause blurring and ghosting, leading to degradation of 
image quality. Image quality can be improved by respiratory gating which suppresses 
motion artefacts in abdominal MRI. In this study, respiratory movement was detected 
using a pneumatic pillow fixed to the abdomen of the mouse. In respiratory gating, the 
inspiration wave was utilized to trigger the imaging sequence so that images were 
acquired during expiration which is the relatively still phase of the respiratory cycle.  
 
Male C57BL/6 mouse was fasted overnight (n = 1, ~ 23 g before fasting) and 
anaesthesia induced with a mixture of 2 L/min oxygen and 4 % isoflurane, and 
maintained during scanning with 1 L/min oxygen and 1-2 % isoflurane via a nose cone. 
Scans were performed with the optimal parameters obtained previously in the mouse 
cadaver experiment (see section 2.3.2.2.1): TR = 900 ms, TE = 15 ms, matrix size = 256 
× 128; FOV = 100 × 50 mm, averages = 2, 10 slices, 1 mm thickness and 0.5 mm gap. 
During MR scanning, respiration and rectal temperature were continuously monitored. 
Core temperature was maintained by a warm air heating system with automated 
feedback control system at a set point of 37°C. ROIs were selected from the pancreas, 
kidney, liver and spleen as described previously (see section 2.3.2.2.1) and SI 
measured. SI differences between the pancreas and its adjacent organs – the liver, left 
kidney and spleen, were calculated.  
 
The same animal was then scanned with the same parameters, but with respiratory 
gating. Since the acquisition was triggered by the inspiration wave, TR in SE images 
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with respiratory gating was dependent on the respiratory rate. To achieve a constant TR 
of 900 ms, the depth of anaesthesia was controlled to maintain a respiratory rate of 67 
beats/min.  
 
2.3.2.3 MP-RAGE 
The MP-RAGE sequence was modified from a standard 3D gradient-echo sequence by 
incorporating a magnetization preparation pulse and a data acquisition loop.  
 
2.3.2.3.1 TI 
As mentioned previously (see section 1.6.3.4.2), the value of TI chosen needs to be 
greater than the TInull of tissues to obtain positive SI data. Further, the variation of SI or 
slope is the greatest around the null point. Therefore, the optimal TI needs to be set to 
be greater than the null point of the tissue with the longest T1. To detect the optimal TI 
value, different TI values were used in the MP-RAGE experiment.  
 
Male C57BL/6 mice were fasted overnight (n = 2, 21.6 ± 0.2 g) and anaesthetized as 
described previously (see section 2.3.2.2.2).  Imaging was performed without MnCl2 
infusion with parameters: TI = 10, 16, 27, 45, 73, 120, 200, 330, 540, 890, 1460, 2400 
ms; flip angles = 10°; TR = 10 ms; TE = 2.4 ms; TD = 2 s; 1 average, matrix size = 256 
× 128 × 64 and FOV = 100 × 50× 32 mm. ROIs were selected from the pancreas, 
kidney, liver, skeletal muscle, heart, spleen and epididymal fat as described previously 
(see section 2.3.2.2.1) and SI measured. Then, polarity of the SI data was restored 
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manually and fitted to the equation: SI (TI) = A – B × 1/ TTIe−  (see equation 1 in section 
1.6.3.4.2) using PRISM 4 (GraphPad Software, Inc., San Diego, CA, USA) where 100 
% longitudinal magnetization recovery was not assumed. 
 
2.3.2.3.2 Flip angle 
An optimal flip angle gives sufficient tissue contrast between the pancreas and 
surrounding organs for the delineation of the mouse pancreas. Therefore, the SI in 
tissues at different flip angles was measured and the difference in SI between the mouse 
pancreas and surrounding organs including the kidney, liver and spleen was also 
calculated.   
 
Male C57BL/6 mouse was fasted overnight (n = 1, ~ 23 g before overnight fasting) and 
anaesthetized as described previously (see section 2.3.2.2.2). MnCl2 solutions were 
prepared by dilution of the 1 M MnCl2 solution with different amount of sterile water. 
A 27 gauge butterfly cannula was inserted into the tail vein. Infusion of the MnCl2 
solution was performed using a syringe pump for delivery of MnCl2 solutions, 
 
MP-RAGE images were acquired prior to and 10-60 min after the end of MnCl2 
infusion (20 mM, 0.2 mL/h, 0.1 mL, taking 30 min) in the same animal with the same 
parameters. Imaging was performed before and after MnCl2 infusion with parameters: 
flip angles = 5°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45° or 50°; TR = 10 ms; TE = 2.4 ms; 
delay time (TD) = 2 s; TI = 740 ms; 1 average, matrix size = 256 × 128 × 64; and FOV 
= 80 × 40× 20 mm. ROIs were selected from the pancreas, kidney, liver and spleen as 
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described previously (see section 2.3.2.2.1) and SI measured. SI differences between 
the pancreas and its adjacent organs – the liver, left kidney and spleen were calculated. 
The same analysis was performed for both with and without MnCl2 infusion images.  
 
2.3.3 Validation of MP-RAGE T1 measurement 
Phantom studies were conducted to test agreement of T1 measurements by MP-RAGE 
and standard inversion recovery spin-echo (IR-SE) methods, the latter being the 
conventional method of measuring T1 (see section 1.6.3.4.2). Both methods were 
performed with TR (or TD) = 15 s (>> 5 × T1 of water) to allow full recovery of 
longitudinal magnetization. A MP-RAGE method with shorter scan time, 5 TIs and TD 
= 2 s, was also applied for comparison. MnCl2 solutions were prepared by dilution of 
the 1 M MnCl2 solution with different amounts of sterile water. Tubes containing 
MnCl2 solutions at concentrations of 0.04, 0.06, 0.08, 0.1, 0.12, 0.14, 0.16, 0.18, 0.2, 
0.22, 0.24, 0.3, 0.5 and 1 mM were placed in a sample holder for MRI.  
 
2.3.3.1 Inversion recovery spin-echo (IR-SE) 
T1 measurements were made using IR-SE with the follow parameters: TI = 20, 40, 60, 
80, 100, 140, 200, 300, 400, 500, 700, 900, 1200, 1500, 2000, 2500, 3000 and 4500 ms; 
TR = 15 s; TE = 11.97 ms; TD = 2000 ms; matrix size = 256 × 128; FOV = 90 × 45 mm; 
2 averages; 2 mm thickness and a single slice. The accuracy of the T1 measurement was 
improved by performing the experiment fully T1-relaxed with TR set at 15 s. Total 
acquisition time for all 18 images was 18 h. 
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2.3.3.2 MP-RAGE 
Imaging parameters for T1 measurement were as follows: TI = 100, 200, 500, 1000 and 
2400 ms; TR = 10 ms; TE = 2.4 ms; TD = 2 s; flip angle = 10°; 1 scan, matrix size = 256 
× 128 × 64; FOV = 80 × 40× 20 mm with a total scan time of ~ 22 min. T1 measurement 
was also performed with the same parameters except TD = 15 s and TI = 20, 40, 60, 80, 
100, 140, 200, 300, 400, 500, 700, 900, 1200, 1500, 2000, 2500, 3000 and 4500 ms with 
a total scan time of ~ 18 h. 
 
2.3.3.3 Imaging and data analysis 
To avoid partial volume effects, ROIs were placed in the centre for each tube. ROIs 
were of the same size for different tubes and placed at the same position for all scans 
using Image J (NIH, USA). Then, the SI data were measured from the ROIs, polarity of 
the modulus data was restored manually. 
 
For T1 estimation, MRI data by both IR-SE and MP-RAGE methods were fitted to the 
usual 3 parameter fit IR equation: SI (TI) = A – B × 1/ TTIe−  (see equation 1 in section 
1.6.3.4.2) using PRISM 4, where 100 % longitudinal magnetization recovery was not 
assumed. The measured T1 values by MP-RAGE MRI method were defined as 
T1-effective values. A scatter plot was made using PRISM 4 to investigate the 
relationship between T1-effective and T1 data obtained by IR-SE and MP-RAGE 
methods, respectively. A Bland-Altman plot was also displayed using PRISM 4 to 
compare T1 measurement methods by IR-SE and MP-RAGE.  
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2.3.4 Dose-dependent effects of MnCl2 
The effects of different MnCl2 doses on SI and T1 values measured by in vivo 
MP-RAGE MRI were established. Further, the T1 values by in vivo MP-RAGE MRI 
data was correlated with in vitro tissue [Mn] analysis by ICP-AES. The objective was to 
determine the appropriate MnCl2 dose for MEMRI of the pancreas. The dose needs to 
be as low as possible to avoid the potentially toxic effects of MnCl2 infusion, while still 
being capable of enhancing the activated pancreas, so that it is distinguishable from the 
non-activated pancreas. Imaging was performed in a serial manner to observe the 
change in enhancement in the pancreas with MnCl2 infusion. A static T1 measurement 
was also made at 36 mins after the start of MnCl2 infusion.  
 
2.3.4.1 Serial MEMRI 
2.3.4.1.1 Animal preparation 
Fifteen male C57BL/6 mice (19.7 ± 0.4 g) were fasted overnight and prepared for MRI 
as detailed previously (see section 2.3.2.2.2). Briefly, animals were anaesthetized and a 
cannula was inserted into the tail vein for infusion of MnCl2 at concentrations of 2, 5, 
10, 20 or 40 mM (n = 3/group) using a syringe pump (0.2 mL/h, 0.1 mL final volume) 
for 30 min. The highest MnCl2 dose (40 mM, 0.1 mL) employed in this study is 
equivalent to the LD50 for C57BL/6 mice, 38 mg/kg body weight (Silva et al., 2004).   
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2.3.4.1.2 MRI measurement  
MEMRI protocols in this thesis were modified from previous MEMRI studies in our 
group (Kuo et al., 2005; Kuo et al., 2007). MP-RAGE MRI was performed with the 
following parameters: TI = 740 ms, TR = 10 ms, TE = 2.4 ms, matrix size = 256 × 128 
× 64, FOV = 100 × 50 × 32 mm, flip angle = 10°, TD = 2 s, 1 scan and acquisition time 
was ~ 4 min. Three datasets were collected prior to MnCl2 infusion and 24 datasets 
during and after the end of infusion according to Figure 2-2. Data was collected for 96 
min after the start of infusion. 
 
 
Figure 2-2. Schematic of MEMRI protocol for determining dose-dependent SI changes 
over time. Prior to MRI, C57BL/6 mice were fasted overnight. After three baseline 
acquisitions, MnCl2 was given intravenously (i.v.) for a period of 30 min (2 mM, 0.1 
mL, 0.2 mL/h). Data were continuously recorded and 27 datasets acquired.  
 
2.3.4.1.3 Image analysis 
ROIs of the pancreas were selected and SI obtained as described previously (see section 
2.3.2.2.1). The baseline signal intensity (SI0) is the average SI of three MRI datasets 
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acquired before the start of MnCl2 infusion and SIt is the SI at time t (Kuo et al., 2005). 
The serial MEMRI data was presented as the percentage change in SI from baseline:  
% SI change = (SIt – SI0) / SI0 × 100 % 
The steady state signal enhancement was defined as the mean of the percentage changes 
in SI during t = 36-96 min after the start of MnCl2 infusion. 
 
2.3.4.2 T1 measurement 
2.3.4.2.1 Animal treatment 
A total of 26 male C57BL/6 mice (21.7 ± 0.2 g after fasting) were fasted overnight and 
animals prepared for MRI as detailed previously (see section 2.3.2.2.2), except six mice 
did not have a cannula implanted in the tail. The remaining animals were divided into 5 
groups (n = 4/group) and each group received MnCl2 at concentrations of 2, 5, 10, 20 or 
40 mM at a rate of 0.2 mL/h and a total infused volume of 0.1 mL for 30 min. There was 
no significant difference in body weight between all the groups.  
 
2.3.4.2.2 MRI measurement 
T1 measurements by MP-RAGE MRI were performed 6 min after the end of MnCl2 
infusion (or 36 min after induction of anaesthesia in non-MnCl2-treated animals) as in 
Figure 2-3. The following parameters were used: TI = 100, 200, 500, 1000 and 2400 ms; 
TR = 10 ms; TE = 2.4 ms, matrix size = 256 × 128 × 64, FOV = 80 × 40 × 20 mm, flip 
angle = 10°, TD = 2 s, 1 scan and total acquisition time was ~ 22 min (as in in vitro 
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study). A smaller FOV than that in serial MEMRI was used to allow isotropic 
resolution due to the upgrade of MRI software and improvement of animal bed.  
 
2.3.4.2.3 Image analysis 
SI data were measured from ROIs placed on the pancreas, kidney, liver, heart, spleen, 
muscle, epididymal fat and interscapular fat as described previously (see section 
2.3.2.2.1). T1-effective was calculated as detailed in section 2.3.3.3.  
 
Figure 2-3. Schematic of T1-effective measurement protocol by MP-RAGE. Prior to 
MRI, C57BL/6 mice are fasted overnight. MnCl2 is given intravenously (i.v.) for a 
period of 30 min. The T1-effective measurement was obtained from MRI data acquired 
6 min after the end of MnCl2 infusion.  
 
2.3.4.3 Correlation of tissue R1-effective and tissue [Mn]  
2.3.4.3.1 Animal treatment 
A total of 18 male C57BL/6 mice (22.0 ± 0.2 g after fasting) were fasted overnight and 
animals prepared for MRI as detailed previously (see section 2.3.2.2.2), except three 
mice did not have a cannula implanted in the tail. 15 of the animals were divided into 
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groups of three and each group received MnCl2 at concentrations of 2, 5, 10, 20 or 40 
mM at a rate of 0.2 mL/h and a total infused volume of 0.1 mL for 30 min. There was no 
significant difference in body weight between all the groups. T1 measurement was 
performed at 36 min after the start of MnCl2 infusion. Animals were euthanized by neck 
dislocation at 66 min after the start of MnCl2 infusion (see Figure 2-4). Tissues 
including the pancreas, kidney, liver, skeletal muscle, epididymal fat, spleen and heart 
were collected, immediately frozen with dry ice and then stored in a -80°C freezer prior 
to ICP-AES.  
 
2.3.4.3.2 MRI measurements and image analysis 
T1-effective measurements were performed by MP-RAGE method as before (section 
2.3.4.2) and T1-effective values were calculated for the pancreas, kidney, liver, heart, 
spleen, skeletal muscle and epididymal fat as described in section 2.3.4.2. R1-effective 
value was also calculated by taking the reciprocal value of T1-effective.  
  
Figure 2-4. Schematic of T1-effective measurement and tissue sampling. Prior to MRI, 
C57BL/6 mice were fasted overnight and MnCl2 given intravenously (i.v.) for a period 
of 30 min. T1-effective measurements were acquired 36-60 min after the start of MnCl2 
infusion. After scanning, animals were euthanized and tissues collected 66 min after the 
end of MnCl2 infusion. 
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2.3.4.3.3 ICP-AES 
Tissues were taken from storage and dried for 60 h at 110°C (n = 3/dose). The dried 
mass was weighed and digested with 3 ml of concentrated nitric acid and 0.5 mL of 
concentrated perichloric acid for 18 h in a fume-hood. For complete solubilisation, the 
acidified sample was heated as follows: 1 h at 120°C, 2 h at 150°C, 1 hr at 180°C and 2 
h at 200°C. Finally, the resulting solutions (0.5 mL) were diluted to a final volume of 10 
mL with 1 % nitric acid for analysis.  
 
Tissue [Mn] was determined by ICP-AES using a SPECTRO CIROS VISION ICP 
spectrometer. The Mn emission line Mn2+ at 257.611 nm was used as the analysis 
wavelength. The [Mn] in solution (μg/mL) was converted into μg/g using the dry-mass 
and solution volume of each sample.  
 
2.3.5 Tissue manganese washout 
The pharmacokinetic profile of Mn2+ after a systemic dose is essential for designing 
MEMRI protocols. However, so far there is no such in vivo information about the 
accumulation and washout of Mn2+ in mouse abdominal organs. To better understand 
its pharmacokinetic properties, wash-in and wash-out curves of Mn2+ in different 
organs were established by measuring T1-effective over time following MnCl2 infusion 
using MP-RAGE MRI.  
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2.3.5.1 Animal preparation 
Male C57BL/6 mice were fasted overnight (n = 3, 21.2 ± 0.3 g) and the animals 
prepared for MRI as detailed previously (see section 2.3.2.2.2). A single dose of MnCl2 
(2 mM, 0.2 mL/h, 0.1 mL) was infused through the i.v. cannula for 30 min. Animals 
were scanned 24 h prior to and 1, 4, 24, 48 and 120 h after the start of MnCl2 infusion 
(Figure 2-5). Mice were recovered from anaesthesia and had free access to standard 
chow between scanning. Anaesthesia was induced again for subsequent scanning.  
 
  
Figure 2-5. Schematic of MEMRI protocol for measuring temporal changes in tissue 
Mn2+ accumulation. The start of MnCl2 infusion was t = 0. Serial MP-RAGE MRI 
images were acquired 24 h prior to (-24 h) and at 1, 4, 24, 48 and 120 h after the start of 
MnCl2 infusion. Animals have no access to food from 18 h prior to MRI scanning. 
 
2.3.5.2 MRI measurement and image analysis 
MP-RAGE sequence was performed with parameters: TI = 100, 200, 300, 400, 500, 
600, 700, 800, 1200 and 3000 ms; TR = 10 ms; TE = 2.4 ms; TD = 3 s; flip angle = 10°; 
1 average, matrix size = 256 × 128 × 64; FOV = 80 × 40× 20 mm with a total scan time 
of ~ 60 min. SI data were measured from ROIs placed on the pancreas, kidney, liver and 
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muscle as described previously (see section 2.3.2.2.1). T1-effective values at different 
time points were calculated as in section 2.3.3.3.    
 
2.3.6 Glucose challenge experiments 
2.3.6.1 Healthy mice 
Intraperitoneal injection of 2 g/kg body weight dose of glucose has been shown to 
trigger β-cell insulin secretion in rodents. Therefore, the effect of glucose or water 
(vehicle, control) on changes in MEMRI SI over time and T1-effective values were 
monitored to determine whether either measurement type was capable of determining 
differences in β-cell activity in vivo. Also, the effect of MnCl2 on glucose levels was 
measured. Further, MEMRI and T1 measurement were also investigated in insulin 
targeted organs: skeletal muscle, liver and adipose tissues.  
 
2.3.6.1.1 Serial MEMRI 
Twelve C57BL/6 mice were fasted overnight and anaesthetized. Animals were 
prepared for MRI as detailed in section 2.3.2.2.2. MnCl2 (2 mM, 0.1 mL at 0.2 mL/h) 
was infused through the tail vein cannula for 30 min. For glucose challenge 
experiments, a 24 gauge radiopaque catheter was also implanted into the right lower 
quadrant of the peritoneal cavity for injection of glucose (50 % w/v, 2g/kg body weight, 
0.004 mL/g body weight) or sterile water (0.004 mL/g body weight) prior to placement 
in the magnetic bore for MRI. One group of mice (2 g/kg, n = 6, 20.1 ± 0.7 g) received 
i.p. injection of glucose solution and another group (control, n = 6, 21.3 ± 0.4 g) 
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received the equivalent amount of sterile water (0.004 mL/g body weight) water at 16 
min after the start of MnCl2 infusion as shown in Figure 2-6. 
 
Briefly, three MRI datasets were collected prior to MnCl2 infusion and 24 datasets 
during and after the end of infusion. Data was collected for 96 min after the start of 
infusion. MP-RAGE MRI was acquired with the parameters: TI = 740 ms, TR = 10 ms, 
TE = 2.4 ms, matrix size = 256 × 128 × 64, FOV = 100 × 50 × 32 mm, flip angle = 10°, 
TD = 2 s, 1 scan and acquisition time was ~ 4 min (as in section 2.3.4.1.2). SI data were 
measured from ROIs placed on the pancreas, left femur, liver and epididymal fat. 
Percentage change in SI was calculated as % SI change = (SIt – SI0) / SI0 × 100 % (as 
in section 2.3.4.1.3).  
 
  
Figure 2-6. Schematic of MEMRI protocol for signal intensity changes over time after 
glucose or vehicle stimuli. Prior to MRI, C57BL/6 mice are fasted overnight. After 
three baseline acquisitions, MnCl2 (2 mM, 0.1 mL, 0.2 mL/h) is given intravenously 
(i.v.) for a period of 30 min. Bolus i.p. injection of glucose or vehicle was given at 16 
min after the start of MnCl2 infusion. The time course is continued until a total of 27 
consecutive images have been acquired.  
 108
2.3.6.1.2 T1 measurement with delay time = 2 s 
Overnight-fasted C57BL/6 mice (n = 15) were treated with i.v. infusion of MnCl2 and 
i.p. injection of either sterile water (n = 7, 20.1 ± 0.6 g) or glucose solution (n = 8, 20.2 
± 0.8 g). T1 measurement was performed at 40-63 min after the start of MnCl2 infusion 
with the following parameters: TI = 100, 200, 500, 1000 and 2400 ms; TR = 10 ms; TE 
= 2.4 ms, matrix size = 256 × 128 × 64, FOV = 80 × 40 × 20 mm, flip angle = 10°, TD 
= 2 s, 1 scan and total acquisition time was ~ 22 min (as in in vitro study).   
 
  
Figure 2-7. Schematic of T1-effective measurement protocol. Prior to MRI, C57BL/6 
mice were fasted overnight. MnCl2 is given intravenously (i.v.) for a period of 30 min. 
Bolus i.p. injection of glucose or vehicle was given at 16 min after the start of MnCl2 
infusion. The T1-effective measurement is obtained from MRI data acquired 36-60 min 
after the start of MnCl2 infusion.  
 
SI data were measured from ROIs placed on the pancreas, muscle, liver and epididymal 
fat as described previously (see section 2.3.2.2.1). T1-effective values were calculated 
as in section 2.3.3.3. R1-effective value was also calculated by taking the reciprocal 
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value of T1-effective. These T1-effective data of the pancreas were also compared with 
that of non-MnCl2 treated group in section 2.3.4.2. Animals were euthanized by neck 
dislocation at 66 min after the start of MnCl2 infusion. Samples including pancreas, 
liver, skeletal muscle from left femur and epididymal fat were collected, immediately 
frozen with dry ice and then stored in a -80°C freezer prior to ICP-AES (see Figure 
2-7).  
 
2.3.6.1.3 T1 measurement with delay time = 3 s 
While skeletal muscle has a longer T1-effective values compared to other organs, a 
longer TR0 is required for recovery of longitudinal magnetization recovery. Therefore, 
T1-effective measurement was also performed in skeletal muscle with a longer TD (= 3 
s) to increase TR0.  
 
C57BL/6 mice (n = 12, 20.9 ± 0.2 g after overnight fasting) were treated as before (see 
2.3.6.1.2) and injected i.p. with water or glucose solution (n = 6/group). T1-effective 
values of skeletal muscle was acquired at 50-110 min after the start of MnCl2 (Figure 
2-8). MP-RAGE MRI was performed with parameters: TI = 100, 200, 300, 400, 500, 
600, 700, 800, 1200 and 3000 ms; TR = 10 ms; TE = 2.4 ms; TD = 3 s; flip angle = 10°; 
1 scan, matrix size = 256 × 128 × 64; FOV = 80 × 40× 20 mm with a total scan time of 
~ 60 min (as in section 2.3.5.2). SI data were measured from ROIs placed on skeletal 
muscle. T1-effective values were calculated as in section 2.3.3.3. R1-effective value was 
also calculated by taking the reciprocal value of T1-effective. 
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Figure 2-8. Schematic of T1-effective measurement protocol. Prior to MRI, C57BL/6 
mice were fasted overnight. MnCl2 is given intravenously (i.v.) for a period of 30 min. 
T1-effective values were obtained from MRI data acquired 50-110 min after the start of 
MnCl2 infusion.  
 
2.3.6.1.4 Tissue [Mn] by ICP-AES 
Pancreas, liver, left femoral muscle and epididymal fat from animals in section 
2.3.6.1.2 were collected at the end of MEMRI (66 min after the start of MnCl2 
infusion), immediately frozen with dry ice and then stored in a -80°C freezer prior to 
tissue [Mn] measurement by ICP-AES. ICP-AES was performed as in 2.3.4.3.3.   
 
Unfortunately, some of the tissue [Mn] obtained from left femoral muscle samples as 
above were below the detection limit of ICP-AES. Therefore, tissue [Mn] in skeletal 
muscle was reanalysed in samples collected from bilateral femoral muscles to increase 
the mass of samples. This was done in another batch of animals as below.  
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Overnight-fasted (18 h) mice received MnCl2 infusion and i.p. glucose (n = 10, 20.4 ± 
1.6 g) or water (n = 10, 20.3 ± 0.9 g), but not MRI scanning, were killed 66 min after the 
start of MnCl2 infusion as above (section 2.3.6.1.2). Additional mice (n = 4, 19.8 ± 0.9 
g) were used as baseline group without receiving i.p. and i.v. treatment. Bilateral 
femoral muscles from animals were collected, immediately frozen with dry ice and then 
stored in a -80°C freezer prior to ICP-AES.  
 
2.3.6.1.5 Tissue [Mn] by LA-ICP-MS: a pilot study 
Two C57BL/6 mice (~ 23 g) were fasted overnight for 18 h. Animals received MnCl2 
infusion (20 mM, 0.2 mL/h, 0.1 mL) and i.p. glucose or water were killed 66 min after 
the start of MnCl2 infusion as above (section 2.3.6.1.2). Samples including the pancreas 
and spleen were collected, immediately frozen with dry ice and then stored in a -80°C 
freezer. Prior to LA-ICP-MS, samples were embedded in OCT media (VWR, UK), and 
sections were cut at 5 μm using a cryostat.  
 
The laser ablation system was configured to perform multiple parallel line rasters to 
generate 2D mapping for elements. The laser was operated at a frequency of 10 Hz and 
a laser power of 1.25 mJ. The scan was performed in a raster pattern at a speed of 60 
μm/s with a laser beam diameter of 100 μm. The rasters were separated by 200μm to 
prevent contamination. Images were produced using Graphis software package 
(Kylebank Software Ltd, Ayr, UK). The isotopes 55Mn and 57Fe were monitored in a 
time-resolved mode by ICP-MS. H&E staining was performed on an adjacent section.  
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2.3.6.1.6 Tissue [Mn] by XRF: a pilot study 
Two C57BL/6 mice (~ 23 g) were fasted overnight for 18 h prior to being anaesthetised. 
Animals received MnCl2 infusion (2 mM, 0.2 mL/h, 0.1 mL) and i.p. glucose or water 
(as described in section 2.3.6.1.2).  The animals were killed 36 min after the start of 
MnCl2 infusion and the pancreas and spleen were harvested and fixed in 10 % neutral 
buffered formalin for 24-48 h. Then, the samples were processed and embedded in wax 
blocks. Paraffin-embedded specimens were cut at 5 µm thickness and sections prepared 
on slides, dried overnight, deparaffinized in xylene and re-hydrated in 100 % and 70 % 
ethanol for H&E staining to indicate islet location. An adjacent section was mounted 
onto XRF film for XRF.    
 
For XRF, the beam energy was tuned to 10 eV and focussed to 300 × 300 µm and 
scanned in a raster fashion.  Samples were mounted at a 45◦ angle with respect to the 
incoming X-ray beam in the plane of the orbiting electrons to minimize the scatter 
contribution to the detected signal. The data at each scan point is collected such that 
each point receives the same amount of incident radiation, and is in the form of a 
spectrum showing the characteristic radiation from elements in the sample.  The spectra 
are then fitted and peak areas quantified using AXIL (a programme that fits the element 
Kα and Kβ peaks under consideration, taking into account of line overlaps and subtracts 
the background) to quantify the iron content: 2D maps of iron distribution were 
constructed using IDL 7.0 (ITT Virtual Information Software).  
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2.3.6.2 Diabetic mouse model 
2.3.6.2.1 Induction of diabetes in a mouse model 
For induction of diabetes, male C57BL/6 mice (~ 27.8g) were injected i.p. with a single 
180 mg/kg dose of STZ (0.2 mL/mouse). STZ was formulated within 15 min prior to 
administration and injected at 2 pm without fasting of the animal. Blood glucose and 
body weight were measured 1 week prior to STZ injection, and at 1 and 3 weeks 
post-injection. Animals were included in the MEMRI study when a blood glucose level 
of ≥ 20 mM was measured; approximately 10-17 days after STZ injection.  
 
2.3.6.2.2 Serial MEMRI 
Overnight-fasted (18 h) STZ-treated diabetic mice were treated with i.v. infusion of 
MnCl2 and i.p. injection of either sterile water (n = 4, 24.4 ± 1.0 g) or glucose solution 
(n = 4, 23.9 ± 0.4 g) as for healthy mice (see section 2.3.6.1.1). Serial MEMRI and 
image analysis were performed as for healthy mice (see section 2.3.6.1.1). SI data were 
measured from ROIs placed on the pancreas, skeletal muscle and liver.  
 
2.3.6.3 The effect of MnCl2 on blood glucose levels 
In order to determine whether MnCl2 infusion affected blood glucose levels, we 
compared the blood glucose changes over time in response to exogenous glucose in 
control and MnCl2-treated mice.  
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Male C57BL/6 mice (n = 23, ~ 23 g) were fasted overnight (18 h) to achieve baseline 
blood glucose levels. Mice received a tail-vein infusion of MnCl2 (2 mM, 0.1 mL at 0.2 
mL/h) for 30 min. At 16 min after the start of MnCl2 infusion, an i.p. injection of 
glucose (2 g/kg) or water (n = 4/group) were given.  
 
A drop of blood was taken from the tail vein by tail vein puncture with a 27 G needle. 
Blood glucose levels were measured by applying a drop of blood (> 0.3 μL) directly to 
a test strip placed in a blood glucose meter. Samples were collected prior to and 32, 36, 
40, 44, 48, 52, 56 and 60 min after the start of MnCl2 infusion. Blood sampling was not 
performed during the period of MnCl2 administration so as to avoid disturbance of Mn 
delivery.  
 
Measurements were also taken at corresponding times in anaesthetized mice that 
received an i.p. injection of either glucose or water, but without MnCl2 infusion (n = 
5/group). For control, tail vein blood was also taken in a group of mice (n = 5) without 
any treatment and were also measured at the corresponding times. All the mice were not 
allowed to recover after the experimental procedures.  
 
2.3.7 Histological analysis of the pancreas 
C57BL/6 mice (~ 23 g) were fasted overnight and treated with or without i.v. infusion 
MnCl2 (2 mM, 0.1 mL at 0.2 mL/h) for 30 min (n = 2/group). The animals were killed 
by neck dislocation at 66 min after the start of MnCl2 infusion and pancreata removed. 
Additional two STZ-induced diabetic mice (~ 27 g, fed blood glucose ≥ 20 mM) 
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without treatment were also killed by neck dislocation and pancreata removed. Samples 
were prepared as describe in section 2.3.6.1.6. Three consecutive sections were 
obtained from each mouse pancreatic sample for H&E, insulin and glucagon staining. 
H&E staining was used to assess the distribution and morphology of pancreatic islets.  
 
Insulin staining was used to assess insulin-containing β-cells. Slides prepared above 
were incubated with guinea pig anti-insulin antibody (1:50) for 90 min at room 
temperature and then with biotinylated swine anti-goat/mouse/rabbit immunoglobulin 
(1:200) for 30 minutes. Visualization was achieved by streptavidin-biotin complex 
conjugated with horseradish peroxidase for 30 minutes followed by diaminobenzidine 
chromogen solution for 10 min.  
 
Glucagon staining was used to analyse glucagon-containing α-cells. Slides were 
incubated with rabbit anti-glucagon antibody (1:200) for 60 min at room temperature, 
with biotinylated sheep anti-rabbit/goat/mouse immunoglobulin (1:200) for 30 minutes. 
Visualization was achieved by streptavidin-biotin complex conjugated with 
horseradish peroxidase for 30 minutes followed by diaminobenzidine chromogen 
solution for 10 min.  
 
2.3.8 Statistical Analysis 
PRISM 4 was used to generate graphs and for data analysis. The t-test was used to 
compare the means of two groups. One-way ANOVA (with Bonferroni test) was used 
to compare means between three or more groups. All values are presented as mean ± 
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standard error of the mean (SEM). PRISM 4 was also used to generate scattered and 
Bland-Altman plot to show the agreement between T1 obtained by IR-SE method and 
T1-effective obtained by MP-RAGE method.  
 
In the SI time course studies, we tracked the SI over time in animals to examine the 
effect of MnCl2 and glucose, allowing the study of dynamic relationships and 
differences heterogeneity. Therefore, the collected data is longitudinal data and the 
temporal ordering of events is important because the values that are close in time within 
a subject are more alike than those that are far apart. Also, the observations on the same 
subject are likely to be positively correlated. Generalized estimating equations (GEEs) 
uses regression models for repeated measures, clustered or longitudinal data sets (Zeger 
and Liang, 1986). Therefore, time course MEMRI SI profiles were tested for significant 
differences using GEE and the Mann-Whitney test used to test groups at individual time 
points (Stata 10, Statacorp, Texas, USA).  
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3 Results 
3.1 Gross anatomy of the mouse pancreas 
The mouse pancreas is a thin and diffuse structure (Figure 3-1). The biggest and 
thickest part of the mouse pancreas is the gastrosplenic portion which makes contact 
with 4 organs: the spleen, stomach, liver and left kidney. It is situated medial to the 
spleen, ventral to the upper pole of the left kidney, and inferior to the stomach and liver. 
The central portion of the pancreas lies adjacent to the duodenal loop, begins at the 
duodenal bulb and ends at the duodenal ligament. The duodenal portion of the pancreas 
extends into the duodenal ligament. This is the thinnest part of the mouse pancreas and 
is adjacent to the jejunum and colon. Therefore, the ideal MRI experiment should allow 
good delineation of the tissue margin.  
 
                                   
Figure 3-1. (A) Anatomic location of the pancreas within the mouse abdomen. (B) 
Solid lines outline margins of the pancreas (P), liver (L) and spleen (S).  
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3.2 Optimization of MRI 
3.2.1 Spin echo 
3.2.1.1 The mouse cadaver imaging 
Optimization of T1-weighted SE images was first performed in the mouse cadaver to 
avoid the complication of motion artefacts. Figure 3-2 shows the SI differences 
between the pancreas and its surrounding organs, the kidney, liver and spleen, where 
various values of TR were used and TE values set at 15, 20 and 30 ms. The SI 
difference between the pancreas and spleen as well as between the pancreas and liver 
was high enough for image interpretation throughout the whole range of TR and TE 
values employed. The difference in the SI between tissues increased with increasing TR. 
In general, the SI difference between the pancreas and kidney was the lowest of the 
organs near the pancreas. The greatest SI difference was obtained at TR = 900 ms and 
TE = 15 ms and thus, these values were chosen as the optimal parameters to delineate 
the pancreas.  
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Figure 3-2. Signal intensity differences between pancreas and spleen (▼P-S), pancreas 
and liver (○ P-L), and pancreas and kidney (■ P-K) at TR = 200-1200 ms, TE = 15 ms, 
20 ms and 30 ms. (n = 1) 
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Figure 3-3A shows the optimal SE image of a mouse cadaver, image parameters were 
as follows: TR = 900 ms, TE = 15 ms, matrix = 256 × 128, FOV = 100 × 50 mm, 2 
averages, slice thickness = 1 mm and gap = 0.5 mm.  In the mouse cadaver, the 
gastrosplenic portion of the pancreas can be well-delineated with reference to a 
standard mouse atlas (Iwaki and Hayakawa, 2005) as can other organs in the mouse 
abdomen (Figure 3-3B). However, the boundaries of the biliary and duodenal portions 
of the pancreas were indistinct.  
 
  
Figure 3-3. Coronal spin-echo MRI images (TR/TE = 900/15 ms) of a mouse cadaver 
without (A) and with (B) outline of organ margins. G: stomach, K: kidney, L: liver, P: 
pancreas, S: spleen. 
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3.2.1.2 Anaesthetized mice imaging 
The optimized parameters for imaging the dead mouse pancreas (TR/TE = 900/15 ms) 
obtained in section 3.2.1.1 were applied to live anaesthetized mice imaging. Figure 
3-4A shows the SE image collected without respiratory gating. On this image, the 
boundaries between solid organs and hollow organs in the mouse abdomen are 
indistinct due to motion artefacts caused by respiration, bowel peristalsis and the 
beating heart. Respiratory gating was introduced into the SE sequence such that data 
was collecting during expiration when respiratory motion was minimal. The depth of 
anaesthesia was adjusted to maintain a fixed respiratory rate of 67 beats/min to achieve 
TR of 900 ms. Despite considerable efforts, the respiratory rate could not be controlled 
well enough throughout the acquisition with the respiratory rate varying between 60-83 
beats/min. Thus, tissue contrast between the pancreas and surrounding organs was 
insufficient to fully discern the pancreas (Figure 3-4B). However, motion artefacts 
were much less evident with respiratory gating and the margins of the liver, right 
kidney and paraspinal muscles could be readily identified (Figure 3-4B). 
 
                               
Figure 3-4. Coronal spin-echo MRI images of a live anaesthetized mouse without (A) 
and with (B) respiratory gating.  
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3.2.2 MP-RAGE  
Live anaesthetized mice were scanned using a MP-RAGE sequence, considered to be 
relatively less susceptible to motion artefacts (section 1.6.3.4). There was less motion 
blur in MP-RAGE images compared to SE images even without respiratory gating, 
(comparing Figure 3-5A and Figure 3-4A, respectively). Further, MP-RAGE images 
were found to have better tissue contrast than SEMS images (comparing Figure 3-5A 
and Figure 3-4B, respectively). The quality of the MP-RAGE images were good 
enough to allow delineation of the mouse pancreas from surrounding organs (Figure 
3-5B). Having established the MP-RAGE sequence was the better sequence for MRI of 
the mouse pancreas, parameters such as TI, flip angle and TD needed to be optimized 
prior to its use in subsequence MEMRI experiments.  
 
                
Figure 3-5. Coronal MP-RAGE MRI images of a live anaesthetized mouse without (A) 
and with (B) outline showing the organ margin. G: stomach, K: kidney, L: liver, P: 
pancrease and S: spleen. Arrowheads indicate phantoms.  
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3.2.2.1 TI 
To achieve a positive correlation between difference in SI and accumulation of contrast 
agent in the tissue, the TI needs to be greater than TInull. Therefore, the greatest TInull for 
the tissues of interest was used as the preferred TI. To determine the TInull, 
polarity-restored SI data at 12 different TIs in various tissues were fitted to signal 
recovery curve using equation 1: SI (TI) = A – B × 1/ TTIe− . TInull for the pancreas, 
muscle, spleen, kidney, liver, heart and epididymal fat were 500, 740, 680, 645, 600, 
670 and 90 ms, respectively (Figure 3-6, n = 2). Thus, the greatest TInull for these tissues 
was 740 ms and therefore a TI of 740 ms was chosen for subsequent experiments.  
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Figure 3-6. Signal recovery curves of various tissues obtained by MP-RAGE MRI (n = 
2). Skeletal muscle has the longest TInull value with a null point around TI = 740 ms. 
The dotted line indicates TI = 740 ms.  
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3.2.2.2 Flip angle 
The optimal flip angle provides greatest contrast between the pancreas and surrounding 
tissues as well as maintaining good image quality. Therefore, differences in SI between 
the pancreas and adjacent tissues at various flip angles with and without MnCl2 
administration were obtained and used to determine a flip angle for subsequent 
MP-RAGE experiments. MP-RAGE images with a range of flip angles (5-50°) were 
performed in the same C57BL/6 mouse (n = 1) prior to and at 40-90 min after the start 
of MnCl2 infusion (20 mM, 0.2 mL/h, 0.1 mL, taking 30 min). The MP-RAGE images 
with MnCl2 infusion were acquired during the steady state signal enhancement period, 
32-96 min after the start of MnCl2 infusion (Figure 3-16). Images with diagnostic 
quality were obtained within the range of flip angles = 5-45°. A flip angle of 50° 
produced images with significant blurring (Figure 3-7, signal level oscillations) and so 
the data was not analysed and higher flip angles were not used. 
 
                                             
Figure 3-7. Coronal MP-RAGE MRI images of an anesthetized mouse using a flip 
angle of 50°. Arrowheads indicate phantoms.   
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Figure 3-8 shows the SI data of different organs at flip angles of 5-45° obtained from 
MP-RAGE MRI of C57BL/6 mouse with and without MnCl2 infusion. In general, a 
similar trend in flip angle-dependent SI changes was observed for each tissue without 
and with MnCl2 infusion (Figure 3-8). MnCl2 infusion did not greatly affect the SI at 
different angles in the epididymal fat, interscapular fat and skeletal muscle (Figure 3-8).  
 
A loss of SI due to low flip angle was noted in all the organs whereas a loss of SI due to 
high flip angle was noted in the pancreas, muscle and heart (Figure 3-8). The magnitude 
of the measured SI increased over the flip angle range of 5-25° and then gradually 
decreased as flip angles decreased from 25 to 45° in the pancreas, muscle and heart 
(Figure 3-8). In the spleen, liver, kidney and interscapular fat, SI increased with 
increasing flip angle from 5° to 20°, reaching a plateau at flip angles of 20-45° (Figure 
3-8). SI increased with increasing flip angle at flip angle of 5-45° in the epididymal fat 
(Figure 3-8). In summary, SI increased with increasing flip angle until a flip angle of 
20-25° is reached. Then, SI plateaued or decreased gradually in all tissues except the 
epididymal fat.  
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Figure 3-8. Signal intensity changes at varying flip angles of different organs of a 
C57BL/6 mouse with and without MnCl2 infusion (n = 1).  
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Given that the main objective was to explore the use of MP-RAGE MRI to image β-cell 
activation and thus, the percentage increase in SI following MnCl2 administration in the 
pancreas must be taken into account. The percentage signal enhancement in the 
pancreas was 83-133 % over the flip angle range 2-45° after a MnCl2 dose (20 mM, 0.1 
mL, 0.2 mL/h) for 30 min (Figure 3-9, n = 1). The whole range flip angles provided a 
detectable change in SI in the pancreas following MnCl2 infusion.  
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Figure 3-9. Percentage change of signal intensity in the pancreas pre- and post-MnCl2 
infusion (20 mM, 0.1 mL, 0.2 mL/h) in an anesthetized mouse (n = 1). 
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While SI of the various organs are important, the tissue contrast between the pancreas 
and its adjacent organs is also crucial for MRI of the pancreas. Figure 3-10A shows the 
SI difference between the pancreas and its surrounding organs including the kidney, 
liver and spleen in MP-RAGE MRI images without MnCl2 administration. In general, 
SI differences increased over the flip angle range 5-15°, peaked at 15° and then 
decreased for values of 15-45°. Tissue contrast was highest between the pancreas and 
spleen, and lowest between the pancreas and kidney. The SI difference between the 
pancreas and spleen, and between pancreas and liver, was high enough throughout the 
range of flip angles for delineation of the pancreas from both the spleen and liver.  
 
After MnCl2 administration (Figure 3-10B), there was no clear trend of the SI 
difference between the pancreas and surrounding organs. However, the SI difference 
between the pancreas and surrounding organs was enough throughout the range of flip 
angles for delineation of the pancreas from the surrounding organs except at a flip angle 
5° at which there was no difference in the SI between the pancreas and liver. Therefore, 
a flip angle of 5° was not recommended according to Figure 3-10.  
 
MP-RAGE MRI is acquired with low flip angles. However, the acquired SI was low by 
using low flip angle (Figure 3-8). Figure 3-10 showed a flip angle of 10° was the 
smallest one which provided readily delineation of the pancreas from surrounding 
organs and also achieved adequate signal enhancement in the pancreas following 
MnCl2 infusion. Therefore, a flip angle of 10° was recommended as a compromise 
between delineation of the pancreas and signal enhancement following MnCl2 
administration. 
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Figure 3-10. Signal intensity differences between pancreas and its surrounding organs, 
the kidney, liver and spleen, at different flip angles in an anesthetized C57BL/6 mouse 
(n = 1) without and with MnCl2 enhancement.  
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3.2.2.2.1 Delay time (TD) 
The scan time for a MP-RAGE sequence is dependant on TR0 × phase encoding steps 
in outer loop, where TR0 = TI + (TR × phase encoding steps in inner loop) + TD. 
Clearly, TI, TD and matrix size affects scan time in MP-RAGE sequence. Ideally, TR0 
should be set to greater than 5 × T1 of longest T1 organ to achieve 99 % recovery of 
longitudinal magnetization 
 
Previously, T1 in the pancreas, kidney, liver, muscle and fat of mouse cadavers have 
been measured to be ~ 550, 800, 625, 825 and 400 ms, respectively by using IR-SE in 
our group by Sahuri and Herlihy (personal communication 2007). In this case, the 
highest T1 is ~ 825 ms in skeletal muscle. Thus, TR0 should be 825 ms × 5 = 4125 ms. 
With imaging parameters of TI = 740 ms, TD = 2000 ms and matrix size = 256 × 128 × 
64, the resultant TR0 in MP-RAGE sequence is 3380 ms which is > 6 × T1 for the 
pancreas and > 4 × T1 for skeletal muscle  (linear ordering). Thus, TD was set to be 
2000 ms as a compromise between shortening scan time and fully longitudinal 
magnetization relaxation.  
 
3.2.2.3    Summary 
The optimized MP-RAGE MRI parameters were as follows: TI = 740 ms, flip angle = 
10°, TD = 2000 ms, FOV = 100 × 50 × 32 mm (or 80 × 40 × 20 mm), matrix = 256 × 
128 × 64 mm and 1 scan. With these parameters, the majority of the mouse pancreas 
can be delineated from the surrounding tissues with MnCl2 infusion (Figure 3-11). 
Employment of respiratory and cardiac gating provides images with less motion 
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artefacts. However, it results in a range of TI in the MP-RAGE image. Since 
MP-RAGE MRI was shown to provide diagnostic-quality images, respiratory and 
cardiac gating was not employed to the sequence.  
 
 
Figure 3-11. Consecutive coronal MP-RAGE MRI images showing the pancreas of a 
C57BL/5 mouse at 40-90 min after the start of MnCl2 infusion in vivo. Note: Solid lines 
demostrate the margin of the mouse pancreas 
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3.3 Validation of MP-RAGE T1 measurement   
IR-SE is the accepted standard for determining T1 values. However, as discussed 
previously, SE-based images failed to delineate the mouse pancreas from the 
surrounding tissues. Therefore, the possibility of using MP-RAGE MRI for T1 
measurement was explored. In this study, an in vitro experiment was performed to 
determine the application of the MP-RAGE method for measurement of T1. The 
acquired MP-RAGE data were fitted to the equation 1: SI (TI) = A – B × 1/ TTIe−  for T1 
estimation and the resultant T1 values were defined as T1-effective to distinguish the T1 
measurement form that obtained by IR-SE.  
 
Three T1 measurement methods were performed in samples containing MnCl2 solutions 
at the concentrations of 0.04-1.00 mM: (1) IR-SE method with 18 data points and TR = 
15 s, (2) MP-RAGE method with 18 data points and TD = 15 s and (3) MP-RAGE 
method with 5 data points and TD = 2 s. The first two methods used a long TR or TD up 
to 15 s to achieve full recovery of longitudinal magnetization (> 5 × T1 of all samples). 
The third method used a shorter TD and therefore achieved lesser degree of 
longitudinal magnetization recovery.  
 
The IR-SE and MP-RAGE data acquired with different TI values were found to be 
well-described by the IR equation (equation 1, see above) with a goodness of fit (R2) > 
0.99 at MnCl2 concentrations of 0.04-1.00 mM even by the MP-RAGE method with a 
shorter TD of 2 s (Figure 3-12). Therefore, the IR equation may be applied to fit the 
MP-RAGE MRI data at various TIs for obtaining T1 values. 
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Figure 3-12. Polarity-restored signal recovery curves obtained for 3 different 
concentrations of MnCl2 solutions by MP-RAGE method with TD = 2 s.  
 
By these three T1 measurement methods, increasing [Mn] led to a decrease in T1 and 
T1-effective (Figure 3-13), consistent with the use of MnCl2 as a MRI contrast agent. In 
addition, there exists a good positive correlation between the R1 or R1-effective values 
and the MnCl2 concentrations by these three methods (R2 > 0.99, Figure 3-13). 
Therefore, these three methods can be used for a quantitative estimation of changes in 
[Mn2+] in vitro.  
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Figure 3-13. T1/T1-effective and R1/R1-effective values obtained by IR-SE method with 
TR = 15 s, MP-RAGE method with TD = 15 s and MP-RAGE method with TD = 2 s for 
increasing concentrations of MnCl2 solutions.  
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There is a strong positive correlation between the T1 values by IR-SE method with TR = 
15 s and T1-effective values obtained by MP-RAGE method with TD = 15 s for 
different concentration of MnCl2 solution (Figure 3-14A, R2 > 0.99). The mean 
difference of T1/T1-effective values obtained by these two methods is 1.5 % and the 
limits of agreement are from -5.8 to 8.8 % (Figure 3-14B). Thus, there is a good 
agreement in the IR-SE and MP-RAGE T1 measurement methods, when the full 
recovery of longitudinal magnetization is achieved.  
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Figure 3-14. Scatter plot (A) and Bland-Altman plot (B) of T1 and T1-effective values 
obtained by IR-SE method and MP-RAGE (TD = 15 s), respectively. Solid line in 
Bland-Altman plot represents the mean difference between measurements, and dashed 
lines represent 2 standard deviations above and below the mean difference.  
 
Figure 3-15A compares T1 values obtained by IR-SE method (TR = 15 s), and 
T1-effective values obtained by MP-RAGE method with TD = 2 s, for different 
concentrations of MnCl2, showing T1-effective values are higher than the 
corresponding T1 values. Thus, T1-effective values obtained by MP-RAGE method do 
 136
deviate from the true T1 as measured by standard IR-SE method) but T1 and 
T1-effective values are highly correlated (R2 > 0.99, Figure 3-15A). With the 
Bland-Altman plot, the level of agreement between the two methods, IR-SE and 
MP-RAGE, of measuring T1 values was assessed (see Figure 3-15B). The mean 
difference of T1/T1-effective values obtained by these two methods is 19.6 % and the 
limits of agreement are from 14.7 to 24.6 % (Figure 3-15B), indicating that the 
T1-effective values obtained by MP-RAGE tended to overestimate T1 values.  
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Figure 3-15. Scatter plot (A) and Bland-Altman plot (B) of T1 and T1-effective values 
obtained by IR-SE method and MP-RAGE (TD = 2 s), respectively. Solid line in 
Bland-Altman plot represents the mean difference between measurements, and dashed 
lines represent 2 standard deviations above and below the mean difference. 
 
Conventionally, tissue T1 values are measured using IR-SE. In this study, the 
MP-RAGE methods for T1 measurement (TD = 2 and 15 s) led to an overestimation of 
T1. There was a better agreement between the MP-RAGE T1 measurement method with 
TD = 15 and the IR-SE method (Figure 3-14B vs. Figure 3-15B). However, the scan 
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time should always take into consideration in in vivo MRI study. Therefore, MP-RAGE 
T1 measurement method with TD = 2 s was used for in vivo study as a compromise 
between accurate T1 value and scan time.  
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3.4 Dose-dependent effects of MnCl2  
3.4.1 Serial MEMRI 
Tissue SI changes following administration of different doses of MnCl2 (2, 5, 10, 20 
and 40 mM; 0.1 mL; 0.2 mL/h) is shown in Figure 3-16 (n = 3/group). All animals 
experienced an increase in respiratory rate within 4 min after all doses of MnCl2 
infusion, but respiratory rate reverted toward normal or below by the end of infusion. In 
general, SI rose during MnCl2 infusion and reached a maximum at the end of MnCl2 
infusion in the pancreas, kidney and liver (Figure 3-16A-C). The maximum 
enhancement plateau in these organs lasted until the latest time point of the experiment 
(~ 60 min after the end of MnCl2 infusion). There was a positive correlation between 
infused MnCl2 dose and SI changes in these organs which uptake Mn2+. Increasing the 
infused MnCl2 dose had a marked effect on the overall SI, but provided different shaped 
dose-response curves and saturation levels. In contrast to the relatively steady state of 
enhancement in the plateau phase in other organs, the plateau phase in the liver had 
greater fluctuations (Figure 3-16C).  
 
There was no such dose-dependent response after various MnCl2 doses in the skeletal 
muscle and spleen. In skeletal muscle, there was no significant difference between SI 
profiles following different doses of MnCl2 except after the administration 0.1 mL 
MnCl2 at 40 mM (Figure 3-16D). After the administration of 0.1 mL MnCl2 at 40 mM, 
there was an early wash-in and followed by gradual wash-out of SI in skeletal muscle 
(Figure 3-16D). In the spleen, there was a general increase in the SI profiles following 
MnCl2 infusion (Figure 3-16E). However, the steady-state signal enhancement in the 
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spleen was not correlated to the infused MnCl2. After the administration of 0.1 mL 
MnCl2 at 40 mM, the signal enhancement pattern in the spleen was similar to that in 
skeletal muscle.  
 
In the heart, epididymal fat and interscapular fat, SI data could not be measured from 
the same ROI throughout the entire serial MEMRI due to motion artefacts and the data 
was not included here. 
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Figure 3-16. Dose-dependent signal intensity time-course in the (A) pancreas, (B) 
kidney, (C) liver, (D) muscle and  (E) spleen following MnCl2 infusion (n = 3/group). 
The grey bar indicates the duration of MnCl2 infusion. Data are presented as mean ± 
SEM. All graphs are plotted on the same scale. 
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Figure 3-16. Continued. 
 141
muscle
0 10 20 30 40 50 60 70 80 90 100
-100
0
100
200
300
400
500
600
700
Time (min)
Si
gn
al
 in
te
ns
ity
 c
ha
ng
e 
(%
)
spleen
0 10 20 30 40 50 60 70 80 90 100
-100
0
100
200
300
400
500
600
700
Time (min)
Si
gn
al
 in
te
ns
ity
 c
ha
ng
e 
(%
)
2 mM
5 mM
20 mM
40 mM
10 mM
2 mM
5 mM
20 mM
40 mM
10 mM
E
D
 
Figure 3-16. Continued. 
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3.4.2 T1 measurement  
Figure 3-17 shows the tissue T1-effective values after infusion of different doses (2, 5, 
10, 20 and 40 mM; 0.1 mL; 0.2 mL/h) of MnCl2 (n = 4/group). The control group 
consisted of 6 animals without contrast administration. T1-effective values were 
measured 36 min after the start of the MnCl2 infusion.  
 
T1-effective decreased with increasing MnCl2 doses in the pancreas, liver and kidney (p 
< 0.001, one-way ANOVA, Figure 3-17). In the heart and spleen, there was a 
dose-dependent relationship between infused MnCl2 doses and the decrease in 
T1-effective values, although this was non-linear. The highest dose of MnCl2 (40 mM, 
0.1 mL, 0.2 mL/h) in this study did not reach saturation in these organs. While in the 
epididymal fat, the T1-effective values remained unaffected throughout the whole 
MnCl2 dose range (P > 0.05, one-way ANOVA). The T1-effective values in skeletal 
muscle also remained unaffected at MnCl2 concentrations of 0-20 mM (P > 0.05, 
one-way ANOVA). The highest MnCl2 dose group in skeletal muscle was not 
compared here as the previous result (see Figure 3-16D) shows an increase in skeletal 
muscle SI after the administration of 0.1 mL MnCl2 at 40 mM. 
 
In the interscapular fat, there was a significant difference in T1-effective values between 
groups with different doses of MnCl2 infusion (P < 0.05, one-way ANOVA). However, 
there was not a correlation between infused MnCl2 doses and change in T1-effective 
values. Therefore, MRI data of the interscapular fat data obtained by this method may 
be unreliable for estimating tissue [Mn].   
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Figure 3-17. Dose-dependent T1-effective in mouse organs in increasing MnCl2 doses (2, 5, 10, 20 and 40 mM, 0.1 mL; n = 4/group). The 
control group were not infused (n = 6). ***= p < 0.001 by one-way ANOVA. Data are presented as mean ± SEM. 
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3.4.3 Tissue [Mn] analysis by ICP-AES 
Tissue Mn assessed by ICP-AES showed increasing tissue [Mn] with increasing 
infused MnCl2 doses (n = 3/group) for the kidney, pancreas, liver and heart (Figure 
3-18A). The strong positive linear correlation in the pancreas (R2 = 0.9714), kidney (R2 
= 09775), liver (R2 = 0.9237) and heart (R2 = 0.9598) indicates a dose-dependent Mn 
uptake. In addition, greater Mn accumulation was observed in the liver, kidney and 
pancreas compared to the heart (Figure 3-18A).  
 
In the spleen, skeletal muscle and epididymal fat, infusion of up to 40 mM of MnCl2 
had no significant effect on the concentrations of Mn by ICP-AES (Figure 3-18B). 
Tissue [Mn] was greater in these tissues in which the animals received MnCl2 infusion 
compared to that not infused with MnCl2, however, a dose-dependent effect was not 
observed (Figure 3-18B). 
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Figure 3-18. Dose-dependent changes in tissue manganese concentrations as measured 
by ICP-AES (n = 3/group). Data are presented as mean ± SEM. 
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3.4.4 Correlation of tissue R1-effective with tissue [Mn] 
As [Mn] increased, the R1-effective values also increased in the pancreas, kidney, liver 
and heart (Figure 3-19). A strong linear correlation between R1-effective values and 
tissue Mn content, as measured by ICP-AES, was obtained in the pancreas (R2 = 
0.7129), kidney (R2 = 0.8563) and heart (R2 = 0.8070) (Figure 3-19). There were two 
different slopes for fitting the linear dose response curve in the liver. The correlation for 
the liver R1-effective values and tissue [Mn] was 0.7527 for doses ranging 2-20 mM of 
MnCl2. At MnCl2 infused doses greater than 20 mM, there appeared to be a greater 
effect of tissue [Mn] on the R1-effective. This unexpected response may be explained if 
the relationship between R1 and [Mn] is non-linear. This may be the case, as in our in 
vitro study, we have only tested the R1-effective below 0.01 ms-1 (Figure 3-13B). It was 
not possible to determine if there was a linear response between R1-effective values and 
tissue Mn content in the spleen, skeletal muscle and epididymal fat since a wide range 
of [Mn] was not obtained at the different MnCl2 doses.  
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Figure 3-19. Correlation between R1-effective obtained by MP-RAGE and tissue 
manganese content by ICP-AES in the (A) pancreas, (B) kidney, (C) heart, (D) liver, 
(E) spleen, (F) muscle and (G) epididymal fat. Data are presented as mean ± SEM. 
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3.4.5 Summary 
Changes in T1-effective values and SI were both dose-dependent and tissue-variable 
except in the adipose tissue and skeletal muscle. Therefore, MP-RAGE MRI can be 
used to obtain semi-quantitative measurements of tissue [Mn] according to the SI and 
T1 measurement data. This is supported by in vitro tissue [Mn] measurement by 
ICP-AES. MnCl2 dose at a concentration of 2 mM, an infusion rate of 0.2 mL/h and a 
total volume of 0.1 mL (about 2 mg/kg) was found to be the lower infused dose 
providing significant signal enhancement in the pancreas. This is the optimal MnCl2 
dose to minimize toxicity but still provide adequate tissue contrast for localization of 
mouse pancreas by MRI. Further, this dose is well below the LD50 of i.v. MnCl2 at 38 
mg/kg (Silva et al., 2004), and so was used for subsequent in vivo studies. 
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3.5 Tissue manganese washout   
Tissue Mn2+ washout in the mouse organs were assessed by longitudinal measurements 
of T1-effective values. A single dose of MnCl2 infusion (2 mM, 0.2 mL/h, 0.1 mL) was 
infused and T1-effective measurements were performed 24 h prior to (- 24 h)  and 1, 4, 
24, 48 and 120 h after the start of MnCl2 infusion. Mice were recovered from 
anaesthesia and had free access to standard chow between scanning. All animals (n = 3) 
survived till the end of this experiment (120 h after MnCl2 infusion) without any 
obvious side effects.  
 
In the pancreas, kidney and liver, T1-effective values decreased rapidly after 
administration of MnCl2, remaining so for over 3 h and then gradually returning to 
baseline within 24 h (Figure 3-20A-C). There were no significant difference in 
T1-effective values between 1 h and 4 h after MnCl2 administration in these organs 
(Figure 3-20A-C, p = NS by one-way ANOVA with Bonferroni test). In addition, there 
were no significant difference in T1-effective values between 24 piror to (-24 h), 24, 48 
and 120 h after MnCl2 administration in these organs (Figure 3-20A-C, p = NS by 
one-way ANOVA with Bonferroni test). T1-effective values after MnCl2 administration 
were decreased by 31 %, 37 % and 33 % in the pancreas, kidney and liver, respectively. 
While in the muscle, there was no significant change of T1-effective values over time 
following MnCl2 administration, indicating no obvious Mn2+ uptake in these tissues 
(Figure 3-20D). 
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Figure 3-20. Tissue manganese washout in the pancreas (A), kidney (B), liver (C) and 
muscle (D) 24 h prior to and 1, 4, 24, 48 and 120 h after the start of  MnCl2 infusion, as 
presented by temporal T1-effective values. n = 3/group. * = p < 0.05, *** = p < 0.001 by 
one-way ANOVA with Bonferroni test. Data are presented as mean ± SEM. 
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3.6 Glucose challenge in healthy mice 
3.6.1 Healthy mice 
3.6.1.1 Pancreas 
3.6.1.1.1 Serial MEMRI 
Figure 3-21 shows the SI change over time following MnCl2 infusion in the 
glucose-stimulated (glucose, n = 6) and vehicle-stimulated (control, water, n = 6) 
pancreas. The SI in the pancreas continued to climb during the period of MnCl2 
infusion and reached a maximum SI value at the end of 30 min MnCl2 infusion. The 
maximum enhancement plateau lasted until the end of the experiment (96 min after the 
start of MnCl2 infusion). The SI profiles revealed a significantly greater SI in the 
pancreas of those mice receiving an i.p. injection of glucose compared to controls (p < 
0.05, GEE).  The SI change in glucose injected animals became significantly higher 
than that of controls at 4 minutes after the i.p. glucose injection and remained so for a 
further 40 min (p < 0.05, Mann-Whitney test). The pancreas of glucose-treated mice 
showed an increase in steady state signal enhancement compared to that of mice which 
received vehicle (67.5 % and 54 % in glucose-treated and vehicle-treated animals, 
respectively).  
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Figure 3-21. The percentage signal intensity change acquired by MP-RAGE following 
i.v. infusion of MnCl2 and i.p. bolus injection of glucose or water (control) in C57BL/6 
mice (n = 6/group). The grey bar indicates the start and duration of the i.v. MnCl2 
infusion. The arrow indicates the timing of the bolus i.p. injection of glucose or sterile 
water at 16 min; * = p < 0.05 by GEE. Data are presented as mean ± SEM. All serial 
MEMRI graph in the glucose challenge experiment are plotted on the same scale.  
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3.6.1.1.2 T1 measurements 
T1-effective values in glucose-stimulated (MnCl2 + glucose, n = 8) and non-stimulated 
pancreas (MnCl2 + water, n = 7) were performed at 10 min after the end of MnCl2 
infusion and were compared to T1-effective values measured in animals receiving no 
treatment (no MnCl2, n = 6). Following MnCl2 infusion and vehicle (water) treatment, 
T1-effective values decreased from 801.3 ± 22.0 ms to 661.0 ± 20.5 ms (p < 0.001, 
Figure 3-22A). With glucose stimulation, T1-effective values decreased further to 633.9 
± 20.3 ms. However, there is no significant difference between T1-effective values in 
mice receiving i.p. glucose or water injection after MnCl2 infusion (p = 0.37, Figure 
3-22A). R1-effective values in the pancreas increased significantly following MnCl2 
infusion (p < 0.01, Figure 3-22B). With glucose stimulation, a greater increase in 
R1-effective values was observed (p < 0.001, Figure 3-22B). However, no difference in 
R1-effective value was observed between mice receiving i.p. glucose or water injection 
after MnCl2 infusion (p = NS, Figure 3-22B). 
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Figure 3-22. T1-effective (A) and R1-effective (B) values of the pancreas in mice given 
no treatment (no MnCl2, n = 6); i.v. MnCl2 and i.p. water (MnCl2 + water, n = 7); and 
i.v. MnCl2 and i.p. glucose (MnCl2 + glucose, n = 8) groups. ** = p < 0.01, *** = p < 
0.01, NS = non-statistically significant by one-way ANOVA with Bonferroni test. Data 
are presented as mean ± SEM.  
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3.6.1.1.3 Tissue [Mn] by ICP-AES 
Tissue [Mn] as assessed by ICP-AES in the pancreas rose from 7.74 ± 0.64 µg/g (no 
MnCl2, n = 3) to 15.94 ± 0.86 µg/g (MnCl2 + water, n = 7) 66 min after the start of 
MnCl2 infusion (Figure 3-23, p < 0.01). With glucose stimulation, greater Mn2+ uptake 
was observed in the pancreas, with tissue [Mn] rising to 16.87 ± 1.3 µg/g (MnCl2 + 
glucose, n = 8; p < 0.001). No difference in tissue [Mn] was observed in mice receiving 
i.p. glucose or water injection after MnCl2 infusion (n = 8/group, p = 0.57). 
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Figure 3-23. Differences in pancreatic manganese content in animals given no 
treatment (no MnCl2, n = 3); with i.v. infusion of MnCl2 and i.p. injection of vehicle 
(MnCl2 + water, n = 7) or glucose (MnCl2 + glucose, n = 8). Samples were collected at 
36 min after the end of MnCl2 infusion. *** = p < 0.001, ** = p < 0.01, NS = 
non-statistically significant by one-way ANOVA with Bonferroni test. Data are 
presented as mean ± SEM. 
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3.6.1.1.4 LA-ICP-MS mapping: a pilot study 
The pancreas samples were collected at 66 min after the start of MnCl2 infusion in mice 
receiving i.v. MnCl2 infusion (20 mM, 0.2 mL/h, 0.1 mL) and i.p. injection of glucose 
or water (n = 1/group). LA-ICP-MS was performed at a resolution of 100 µm in the 
frozen section of mouse pancreas to illustrate Mn and iron distribution in vitro. The 
quality of H&E stained frozen sections (Figure 3-24) was not good enough to delineate 
the pancreatic islets but still gave information about the tissue margins of the pancreas 
and spleen. The Mn map shows a general higher level of Mn in the glucose-stimulated 
pancreas compared to that of vehicle-treated pancreas (Figure 3-24). Further, the 
glucose- and vehicle-treated samples analysed by LA-ICP-MS also contained spleen 
and Mn levels were found to be higher in the pancreas than the spleen in both glucose- 
and vehicle-treated samples. Mapping of the iron content of the samples showed that 
the spleen contained much higher amounts of iron than that in pancreata.  
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Figure 3-24. Comparison of LA-ICP-MS Mn and Fe maps with corresponding H&E 
staining of pancreas from C57BL/6 mice given an i.p. dose of glucose and water. Color 
bar indicates element counts per second.   
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3.6.1.1.5 XRF mapping: a pilot study 
The pancreas samples were collected at 36 min after the start of MnCl2 infusion in mice 
receiving i.v. MnCl2 infusion (2 mM, 0.2 mL/h, 0.1 mL) and i.p. injection of glucose or 
water (n = 1/group). XRF maps of Mn and Zn were obtained (resolution of 300 × 300 
µm) of the paraffin sections of mouse pancreas as well as the adjacent H&E stained 
section. β-cells are known to contain high amount of Zn and correlation between the Zn 
maps and the presence of islets were observed (Figure 3-25). However, the correlation 
is unclear due to the much lower resolution of the XRF maps compared to the H&E 
stained sections. A high degree of correlation was observed between Mn and Zn 
locations in the glucose-stimulated pancreas, compared to the control pancreas (Figure 
3-25). The correspondence is not exact and may arise from not all islets being activated 
following pancreas stimulation by glucose. Further, mean normalised Mn intensity was 
higher in the glucose-treated pancreas than the control, 3.17 ± 1.17 vs 1.67 ± 0.63, 
respectively.  
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Figure 3-25. Comparison of XRF Mn and Zn maps with corresponding H&E staining 
of pancreas from C57BL/6 mice give i.p. dose of glucose and water.  
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3.6.1.2 Skeletal muscle 
3.6.1.2.1 Serial MEMRI 
MEMRI was further used to measure Mn2+ uptake in skeletal muscle. Figure 3-26 
shows the effect of glucose on the SI over time in skeletal muscle in healthy mice. 
Immediately after the administration of MnCl2, there was a small peak in the SI profile 
in the glucose-stimulated and non-stimulated group (p > 0.05, Mann-Whitney test). 
Then, SI increase became faster, reaching a peak 20 min after glucose injection and 
remaining elevated until the end of the experiment. SI was increased by 20 % in the 
glucose-stimulated group (p = 0.006, GEE; n = 6/group). While in the control group, 
there was also a small signal enhancement peak in early phase of MnCl2 infusion, it 
then returned to baseline and remained so until the end of the experiment.  
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Figure 3-26. Signal intensity profiles in skeletal muscle following MnCl2 infusion (2 
mM, 0.1 mL, 0.2 mL/h) in healthy mice. The grey bar indicates the start and duration of 
the i.v. MnCl2 infusion. The arrow indicates the timing of the bolus i.p. injection of 
glucose or sterile water at 16 min. ** = p < 0.01 by GEE. Data are presented as mean ± 
SEM. All serial MEMRI graph in the glucose challenge experiment are plotted on the 
same scale.  
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3.6.1.2.2 T1 measurement 
In the skeletal muscle, T1-effective values were obtained at 40 min after the start of 
MnCl2 infusion using standard parameters. Both T1-effective and R1-effective values 
were not affected by the administration of MnCl2 (no MnCl2 vs. MnCl2 + water, Figure 
3-27, p > 0.05 by one-way ANOVA). There were generally lower T1-effective and 
higher R1-effective values in the muscle following glucose stimulation (at 16 min after 
the start of MnCl2 infusion). However, the difference did not reach statistically 
significant (MnCl2 + glucose vs. MnCl2 + water, Figure 3-27, p > 0.05 by one-way 
ANOVA)  
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Figure 3-27 T1-effective (A) and R1-effective (B) values of skeletal muscle obtained by 
MP-RAGE MRI (TD = 2 s) in animals given no treatment (no MnCl2, n = 6), i.v. MnCl2 
and i.p. water (MnCl2 + water, n = 7) and i.v. MnCl2 and i.p. glucose (MnCl2 + glucose, 
n = 8). NS = p > 0.05 by one-way ANOVA with Bonferroni test. Data are presented as 
mean ± SEM.  
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Since skeletal muscle has longer T1-effective values compared to the rest organs of 
interest and a longer TD (3 s) was also required to increase TR0. T1-effective values of 
skeletal muscle were obtained 50-110 min after the start of MnCl2 infusion and glucose 
stimulation was performed at 16 min after the start of MnCl2 infusion. Both 
T1-effective and R1-effective values were not affected by the stimulation of glucose 
following MnCl2 infusion (Figure 3-28A and B, p > 0.05 by t-test). 
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Figure 3-28. T1-effective and R1-effective values of skeletal muscle obtained by 
MP-RAGE MRI (TD = 3 s) in mice given MnCl2 and i.p. glucose (MnCl2 + glucose, n = 
6) or water (MnCl2 + water, n = 6). NS = p > 0.05 by t-test. Data are presented as mean 
± SEM.  
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3.6.1.2.3 Tissue [Mn] by ICP-AES 
Tissue [Mn] obtained at 66 min after the start of MnCl2 infusion rose from 0.89 ± 0.02 
µg/g (no MnCl2, n = 4) to 1.17 ± 0.02 µg/g (MnCl2 + water, n = 10) (p < 0.01). With 
glucose stimulation, tissue [Mn] rose further to 1.23 ± 0.06 µg/g (MnCl2 + glucose, n = 
10), however, this did not reach significance (Figure 3-29, p > 0.05 by one-way 
ANOVA with Bonferroni test). 
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Figure 3-29. Differences in manganese content in skeletal muscle in animals given no 
treatment (no MnCl2, n = 4); with i.v. infusion of MnCl2 and i.p. injection of vehicle 
(MnCl2 + water, n = 10) or glucose (MnCl2 + glucose, n = 10). Samples were collected 
36 min after the end of MnCl2 infusion. ** = p < 0.01, NS = non-statistically significant 
by one-way ANOVA with Bonferroni test. Data are presented as mean ± SEM. 
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3.6.1.3 Liver 
3.6.1.3.1 Serial MEMRI 
Figure 3-30 shows the SI change over time following MnCl2 infusion in the 
glucose-stimulated (glucose, n = 6) and vehicle-treated (control, n = 6) liver in healthy 
mice. SI in the liver continued to climb during the period of MnCl2 infusion and 
reached a maximum SI value at the end of the MnCl2 infusion, which plateaued and 
lasted until the end of the experiment (66 min after the end of MnCl2 infusion). The 
overall SI profiles revealed no significant change in SI in the liver receiving an i.p. 
injection of glucose compared to controls in healthy mice (p = 0.19, GEE; Figure 3-30).  
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Figure 3-30. Signal intensity profiles in the mouse liver following MnCl2 infusion (2 
mM, 0.1 mL, 0.2 mL/h) in healthy mice receiving i.p glucose (glucose) or vehicle 
(control). The grey bar indicates the start and duration of the i.v. MnCl2 infusion. The 
arrow indicates the timing of the bolus i.p. injection of glucose or sterile water at 16 
min. Signal intensity profiles were tested by GEE. All serial MEMRI graph in the 
glucose challenge experiment are plotted on the same scale.  
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3.6.1.3.2 T1 measurement 
T1-effective measurement was performed at 40 min after the start of MnCl2 (Figure 
3-31A). In the non-treated liver, the T1-effective value was 1160.0 ± 28.5 ms (no MnCl2, 
n = 6). After MnCl2 administration, T1-effective values were decreased to 731.3 ± 43.6 
ms in the glucose-stimulated liver (MnCl2 + glucose, n = 8) and 762.5 ± 69.5 ms in the 
vehicle-stimulated liver (MnCl2 + water, n = 7). Both T1-effective and R1-effective 
values were not affected by the stimulation of glucose following MnCl2 infusion 
(Figure 3-31, p > 0.05 by one-way ANOVA with Bonferroni test). 
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Figure 3-31. T1-effective (A) and R1-effective (B) values in the mouse liver given no 
treatment (no MnCl2, n = 6); i.v. MnCl2 and i.p. water (MnCl2 + water, n = 7); and i.v. 
MnCl2 and i.p. glucose (MnCl2 + glucose, n = 8) groups. ** = p < 0.01, *** = p < 0.01, 
NS = non-statistically significant by one-way ANOVA with Bonferroni test. Data are 
presented as mean ± SEM. 
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3.6.1.3.3 Tissue [Mn] by ICP-AES 
Tissue [Mn] in the liver was 5.3 ± 0.5 µg/g (no MnCl2, n = 3) in animals given no 
treatment (Figure 3-32). At 66 min after the start of MnCl2 infusion, tissue [Mn] in the 
liver rose to 11.1 ± 0.4 µg/g (MnCl2 + water, n = 7) in vehicle-stimulated mice and 10.7 
± 0.5 µg/g (MnCl2 + glucose, n = 8) in glucose-stimulated mice (Figure 3-32). 
However, no difference in tissue [Mn] was observed in mice receiving i.p. glucose or 
vehicle treatment after MnCl2 infusion (Figure 3-32, p > 0.05 by one-way ANOVA 
with Bonferroni test).  
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Figure 3-32. Differences in manganese content in the mouse liver given no treatment 
(no MnCl2, n = 3), with i.v. infusion of MnCl2 and i.p. injection of vehicle (MnCl2 + 
water, n = 7) or glucose (MnCl2 + glucose, n = 8). Samples were collected at 66 min 
after the start of MnCl2 infusion. *** = p < 0.001, NS = non-statistically significant by 
one-way ANOVA with Bonferroni test. Data are presented as mean ± SEM 
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3.6.1.4 Epididymal fat (white adipose tissue) 
3.6.1.4.1 Serial MEMRI 
As mentioned previously (see section 3.4.1), the SI measurements could not be 
obtained from the same ROI in the epididymal fat throughout a given scan set. After 
adjustment of ROIs, SI changes over time following MnCl2 infusion in the 
glucose-stimulated (glucose, n = 6) and vehicle-treated (control, n = 6) mice are shown 
in Figure 3-33. A significant difference in the SI profiles prior to administration of 
glucose and vehicle (Figure 3-33, p = 0.04 by GEE) can be observed. This probably 
arises from the inconsistency in ROI placement. With glucose stimulation, SI profiles 
was significantly low compared to control group (Figure 3-33, p = 0.01 by GEE). 
However, the data is not reliable as a significant difference in SI was found prior to the 
application of i.p. stimuli when both groups were treated with only MnCl2.  
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Figure 3-33. Signal intensity profiles in the mouse epididymal fat following MnCl2 
infusion (2 mM, 0.1 mL, 0.2 mL/h) in healthy mice receiving i.p glucose (glucose, n = 6) 
or vehicle (control, n = 6). Both figure (A) and (B) were plotted using the same data but 
with different scales on the vertical (y) axis. The grey bar indicates the start and 
duration of the i.v. MnCl2 infusion. The arrow indicates the timing of the bolus i.p. 
injection of glucose or sterile water at 16 min. Signal intensity profiles were tested by 
GEE. 
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3.6.1.4.2 T1 measurement 
T1-effective values measurements were obtained from the epididymal fat of 
glucose-stimulated (glucose, n = 8) and non-stimulated mice (control, n = 7) at 40 min 
after the start of MnCl2 infusion and were compared to those from animals not treated 
with MnCl2, glucose or water (no MnCl2, n = 6). All ROIs were selected from the same 
place for each animal. Following MnCl2 infusion and water injection, T1-effective 
values decreased from 231.4 ± 26.6 ms to 123.0 ± 27.5 ms (p < 0.05, Figure 3-34A). 
With glucose stimulation, T1-effective values were 166.8 ± 24.9 ms and not 
significantly different from the epididymal fat of animals having no treatment (p > 0.05, 
Figure 3-34A). No difference was observed in T1-effective values in mice receiving i.p. 
glucose or water injection after MnCl2 infusion (p > 0.05, Figure 3-34A). R1-effective 
values in the epididymal fat increased significantly following MnCl2 infusion (p < 0.01, 
Figure 3-34B). However, no difference in R1-effective value was observed between 
mice receiving i.p. glucose or water injection after MnCl2 infusion (p > 0.05, Figure 
3-34B). 
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Figure 3-34. T1-effective (A) and R1-effective (B) values of the epididymal fat in mice 
given no treatment (no MnCl2, n = 6), i.v. MnCl2 and i.p. water (MnCl2 + water, n = 7) 
and i.v. MnCl2 and i.p. glucose (MnCl2 + glucose, n = 8) groups. * = p < 0.05, NS = 
non-statistically significant by one-way ANOVA with Bonferroni test. Data are 
presented as mean ± SEM. 
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3.6.1.4.3 Tissue [Mn] by ICP-AES 
Even after MnCl2 infusion, tissue [Mn] in the epididymal fat was below the detection 
limit in 5 out of 15 samples and therefore, only the available data were analysed here. 
Tissue [Mn] in the epididymal fat appeared to decline from 0.16 ± 0.05 µg/g (MnCl2 + 
water, n = 5) to 0.09 ± 0.05 µg/g (MnCl2 + glucose, n = 5) following glucose 
stimulation although not significantlly (Figure 3-35, p > 0.05).  
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Figure 3-35. Differences in manganese content in the mouse epididymal fat given 
MnCl2 and i.p. glucose (MnCl2 + glucose, n = 5) or water (MnCl2 + water, n = 5). NS = 
non-statistically significant by t-test. Data are presented as mean ± SEM.  
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3.6.1.5 Interscapular fat (brown adipose tissue) 
3.6.1.5.1 Serial MEMRI 
The interscapular fat contains a mixture of WAT and BAT. The interscapular fat is a 
triangular-shaped fat pad between the scapulae and ROIs were placed here. In this 
experiment, the interscapular fat was discerned in 8 out of 12 animals and so only this 
data was analysed. Therefore, only the available data were analysed. Figure 3-36 shows 
the SI change over time following MnCl2 infusion in the glucose-stimulated (glucose, n 
= 5) and vehicle-treated (control, n = 3) mice. SI rose following MnCl2 infusion and 
immediately reached a maximum enhancement plateau at 4 min after the start of 
infusion. The maximum enhancement plateau lasted until the latest time point of the 
experiment (~ 96 min after the start of MnCl2 infusion). No significant change in SI 
profiles was observed between glucose-treated and control mice (Figure 3-36, p = 0.59 
by GEE).  
 
However, the SI in the interscapular fat could not be measured from the same ROI 
throughout a given serial MEMRI experiment. Moreover, dose-dependent T1 
measurement results in section 4.4.2 show that this MP-RAGE method may be 
unreliable in estimating T1 values in the interscapular fat. Therefore, SI profiles in the 
interscapular fat were not analysed further.   
 178
0 10 20 30 40 50 60 70 80 90 100
-25
0
25
50
75
100
125
150
175
Control (n=3)
Glucose (n=5)
MnCl2
Time (min)
Si
gn
al
 in
te
ns
ity
 c
ha
ng
e 
(%
)
i.p. glucose
or water
0 10 20 30 40 50 60 70 80 90 100
-2
-1
0
1
2
3
4
5
6
7
8
Control (n=3)
Glucose (n=5)
MnCl2
i.p. glucose
or water
p=0.59
Time (min)
Si
gn
al
 in
te
ns
ity
 c
ha
ng
e 
(%
)
A
B
 
Figure 3-36. Signal intensity profiles in the interscapular fat following MnCl2 infusion 
(2 mM, 0.1 mL, 0.2 mL/h) in mice receiving i.p glucose (glucose, n = 3) or vehicle 
(control, n = 5). Both figure (A) and (B) were plotted using the same data but with 
different scales on the vertical (y) axis. The grey bar indicates the start and duration of 
the i.v. MnCl2 infusion. The arrow indicates the timing of the bolus i.p. injection of 
glucose or sterile water at 16 min. Signal intensity profiles were tested by GEE. 
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3.6.1.6 Effect of MnCl2 infusion on blood glucose levels 
Serial blood glucose measurements were performed in anesthetized mice following 
overnight fasting. Blood samples were taken from the tail vein at the start and at 32, 36, 
40, 44, 48, 52, 56 and 60 min after the start of the experiment. Tail vein sampling was 
not performed in the first 30 min of the experiment when MnCl2 infusion was 
performed in some of the animals.  
 
 The initial mean blood glucose level of all animals at the start of this experiment was 
5.6 ± 0.3 mM (Figure 3-37, n = 23). There was a general increase in blood glucose 
levels over time in animals receiving no treatment (n = 5) and i.p. water injection (n = 4 
and 5 in animals with and without MnCl2 infusion, respectively), but the increase was 
not significant (Figure 3-37, p = NS by one-way ANOVA with Bonferroni test). In 
Figure 3-37, glucose i.p. injection resulted in a significant increase in blood glucose 
levels of up to 20 mM in C57BL/6 mice with and without MnCl2 infusion (n = 4 and 5, 
respectively; p < 0.001 by one-way ANOVA with Bonferroni test) compared to 
controls.  
 
The peak blood glucose levels were defined as the average blood glucose levels 
acquired at 32-60 min after the start of MnCl2 infusion or at the corresponding time. 
There was no significant difference in the mean peak blood glucose levels in animals 
receiving no treatment; i.p. water treatment; and MnCl2 infusion with i.p. water (Figure 
3-37, p = NS by one-way ANOVA with Bonferroni test). There was also no significant 
difference in the mean peak blood glucose levels of glucose-treated animals with 
without MnCl2 infusion (Figure 3-37, p = NS by t-test). In summary, intravenous 
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infusion of MnCl2 appeared to have no effect upon the blood glucose levels in control 
and that induced by i.p. injection of glucose.  
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Figure 3-37. Blood glucose levels following i.p. administration of glucose, water or 
non-i.p. administration in non-MnCl2 and MnCl2 infused mice. The grey bar indicates 
the start and duration of the i.v. MnCl2 infusion. The arrow indicates the timing of the 
bolus i.p. injection of glucose or water (n = 4-5/group). Data are presented as mean ± 
SEM. 
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3.6.2 Diabetic mouse model 
3.6.2.1 Pancreas 
3.6.2.1.1 Serial MEMRI 
Figure 3-38 shows the pancreatic SI changes over time following MnCl2 infusion in the 
glucose-stimulated (STZ + glucose) and vehicle-treated (STZ - control) diabetic mice 
(n = 4/group). SI rose during the period of MnCl2 infusion and reached a maximal value 
at ~ 40 min. The maximum enhancement plateau lasted until the end of the experiment, 
96 min after the start of infusion. The SI profiles in the pancreas were not significantly 
different between glucose-stimulated and control groups in the diabetic mice (p = 0.78, 
GEE).   
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Figure 3-38. The percentage signal intensity change in the pancreas following i.v. 
infusion of MnCl2 and i.p. bolus injection of glucose (STZ + glucose, n = 4) or vehicle 
(STZ - control, n = 4) in STZ-induced diabetic mice. The grey bar indicates the start and 
duration of the i.v. MnCl2 infusion. The arrow indicates the timing of the bolus i.p. 
injection of glucose or sterile water at 16 min. Signal intensity profiles were tested by 
GEE. Data are presented as mean ± SEM. All serial MEMRI graph in the glucose 
challenge experiment are plotted on the same scale.  
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3.6.2.2 Skeletal muscle 
3.6.2.2.1 Serial MEMRI 
In STZ-treated diabetic mice (Figure 3-39), there was a similar signal enhancement 
pattern in skeletal muscle as in healthy mice. There was no significant difference in SI 
in the glucose-stimulated (STZ + glucose, n = 4) and control groups (STZ – control, n = 
4) following MnCl2 infusion (Figure 3-39, p = 0.16 by GEE). 
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Figure 3-39. The percentage signal intensity change in skeletal muscle following i.v. 
infusion of MnCl2 and i.p. bolus injection of glucose (STZ + glucose, n = 4) or vehicle 
(STZ - control, n = 4) in STZ-induced diabetic mice. The grey bar indicates the start and 
duration of the i.v. MnCl2 infusion. The arrow indicates the timing of the bolus i.p. 
injection of glucose or sterile water at 16 min. Signal intensity profiles were tested by 
GEE. Data are presented as mean ± SEM. All serial MEMRI graph in the glucose 
challenge experiment are plotted on the same scale.  
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3.6.2.3 Liver 
3.6.2.3.1 Serial MEMRI 
Figure 3-40 shows the SI change over time following MnCl2 infusion in the 
glucose-stimulated and vehicle-stimulated (water, control) liver in STZ-treated mice. 
SI in the liver rose during the period of MnCl2 infusion and reached maximum SI value 
after 30 min. The maximum enhancement plateau lasted until the end of the experiment, 
96 min after the start of infusion. The overall SI profiles revealed no significant change 
in the liver of diabetic mice receiving an i.p. injection of glucose compared to those 
receiving i.p. injection of the vehicle (p = 0.82, GEE; n = 4/group; Figure 3-40).   
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Figure 3-40. The percentage signal intensity change in the livers following i.v. infusion 
of MnCl2 and i.p. bolus injection of glucose (STZ glucose, n = 4) or vehicle (STZ 
control, n = 4) in STZ-induced diabetic mice. The grey bar indicates the start and 
duration of the i.v. MnCl2 infusion. The arrow indicates the timing of the bolus i.p. 
injection of glucose or sterile water at 16 min. Signal intensity profiles were tested by 
GEE. All serial MEMRI graph in the glucose challenge experiment are plotted on the 
same scale.  
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3.7 Histology of the pancreas 
3.7.1 The effect of MnCl2 infusion on islet morphology 
In this study, mouse pancreatic sections were probed with insulin or glucagon antibody. 
Insulin-positive β-cells and glucagon-positive α-cells in pancreatic sections were 
stained brown by insulin and glucagon staining, respectively (Figure 3-41). The islets 
of control mice (no MnCl2) consisted mostly of insulin-positive cells while 
glucagon-positive α-cells were much less abundant (Figure 3-41A-C). Infusion of 
MnCl2 (2 mM, 0.1 mL) had no significant effect on islet morphology and cell numbers, 
as determined by H&E stain and immunostaining (Figure 3-41A-C versus D-F), 
indicating no sign of acute toxicity.  
        
 
Figure 3-41. H&E stain (A, D), insulin immunostain (B, E) and glucagon immunostain 
(C, F) of pancreas sections in C57BL/6 mice receiving no treatment (control, A-C) and 
MnCl2 infusion (2 mM, 0.1 mL; D-F). Note: H&E, insulin and glucagon stained islets 
represent different sections from the same islet. (× 40 magnification) 
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3.7.2 Histological assessment of the pancreas from diabetic mice 
The STZ-treated pancreas shows a reduction in islet numbers by H&E staining (Figure 
3-42). In addition, STZ-treated islets were distorted with macrophage infiltration 
around islets (Figure 3-42). Figure 3-43 D shows pyknotic nuclei, cytoplasmic 
degeneration and decreased cytoplasmic eosinophilia in the STZ-treated islets 
compared to controls (Figure 3-43A). Insulin staining shows a decrease in the number 
of the β-cells (Figure 3-43 E) in the pancreas of STZ-treated mice compared to those of 
non-STZ-treated mice (Figure 3-43B). In contrast, there was no α-cell loss in the 
pancreas of STZ-treated mice compared to those of non-STZ-treated mice, as shown by 
glucagon staining (Figure 3-43 F v.s Figure 3-43C).  
 
 
Figure 3-42. H&E staining of normal (control) and STZ-treated mouse pancreas. The 
islets of Langerhans (light red, arrow) are surrounded by exocrine pancreas (darker 
purple), scattered throughout the pancreas. (× 2.5 magnification) 
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Figure 3-43. Pancreatic islet of control (A-C) and STZ-treated C57BL/6 mice stained 
by H&E stain (A, D), insulin immunostain (B, E) and glucagon immunostain (C, F). (× 
40 magnification) 
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4 Discussion 
4.1 Gross anatomy of the mouse pancreas 
The human pancreas is a solid organ located in the retroperitoneal cavity. MRI plays an 
important role in medical imaging of the human pancreas (Semelka and Ascher, 1993). 
However, imaging the mouse pancreas by MRI in situ is challenging as the mouse 
pancreas is a diffuse organ (Kara, 2005). Therefore, partial volume effect and motion 
artefacts can degrade the image quality of the mouse pancreas. The study of the gross 
anatomy is essential for the interpretation of the mouse pancreatic MR images (Grimm 
et al., 2003). In this study, the mouse pancreas was indeed found to be a thin and diffuse 
organ closely adjacent to the spleen, stomach, liver, upper poles of left kidney, 
duodenum, jejunum and colon (Figure 3-1).  
 
The thickest part of the mouse pancreas was found to be the gastrosplenic portion 
situated medial to the splenic hilum and ventral to the upper pole of the left kidney. The 
spleen and left kidney are solid organs and therefore the delineation of these two organs 
on MR images is possible.  Localization of the spleen and left kidney was found to be 
useful in discerning the gastrosplenic portion of pancreas on MR images based in our 
experience.   
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4.2 Optimization of MRI 
The SE sequence is one of the most commonly used MRI sequences. However, the 
pancreas in mice in vivo was not readily delineated in the optimized SE sequence 
without respiratory gating. The image quality of the mouse pancreas was poor due to 
significant motion artefacts from the beating heart, respiration and bowel peristalsis 
when respiratory gating was not employed in SE sequences. With respiratory gating, 
SE images are capable of delineating the gastrosplenic portion of the pancreas, 
although blurred boundaries for the biliary and duodenal pancreas are still produced. 
While employment of respiratory gating significantly improved image quality, the 
difficulty in maintaining a fixed respiratory rate led to effectively a range of TR values 
and therefore degradation in image quality. The SE sequence was limited in providing 
good delineation between the whole of the pancreas and surrounding tissues. Thus, it is 
not an ideal MRI method for imaging the mouse pancreas in situ.  
 
The MP-RAGE MRI sequence is widely used for abdominal imaging (Mugler and 
Brookeman, 1990b) and brain morphology (Good et al., 2001; van der Kouwe et al., 
2008). The MP-RAGE method is less prone to detrimental motion artefacts due to the 
nature and order of data acquisition (Lee and Price, 1994; Mugler and Brookeman, 
1990b). We used a gradient echo based MP-RAGE sequence and demonstrated it to be 
superior to the SE sequence in delineating the mouse pancreas from adjacent organs. 
This is attributable to both improved contrast as well as less motion artefacts, even 
without respiratory gating.  
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Having established the superiority of the MP-RAGE sequence for imaging the mouse 
pancreas in situ, imaging parameters of the sequence including TI, flip angle and TD 
needed to be optimized. In order to achieve positive correlation between the changes in 
SI and tissue Mn2+ uptake, the TI value in serial MP-RAGE MRI had to be set to a value 
not less than the TInull of the organs of interest. The signal recovery graphs show that 
skeletal muscle had the longest T1 value of all the organs of interest (see Figure 3-6). 
The TInull of skeletal muscle was approximately equivalent to 740 ms according to our 
study (see Figure 3-6). Therefore, the TI value in serial MP-RAGE MRI was set to 740 
ms to achieve positive correlation between the changes in SI and tissue Mn2+ uptake.  
 
The flip angle used is a major factor affecting SI in MP-RAGE images with lower SI at 
low flip angle in all the organs (see Figure 3-8). Flip angles above 25° did not increase 
SI, suggesting this to be the optimum value for our studies. However, even this flip 
angle can lead to artefacts such as blurring (Lee and Price, 1994). Previous studies have 
suggested a flip angle of less than 10-12° for the MP-RAGE MRI sequence 
(Deichmann et al., 2000; Deichmann and Haase, 1992; Jivan et al., 1997) and thus, we 
employed a flip angle of 10° for imaging the mouse pancreas.  
 
To measure T1 values, a TR0 > 5 × T1 needs to be used for MP-RAGE MRI to allow full 
T1-relaxation and prevent underestimation of R1 values (Jivan et al., 1997). However, 
longer TR0 results in prolonged scan times. As a compromise between shortening scan 
time and allowing full relaxation of longitudinal magnetization, the TD was set to be 
2000 ms. Based on the T1 measurement results by Sahuri and Herlihy (personal 
communication, 2007), the T1 values in the pancreas, kidney, liver, muscle and fat of 
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mouse cadavers were ~ 550, 800, 625, 825 and 400 ms, respectively, using the IR-SE 
method. Therefore, based on their T1-measurements, our MP-RAGE T1-measurements 
using a TD value = 2 s gives TR0 is > 6 × T1 for the pancreas and > 4 × T1 for skeletal 
muscle in the non-MnCl2-treated mouse cadavers. In our study, there was an 
overestimation of T1-effective values by MP-RAGE. In the case, TR0 was ~ 4 × 
T1-effective for the pancreas and ~ 2 × T1-effective for skeletal muscle in the 
non-MnCl2-treated mice (Figure 3-17).  
 
In summary, the optimized parameters for serial MP-RAGE MRI were: TI = 740 ms, 
flip angle = 10°, TD = 2000 ms, FOV = 100 × 50 × 32 mm (or 80 × 40 × 20 mm), matrix 
= 256 × 128 × 64 mm and 1 scan with a scan time of 4 min. With optimized parameters, 
MP-RAGE MRI can readily delineate the whole mouse pancreas as well as other mouse 
abdominal organs. Thus, the MP-RAGE sequence was chosen for imaging the mouse 
pancreas in vivo in the present study. 
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4.3 Validation of MP-RAGE T1 measurement 
In order to be able to measure the T1 values of the mouse pancreas, it is necessary to use 
a pulse sequence that provides high resolution images with diagnostic quality. As we 
have shown, SE MRI is inadequate for the delineation of the mouse pancreas. 
MP-RAGE MRI provides excellent delineation and good contrast of abdominal organs 
but the relationship between SI and T1 measurement is complex (Deichmann et al., 
2000; Jivan et al., 1997; Kingsley, 1999; Wright et al., 2008). However, the MP-RAGE 
T1 measurement equation can be simplified to the standard IR equation: SI (TI) = A – B 
× 1/ TTIe−  when low flip angles and the overall image-repetition time (TR0) > 5 T1 are 
employed (Jivan et al., 1997). The calculated T1 values by fitting the MP-RAGE data to 
the IR equation are named as T1-effective values.  
 
In this study, T1 was measured in three ways: IR-SE method with TR = 15 s; 
MP-RAGE method with TD = 15 s; and MP-RAGE method with TD = 2 s on samples 
with MnCl2 concentrations of 0.04-1.00 mM, to validate the MP-RAGE T1 
measurement method. The MP-RAGE SI data were well described by the usually IR 
equation as well as the IR-SE data itself (R2 > 0.99). These three T1 measurement 
methods all show a positive linear correlation between the R1-effective value and 
MnCl2 concentration (R2 > 0.99) suggesting their validity for quantitative measurement 
in vitro. There was also a good agreement between T1 measurement results by the 
IR-SE method with TR = 15 s and MP-RAGE method with TD = 15 s in vitro.  
 
However, a difference was nevertheless observed between the T1 measurement results 
by MP-RAGE method with TD = 2 s and IR-SE method with TR = 15 s. The 
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MP-RAGE method with TD = 2 s resulted in T1-effective measurements which 
deviated from the true T1. Deviations of T1-effective by MP-RAGE sequence became 
more significant as T1 become longer and the T1-effective value tended to be an 
overestimate of the actual T1 values. A TR0 > 5 × T1 is suggested for MP-RAGE MRI 
since shorter TR0 can cause an underestimation of R1 values (Jivan et al., 1997). This 
may explain the error of T1 values in this experiment.  
 
In MP-RAGE MRI, the image data are sampled during the approach to steady state and 
so relaxation occurs during data acquisition (Mugler and Brookeman, 1991). Large 
signal variation during the data sampling period can lead to artefacts such as blurring 
and edge enhancement (Lee and Price, 1994). Therefore, the ideal MP-RAGE MRI 
should be performed with a small flip angle, short TR and decreased number of 
phase-encoding steps to ensure identical signal amplitudes during the data sampling 
period (Hanicke et al., 1990). In this case, MP-RAGE MRI was acquired using a 
smaller flip angle (10°) but a high number of phase-encoding steps in the inner loop (n 
= 128). Therefore, one possible explanation for the deviation of T1-effective results in 
phantoms would be the effect of the long readout time (1.28 s in the optimized sequence) 
of the MP-RAGE sequence.  
  
3D MP-RAGE MRI can readily delineate the mouse pancreas and provide a surrogate 
T1/R1 (T1–effective/R1–effective) measurement of MnCl2 concentrations of 0.04–1.00 
mM. Such concentrations are comparable to estimated tissue [Mn] following MnCl2 
administration in our in vivo experiments. Therefore, this MP-RAGE method was 
applied to section 2.3.4-2.3.6. 
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4.4 Dose-dependent effects of MnCl2 
Mn2+ is a positive T1 contrast agent and accumulation of Mn2+ in tissues can lead to an 
increase in SI and a shortening of T1 value (Lin and Koretsky, 1997). In our study, 
MP-RAGE was demonstrated to be a semi-quantitative tool for measuring tissue [Mn] 
by both SI and T1 measurements and these results were verified by ICP-AES method. A 
MnCl2 dose of 2 mM, 0.1 mL infused at a rate of 0.2 mL/h was found to be the lowest 
dose which led to detectable signal enhancement in the optimized MP-RAGE MRI 
method in the mouse pancreas.  Furthermore, this [MnCl2] had no significant toxic 
effects. Therefore, this dose was applied for all subsequent experiments.  
 
4.4.1 Serial MEMRI 
In general, a similar signal enhancement pattern was observed in organs which readily 
take up Mn2+, such as the pancreas, liver and kidney, following administration of 
MnCl2 (2, 5, 10, 20 and 40 mM). During MnCl2 infusion, SI rose reaching a maximum 
at the end of infusion period. The maximum enhancement plateau persisted for at least 
96 min after the start of MnCl2 infusion. With different doses of MnCl2 (2, 5, 10, 20 and 
40 mM), there was a dose-dependent increase in the rate of signal enhancement and 
steady state signal enhancement.  
 
As can be seen, the SI plateau in the pancreas, kidney and liver lasted until the end of 
experiment, 96 min after the start of MnCl2 infusion. Mn2+ is washed out from plasma 
very quick, with a plasma half life of 4.7 min but the clearance after tissue accumulation 
of Mn2+ is slow (Lin and Koretsky, 1997). Therefore, signal enhancement in organs 
 196
following plasma MnCl2 washout is due to the uptake of Mn2+ which can enter cells via 
Ca2+ channels such as VGCCs (Koretsky and Silva, 2004; Silva et al., 2004).  
 
The SI plateau towards the end of the MnCl2 infusion in most organs fluctuated within a 
small range. However, greater fluctuations in SI were observed in the liver, as 
compared to the pancreas and kidney (Figure 3-16). This may arise from the fact that 
the liver has a dual blood supply system. As the liver is supplied by blood from the 
hepatic artery and the portal vein, in theory, these can have different Mn2+ 
concentrations and thus can cause fluctuating SI from the liver. Moreover, MnCl2 is 
eliminated mainly via the hepatobiliary system (Ni et al., 1997) and the Mn2+ 
containing bile ducts could contribute to the SI fluctuations in the liver.  
 
In skeletal muscle, there was a complete lack of SI change after MnCl2 infusion at 
concentrations of 2-20 mM, indicating no Mn2+ uptake under this physiological 
condition. The relative constancy of the signal in the muscle makes it an ideal internal 
reference on time-course MEMRI. Furthermore, the volume of skeletal muscle is larger 
such that partial-volume effects caused by adjacent structures can be minimized. 
Therefore, skeletal muscle may act as an internal reference for MEMRI and this is 
consistent with previously published findings in which skeletal muscle was used to 
normalise SI in Mangafodipir-enhanced MRI (Wang et al., 1997).  
 
Following MnCl2 infusion at a concentration of 40 mM, the SI in the skeletal muscle 
increased during MnCl2 infusion and then gradually decreased. Indeed, the rate of 
decline in tissue Mn2+ was faster in skeletal muscle compared to that in the pancreas, 
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kidney and liver. Therefore, it is reasonable to assume that intravascular Mn2+ rather 
than intracellular Mn2+ contribute to the SI change in skeletal muscle following MnCl2 
infusion at a concentration of 40 mM. However, it is still unclear why there was no 
signal enhancement observed after Mn2+ administration at lower doses. VGCCs are 
known to be present in skeletal muscle (Catterall et al., 2005; Ko et al., 1997) and 
therefore it is also possible that Mn2+ can enter into skeletal muscle cells via VGCCs 
but may be the threshold for skeletal muscle Mn2+ uptake is relatively higher compared 
to that of other organs.   
 
In the heart, muscle contraction is related to cellular Ca2+ influx through VGCCs (Wang 
et al., 2004). Hu et al. has previously shown that clearance of Mn2+ from infarcted 
myocardium can be as rapid as 3-5 min after a 15 min infusion period (Hu et al., 2004). 
Thus, MnCl2 appears to have a very short half-life in plasma and interstitial space. 
Therefore, the discrepancy between the rapid plasma Mn2+ clearance and the extended 
period of steady state signal enhancement in these organs suggests that Mn2+ may be 
accumulating in the intracellular space. Based on the fact that Mn2+ acts as an 
intracellular contrast agent and the existence of dose-dependent Mn2+ uptake, 
MP-RAGE MRI may provide a semi-quantitative tool for imaging Ca2+ hemostasis in 
these tissues.   
 
The spleen also showed low SI by MP-RAGE MRI. An increase in signal was observed 
in the spleen over the 30 min infusion of MnCl2, which was then maintained at a steady 
state for at least 96 min after the start of infusion. The different doses of MnCl2 applied 
did show differences in signal enhancement but unlike in the other tissues, the degree of 
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enhancement did not correlate with the dose level (figure Figure 3-16). This may arise 
from the high vascularity of the spleen and the different SI of blood flowing at different 
rates by MP-RAGE MRI; with arterial and venous blood appearing bright and dark, 
respectively, (Jeffrey et al., 1995). Furthermore, the SI of the slower venous blood 
becomes bright on administration of a T1 contrast agent (Jeffrey et al., 1995). Thus, a 
number of factors contribute to the resultant SI in the spleen, and explains the lack of 
dose-dependency.  
 
Mn and iron have been demonstrated to be essential cofactors for many enzymes and 
both are transported across cell membrane via DMT1 (Roth and Garrick, 2003). 
Deficiency or excess of iron can influence tissue Mn levels, showing an inverse 
association between Mn and iron (Garcia et al., 2007). It is possible that Mn exposure 
results in a change in tissue iron accumulation in the spleen. However, it is less likely 
that an acute dose of Mn2+ can affect iron accumulation in a short period of time such as 
in our experiment (< 2 h) and more studies are needed to assess the interactions between 
Mn and iron uptake in the spleen.  
  
We also looked at the SI data in the heart, epididymal fat and interscapular fat (brown 
fat) by serial MP-RAGE MRI. However, SI data could not be measured from the same 
ROI throughout the 27 consecutive scans in these organs. Therefore, these data were 
not robust and were not included here. One possible reason for the failure to obtain SI 
from the same ROI may arise from motion artefacts associated with the beating heart, 
respiration and bowel peristalsis. Further, distension of urinary bladder was noted 
during the serial MEMRI which may cause the displacement of the epididymal fat.  
 199
4.4.2 T1 measurement 
There was a dose-response relationship between infused dose of MnCl2 and shortening 
of T1-effective values in the pancreas, kidney, liver and heart, and this is consistent with 
the results in dose-dependent serial MEMRI. In addition, this dose-dependent 
relationship was not observed in skeletal muscle following MnCl2 infusion at the 
concentrations of 2-40 mM, and this is also consistent with the serial MEMRI results. 
 
In the spleen, a dose-dependent relationship was not observed with serial MEMRI, a 
relationship was observed between the infused dose of MnCl2 and T1-effective 
measurements.  The spleen has a high content of erythrocytes and lymphocytes, both of 
which have been shown to uptake extracellular Mn2+ in a dose-dependent manner (Aoki 
et al., 2006; Matsuda et al., 1989; Weed and Rothstein, 1960). The uptake of Mn2+ by 
splenic erythrocytes and lymphocytes may explain the dose-dependent effects on T1 
measurements. 
 
Exposure to increasing doses of MnCl2 did not affect tissue Mn2+ accumulation in the 
epididymal fat, suggesting this tissue does not uptake Mn2+, at least under the 
physiological condition in this study. This is consistent with previous in vitro finding 
showing that the T1 values of the adipose tissue from dogs does not change after i.v. 
MnCl2 (Wolf and Baum, 1983).  
 
In the absence of MnCl2 infusion, the T1-effective value in the interscapular fat was 
significantly greater than that in the epididymal fat (Figure 3-17) which reflected their 
morphological differences. The latter consists of WAT whereas intercapsular fat 
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contains a mixture of WAT and BAT. Adipocytes of WAT contain one large fat droplet 
whereas those of BAT contain numerous small fat droplets, a high number of 
mitochondria and iron which make it brown in colour (Enerback, 2009; Hull, 1966). 
Unsurprisingly, WAT and BAT have different T1 values (Houchun and Krishna, 2010) 
and the heterogeneity of interscapular fat may explain the difference in T1 estimation 
with that of epididymal fat in our study. 
 
Given the larger mitochondrial content of BAT and the role that Ca2+ plays in the 
function of this organelle, we expected to see an increase in Mn2+. This would allow us 
to develop a non-invasive method to assess BAT content and function. Unfortunately, 
under current physiological condition (anaesthesia, immobilisation and warm 
temperature), no Mn2+ uptake was observed. Further studies are needed to determine if 
by stressing BAT (e.g. cold temperature, hormones, etc) may induce increased Mn2+ 
uptake.  
 
4.4.3 Tissue [Mn] analysis by ICP-AES 
ICP-AES is a multi-element analytical technique and has been used to measure the Mn 
content in biological samples (Jiang et al., 2007). In the pancreas, kidney, liver and 
heart, a dose-dependent Mn2+ uptake was observed following a 30 min i.v. infusion of 
MnCl2 at concentrations of 2-40 mM. This is consistent with previous studies showing 
a dose-dependent Mn2+ uptake in these organs in sheep (Ivan and Hidiroglou, 1980; 
Watson et al., 1973). The detection limit of Mn by our method was 0.0003 μg/mL and 
the lower limit of quantification was 0.0015 μg/mL. In the muscle, spleen and adipose 
tissue, Mn was about or below the detection level of the technique.  
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It is worth noting that SI and T1 changes measured by MRI could arise from 
intracellular, interstitial and intravascular Mn2+ accumulation whereas some of the 
intravascular Mn2+ component may not be measured by ICP-AES due to the rupture of 
vessels and blood loss during sample collection. This is especially relevant to the spleen 
due to its well known function as a blood reservoir. If the majority of Mn2+ was present 
in the intravascular space, it is reasonable that ICP-AES would only detect low tissue 
[Mn], failing to reflect the decreased T1-effective values observed in the spleen by 
MRI. 
 
4.4.4 Correlation of tissue R1-effective with tissue [Mn]  
The correlation of R1-effective values and tissue [Mn] were linear in the pancreas, 
kidney, heart, and liver after MnCl2 infusion. However, tissue Mn2+ accumulation was 
tissue-variable being high in the pancreas, kidney and liver; and low in the heart. In the 
spleen, epididymal fat and skeletal muscle, tissue [Mn] remained low with small 
changes between varying MnCl2 dose group. Therefore, it may be difficult to detect the 
small change in tissue [Mn] accumulation in these organs.  
 
Aside from the discrepancy in the spleen, a good correlation between R1-effective by 
MP-RAGE and tissue [Mn] by ICP-AES was demonstrated in a range of tissues in our 
experiments. These results suggested that our serial MEMRI and T1-effective 
measurement methods can be used to estimate tissue [Mn] in vivo and therefore may 
provide possible method for assessing Ca2+ influx during cell activation. Ca2+ influx is a 
key step during glucose-stimulated insulin secretion in the β-cell and therefore MEMRI 
was used to image excited β-cells following glucose stimulation.  
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4.5 Tissue manganese washout 
Despite its importance, there is a lack of understanding concerning Mn2+ transport, 
accumulation and clearance in live organisms following an exogenous dose 
(Armstrong, 2008;Pittman, 2005). While there are studies on the transport of Mn into 
the brain via the blood-brain barrier (Yokel, 2002), Mn2+ flux through non-CNS organs 
is relatively unknown. Mn2+ presents in the intravascular, interstitial and intracellular 
spaces after a Mn2+ dose. With an i.v. infusion, Mn2+ is rapidly cleared from the blood 
within minutes (Borg and Cotzias, 1958; Gerdin et al., 1985) and the plasma Mn2+ level 
is restored to the baseline by 12 h in rat (Zheng et al., 2000). Once leaving the plasma, 
Mn2+ distributes in tissues and then slowly washes out from tissues (Aoki et al., 2006; 
Brurok et al., 1997; Hu et al., 2004; Lin and Koretsky, 1997).   
 
In this study, a Mn2+ washout model was established up to 120 h after the start of MnCl2 
infusion by T1-effective measurement, providing useful information for future study 
design. Our results indicate that T1-effective values decreased rapidly following 
administration of MnCl2, remained at this level for over 3 h and then gradually returned 
to baseline, in the pancreas, kidney and liver. Combined serial MEMRI results which 
show a maximum enhancement plateau lasted from the end of MnCl2 infusion for up to 
60 min, suggesting a steady-state MnCl2 accumulation period. This steady-state signal 
enhancement period indicates a period of constant tissue [Mn]. In skeletal muscle, 
T1-effective values remained no change over time after of MnCl2 infusion, suggesting 
no obvious Mn2+ accumulation. Therefore, skeletal muscle may act as an internal 
reference in MEMRI under well controlled physiological conditions.  
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4.6 Glucose challenge experiment in the pancreas 
The size of pancreatic β-cells is far below the spatial resolution of current MRI 
technology and there is also a need to use β-cell-specific contrast agent to enhance the 
sensitivity and specificity for imaging the functional β-cell mass (Medarova and Moore, 
2009). It is known that the degree of insulin secretion is closely related to the frequency 
of Ca2+-dependent action potentials in the pancreatic β-cell (Jacobson and Philipson, 
2007). Therefore, movement of Ca2+ may provide a surrogate marker for β-cell 
function. Mn2+, a surrogate for Ca2+, is paramagnetic and therefore MEMRI has been 
used to image Ca2+-related cellular activation in the neuron (Silva et al., 2004) and heart 
(Hu et al., 2001). 
 
Mn2+ accumulates in high concentrations within the pancreas following an exogenous 
dose (Ni et al., 1997). It has been shown to inhibit insulin secretion at very high Mn2+ 
concentrations following glucose stimulation in vitro (Rorsman et al., 1982). 
Therefore, a balance between minimizing potential toxicity arising from MnCl2 and the 
need for high tissue contrast for localization of the mouse pancreas is vital. The dosage 
we have implemented in our MEMRI protocol is significantly lower than the reported 
LD50 for i.v. MnCl2 in mice (Silva et al., 2004). Crucially, we have shown that MnCl2 
infusion (2 mM, 0.1 mL) has no effects on blood glucoses levels by i.p. injection of 
glucose (2 g/kg body weight). Further, MnCl2 infusion at this dose did not affect the 
islet and β-cell numbers by histological analysis including H&E and 
immunohistochemistry staining.  
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For imaging the pancreatic β-cell activation, both SI profiles and T1 measurements 
were obtained in healthy mice with and without glucose challenge. SI profiles of a 
STZ-treated diabetic mouse model were also obtained for comparison. Two articles 
highly related to this project were published during the course of this study, one in vitro 
and one in vivo experiment. The in vitro study showed that β-cells take up Mn2+ in 
response to glucose stimulation in the presence of MnCl2 and the increased cellular 
Mn2+ uptake yielded an SI increase of 200 % by MRI (Gimi et al., 2006). The in vivo 
study showed that MEMRI can detect a 51 % increase in the maximal SI of the pancreas 
after glucose stimulation, as compared to control. The results from our study are 
discussed below in light of these papers.   
 
4.6.1 Healthy mice 
This in vivo MRI protocol requires that I select a mean SI value from an ROI from the 
pancreas, as MEMRI currently lacks the resolution to study single β-cells or even islets. 
Despite the fact that the endocrine pancreas contributes only 1-2 % of the total 
pancreatic volume, I have demonstrated in vivo a statistically greater SI in the pancreas 
following a glucose challenge compared to the control group. The serial MEMRI 
protocol provided a sufficient temporal resolution (4 min) to detect a significant 
difference in SI, starting at 4 min post i.p. glucose injection. I have recorded a peak in 
circulating glucose at around 30 min post i.p. injection, similar to that observed in 
previous C57BL/6 mice studies (Sone and Kagawa, 2005). The timing of this peak in 
blood glucose also corresponds to a peak in temporal SI, suggesting that the MEMRI 
data may accurately reflect pancreatic insulin secretion. Therefore, MEMRI appears to 
provide a quantitative representation of β-cell activity. 
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Thus, I have demonstrated that MEMRI is an effective means of non-invasively 
monitoring β-cell function, in agreement with a recent publication which showed a 50 
% increase in normalized pancreas SI after glucose stimulation (Antkowiak et al., 
2008). In their study, C57BL/6 mice (~ 29 g) were fasted for 2 h prior to MRI and 
treated with i.p. MnCl2 (0.1 μmol/g) and i.v. glucose (1.5 g/kg). The MnCl2 dose they 
used was ~ 20 mg/kg, which is half the dose of LD50 and 10 times more than the dose in 
my study. It is clear that the MnCl2 dose they used can yield greater SI increases but the 
dose I used is less toxic, with minimal effect on β-cell function. They used a 2D 
MP-RAGE without physiological gating to image the mouse pancreas. In agreement 
with their study, I found that a 3D MP-RAGE sequence without gating can better 
delineate the mouse pancreas in vivo. Flip angle is always a concern (see section 4.2) 
when performing MP-RAGE sequence and a flip angle of less than 10-12° for the 
MP-RAGE MRI sequence has been suggested (Deichmann et al., 2000; Deichmann 
and Haase, 1992; Jivan et al., 1997).  A flip angle of 20° was used in their study, 
whereas I used a flip angle of 10°. Clearly, a high flip angle achieves greater SI 
difference in the pancreas following MnCl2 dose but with the penalty of poor image 
quality (Holsinger A and Riederer SJ, 1990).  
 
In the study by Antkowiak and colleagues, a TI = 580 ms was used. I measured TInull of 
the pancreas to be 500 ms (Figure 3-6) and therefore, a TI = 580 ms (> TInull of the 
pancreas) yields positive correlation between changes in SI and tissue [Mn2+] 
accumulation. However, their choice of TI value renders it difficult to analyse the SI 
changes in other insulin target organs, such as the liver and skeletal muscle. TInull values 
for the liver and skeletal muscle were 600 ms and 740 ms, respectively and therefore, 
using a TI of 580 ms means that the SI change is not directly correlated to tissue [Mn2+]. 
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Furthermore, SI data in the pancreas was normalized to the SI in the liver to account for 
variations in the Mn2+ delivery, whereas I normalized the pancreatic SI at each time 
point to the baseline pancreatic SI prior to Mn2+ infusion. Insulin-target organs are not 
ideal internal standards, as tissue [Mn] may change following glucose stimulation. 
Furthermore, the liver is the main organ for Mn2+ excretion and a target organ for 
glucose homeostasis (Barritt et al., 2008) and the selection of liver as an internal 
standard further complicates the situation. Thus, I do not recommend that the liver SI 
should be used to normalise the pancreas SI. 
 
Although Antkowiak et al. (2009) showed that MEMRI can detect a significant 
increase in the maximal SI of the pancreas after glucose stimulation; we have further 
validated the application of MEMRI by obtaining T1 measurements to confirm Mn 
accumulation in tissues.  Also, I employed non-MRI methods to understand the 
changes in the MEMRI enhancement profile by analysing tissue [Mn] in vitro by 
ICP-AES, LA-ICP-MS and XRF. 
 
T1-effective/R1-effective measurements did not suggest an increase in Mn2+ 
accumulation in the mouse pancreas following glucose stimulation, despite the serial 
MEMRI findings. The T1-effective measurements took ~ 22 min whereas the temporal 
resolution for the serial MEMRI experiment is ~ 4 min. Relatively poor spatial 
resolution may explain the inability of T1-effectve/R1-effective measurements to detect 
the increase in Mn2+.  
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Bulk tissue Mn measurements by ICP-AES also failed to detect differences between the 
pancreas with and without glucose stimulation. Errors may occur due to detection limits 
and sample contamination. Pancreatic islets consists of only 1-2 % of pancreatic mass 
and thus tissue Mn mapping with high spatial resolution at the level of the islet is 
needed to visualize the Mn distribution inside and outside the islet or β-cell. ICP-AES 
is a bulk analytical technique and therefore LA-ICP-MS was also employed for a 2D 
elemental mapping. 
 
A pilot study of Mn and iron mapping of frozen sections of mice pancreata was 
performed at a resolution of 100 µm with and without glucose activation by 
LA-ICP-MS. H&E staining of adjacent slice was performed to localize the pancreas. 
The Mn map shows a general higher level of Mn in the glucose-stimulated pancreas 
compared to that of vehicle-treated pancreas (Figure 3-24). However, both pancreata 
samples also contained spleen which had different iron levels suggesting that SI is not 
comparable between samples as iron concentrations should be comparable between the 
spleens. Thus, direct comparison of elemental concentrations is allowed within each 
sample but not across samples and our LA-ICP-MS method requires further refinement 
and calibration for generation of quantitative elemental maps. Despite this, our 
LA-ICP-MS data does demonstrate Mn to be lower in the spleen than in the pancreas, 
consistent with the serial MEMRI and T1-effective measurement data (see section 3.4). 
Further, the LA-ICP-MS data showed higher iron concentrations in the spleen than in 
the pancreas as expected from the known function of the spleen to act as a reservoir for 
erythrocytes (Hamza and Kaufman, 2009).   
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A pilot study of Mn and Zn mapping for the paraffin wax sections of the pancreas was 
also performed in mice with and without glucose activation by XRF. Zn mapping and 
H&E staining of adjacent slice were used to localize the islet. A high degree of 
correlation was observed between Mn and Zn distribution in the glucose-stimulated 
pancreas whereas a lesser degree of correlation was observed in the control pancreas. 
These findings suggest specific Mn accumulation in areas of high Zn, i.e., within or at 
least in the vicinity of β-cells. The lack of exact correspondence between Mn mapping 
and islet distribution may be due to the fact that not all β-cells are activated following a 
glucose load. Since XRF was performed a resolution of 300 µm, partial volume effects 
may contribute to the lack of correspondence. The mean normalized Mn intensity was 
higher in the glucose-treated pancreas than the control by XRF. Thus, the employment 
of metal mapping by XRF suggests that the increase in signal enhancement by MEMRI 
in the activated pancreas may indeed result from entry and accumulation of Mn along 
with Ca2+ during glucose-mediated β-cell activation. 
 
4.6.2 Diabetic mouse model 
STZ is diabetogenic and its structure is similar to glucose and can be taken up by β-cells 
via GLUT-2, resulting in specific β-cell toxicity (Wang and Gleichmann, 1998). 
Histological assessments of pancreatic islets in STZ-treated diabetic mice illustrated 
β-cell degeneration and loss and macrophage infiltration with α-cell retention, therefore 
making this a good type 1 diabetic mouse model.  
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Glucose stimulation resulted in a significant increase in pancreatic SI by MEMRI in 
healthy mice but not in STZ-induced diabetic mice. Since STZ treatment induces β-cell 
necrosis but does not appear to affect non-β-cells, it is very likely that  β-cells are 
responsible for the further Mn2+ uptake following glucose stimulation in the pancreas of 
Mn2+-treated animals. Therefore, MEMRI appears to provide a quantitative 
representation of β-cell loss. 
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4.7 Glucose challenge in insulin-target organs 
4.7.1 Skeletal muscle 
In this study, in vivo MEMRI was also carried out to assess glucose uptake activity in 
skeletal muscle in healthy mice and the diabetic mouse model. An increase in SI 
following glucose stimulation was detected in healthy mice. A glucose load can induce 
an increase in plasma insulin levels in anesthetized animals and the resultant 
hyperinsulinemia state initiates the muscle glucose uptake pathway. VGCCs are known 
to be present in skeletal muscle (Catterall et al., 2005; Ko et al., 1997) and therefore 
Mn2+ may enter into skeletal muscle cells through Ca2+ transport pathway upon glucose 
stimulation in the presence of extracellular Mn2+.  
 
In skeletal muscle, glucose homeostasis is regulated by insulin-mediated and 
contracture-stimulated glucose uptake (Goodyear and Kahn, 1998). Exercise-mediated 
skeletal muscle glucose uptake is related to an increase in intracellular Ca2+ but the 
increase is due to release of Ca2+ from intracellular stores not cellular Ca2+ influx 
(Goodyear and Kahn, 1998; Rose and Richter, 2005). The role of Ca2+ in 
insulin-mediated glucose uptake is still unclear (Lanner et al., 2008). However, as mice 
used in our studies were maintained under anaesthesia throughout the MRI scan, the 
muscle was in a resting state.  Thus, exercise-induced skeletal muscle uptake is unlikely 
to be responsible for the increase in SI in our MEMRI. It is therefore reasonable to 
suggest that the SI increase in skeletal muscle following glucose stimulation is due to 
insulin-mediated skeletal muscle glucose uptake.    
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Cellular Ca2+ influx has been shown to be an important modulator of insulin-mediated skeletal 
muscle glucose uptake in vitro (Lanner et al., 2006). In agreement with their result, we 
demonstrate an increase of Mn2+ influx into skeletal muscle following a glucose load in 
healthy mice. Therefore, MEMRI may be used as a non-invasive tool to detect the 
insulin-mediated glucose uptake in skeletal muscle.  
 
Impaired insulin-mediated skeletal muscle glucose uptake is present in both type 1 and 
type 2 diabetes (Napoli et al., 1995). Increase in SI change was expected in 
glucose-stimulated skeletal muscle in STZ-treated diabetic mice but of a smaller 
magnitude compared to that in healthy mice. However, our results show that glucose 
induces Mn2+ influx, was of similar magnitudes to those of healthy mice. While it is 
reasonable to conclude that the Mn2+ influx is associated with muscle glucose uptake in 
healthy subjects, the similar increase in skeletal muscle of STZ mice is more difficult to 
explain. Antioxidant enzymes such as MnSOD play a role in insulin sensitivity in 
skeletal muscle (Hoehn et al., 2009), and the administration of Mn may increase muscle 
insulin sensitivity in the STZ mice so as to compensate for the insulin deficiency as a 
result of STZ destruction of β cells. Further investigations involving assessments of 
muscle insulin sensitivity and measurements of blood insulin are required to determine 
whether Mn administration can restore insulin sensitivity to a significant extent in STZ 
mice. 
 
4.7.2 Liver 
In the liver, Ca2+ is involved in a wide range of cellular activities, as discussed in 
section 1.5.2. Further, increased SI in the liver following Mn2+ infusion can arise from 
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its accumulation in bile ducts, vessels, interstitial spaces as well as in hepatocytes. 
These SI changes reported here may not be a simple reflection of increased 
hepatocellular Mn2+ uptake as a result of Ca2+-mediated processes. Mn2+ uptake was 
high by the non-stimulated liver as shown in Figure 3-18 and further cellular Mn2+ entry 
following stimulation may be masked by the already high tissue Mn2+ accumulation. 
Therefore, it is a challenge to interpret the MEMRI data in the liver. As expected, there 
was no difference in Mn2+ accumulation between glucose-stimulated or control groups 
by both MEMRI and ICP-AES data in healthy and diabetic mice.  This is likely to be 
the case as the SI increase in the liver is as high as 120 % and therefore, the large influx 
of Mn2+ into this region may mask the relatively smaller cellular Mn2+ influx. 
 
4.7.3 Adipose tissue 
It is reasonable to hypothesize that MEMRI could be used to image the function of the 
adipose tissue in glucose homeostasis. Serial MEMRI was therefore performed in these 
tissues. Unfortunately, the ROIs from the epididymal fat had to be moved for each scan 
to compensate for motion throughout the experiment, as discussed in section 4.4.1. 
Furthermore, significant difference in SI was found between glucose-stimulated 
epididymal fat and control prior to the application of i.p. stimuli when both groups were 
treated with only MnCl2 infusion. These findings suggested that our current MEMRI 
protocol, designed for the pancreas, may not be readily applied to measure the SI 
change in the epididymal fat. Clearly, future work is needed to further optimize the 
serial MEMRI protocol for imaging the epididymal fat. No difference was observed in 
T1-effective values of the epididymal fat in mice receiving glucose or vehicle after 
MnCl2 infusion. This may due to the lower tissue [Mn] in the epididymal fat, consistent 
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with the ICP-AES results which showed that some of the tissue [Mn] in the epididymal 
fat was lower than the detection limit.  
 
The serial MEMRI results for the interscapular fat were also unreliable as again a 
constant ROIs could not be obtained, probably due to effects arising from motion 
associated with heat from beating heart, respiration and bowel peristalsis. In the 
interscapular fat, there was no difference in SI in mice with and without stimulation 
following MnCl2 infusion in the serial MEMRI study. Moreover, margins of the 
interscapular fat can only be delineated from 8 out of 12 animals in the study. The 
MP-RAGE sequence employed here was optimized for the pancreas and therefore, may 
not be ideal for imaging the interscapular fat. T1 measurement study was not performed 
in the interscapular fat as a lack of dose-dependent relationship between infused Mn2+ 
dose and changes in T1 values as described in section 3.4.2.  
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4.8 Limitations and future works 
While MEMRI allowed the in vivo imaging of pancreatic β-cell activation, there are 
limitations to the method presented here . Firstly, delineation of the mouse pancreas by 
MP-RAGE MRI is difficult, and the inter-observer variability for the selection of ROIs 
for the mouse pancreas had not been assessed in this study due to a lack of experienced 
operators. Secondly, the Mn2+-based contrast agent used in this work, MnCl2, is toxic 
and may effect β-cell function. Thirdly, this work did not show dose-dependent glucose 
stimulation of the mouse pancreas by MEMRI. Finally, the effect of MnCl2 on β-cell 
insulin secretion was not tested in these studies.   
 
Future work would include the use of a FDA-approved Mn2+-based contrast agent, 
MnDPDP, to replace MnCl2 which may have toxic effects. Other studies include the 
employment of MEMRI to quantitatively assess β-cell function over a range of glucose 
doses. An ex vivo study can be performed to monitor whether β-cells following glucose 
stimulation demonstrate enhancement compared to non-stimulated β-cells in the 
presence of extracellular Mn2+ by T1-weighted MRI, further supporting the 
methodology in the in vivo studies presented here.   
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4.9 Conclusions 
Exocytosis of insulin granules in pancreatic β-cells is regulated by cellular influx of 
extracellular calcium ions (Ca2+). Using Mn2+ as a surrogate for Ca2+, I have 
demonstrated that serial MEMRI can be used to assess β-cell function following 
glucose stimulation in normal and diabetic mice in vivo and may offer a valuable 
diagnostic tool for therapy against diabetes. I have also demonstrated that serial 
MEMRI can detect an increase in tissue Mn2+ accumulation in skeletal muscle 
following a glucose load, indicating an increase in cellular Ca2+ influx during skeletal 
muscle glucose uptake. Therefore, my MEMRI methodology may be a powerful tool to 
assess glucose homeostatic processes in vivo and can improve our understanding of the 
mechanisms underlying the development of diabetes. The relationship between the 
number of activated β-cells, the degree of β-cell activation and Mn2+ entry remain 
unclear. Moreover, glucose administration has been shown to increase islet vascularity 
(Jansson, 1988; Jansson and Hellerstrom, 1983) which might contribute to the tissue 
Mn2+ uptake. So while VGCCs are an obvious candidate for the increased Mn2+ entry 
into the pancreas following stimulation with glucose, it is important to further clarify 
the origin of signal enhancement observed by MEMRI.   
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Abstract 
Manganese-enhanced magnetic resonance imaging 
(MEMRI) is a novel imaging technique capable of 
monitoring calcium influx, in vivo. Manganese (Mn2+) ions, 
similar to calcium ions (Ca2+), are taken up by activated 
cells where their paramagnetic properties afford signal 
enhancement in T1-weighted MRI methodologies. In this 
study we have assessed Mn2+ distribution in mice using 
magnetization-prepared rapid gradient echo (MP-RAGE) 
based MRI, by measuring changes in T1–effective 
relaxation times (T1-eff), effective R1-relaxation rates  
(R1-eff) and signal intensity (SI) profiles over time. The 
manganese concentration in the tissue was also determined 
using inductively coupled plasma atomic emission 
spectrometry (ICP-AES). Our results show a strong 
positive correlation between infused dose of MnCl2 and the 
tissue manganese concentration. Furthermore, we 
demonstrate a linear relationship between R1-eff and tissue 
manganese concentration and tissue-specific Mn2+ 
distribution in murine tissues following dose-dependent 
Mn2+ administration. This data provides an optimized 
MnCl2 dose regimen for an MP-RAGE based sequence 
protocol for specific target organs and presents a potential 
3D MRI technique for in vivo imaging of Ca2+ entry during 
Ca2+-dependent processes in a wide range of tissues. 
 
Introduction 
Manganese-enhanced magnetic resonance imaging 
(MEMRI) is an emerging contrast agent based MRI 
technique that can be used for high-resolution anatomical 
and functional imaging in vivo (Kuo et al., 2007; Lin and 
Koretsky, 1997; Silva et al., 2004). The technique is based 
upon the ability of paramagnetic manganese ions (Mn2+) to 
alter the proton MRI signal, resulting in an increase in 
signal intensity (SI) by T1-weighted MRI (Fornasiero et al., 
1987; Mendonca-Dias et al., 1983). The change in SI is 
proportional to the concentration of Mn2+ within a given 
region of interest (ROI) and yields a quantitative measure 
of the transport and accumulation of Mn2+ in specific 
tissues (Lee and Koretsky, 2004; Mendonca-Dias et al., 
1983). Importantly, systemic administration of MnCl2 
results in an increased SI from both cells and extracellular 
components including blood (Kang et al., 1984) and after 
wash out of MnCl2 from blood, SI only arises from 
intracellular Mn2+ (Bremerich et al., 2000). Hu et al., have 
shown that Mn2+ can wash out of the infarcted myocardium 
as rapid as 3-5 min after MnCl2 infusion (Hu et al., 2004). 
Unlike other T1 contrast agents such as gadolinium chelates 
which remain extracellular, Mn2+ offers a unique 
perspective of tissue, mapping SI according to cellular 
function, i.e. it is an activity-dependent contrast agent.  
 
In addition to its paramagnetic properties, Mn2+ has an ionic 
radius comparable to the calcium ion (Ca2+) (Shannon, 
1976) and behaves similarly in biological systems, entering 
and exiting various tissues via Ca2+ transport systems 
(Cross et al., 2007; Narita et al., 1990; Rorsman et al., 1982; 
Simpson et al., 1995; Wollheim and Sharp, 1981). In 
excitable cells, voltage-gated Ca2+ channels (VGCC) in the 
cell membrane open following stimulation, resulting in 
enhanced uptake of Mn2+ (Drapeau and Nachshen, 1984). 
As the change in SI is proportional to the concentration of 
Mn2+, the resulting contrast enhancement can therefore be 
used as a direct marker for Ca2+-dependent cellular activity 
and function. Based upon these principles, MEMRI has 
been used to image cellular activity in the brain and heart 
(Morita et al., 2002; So et al., 2007) and also trace neuronal 
tracts in visual and olfactory pathways (Silva and Bock, 
2008; Silva et al., 2004). 
 
The kinetics of Mn2+ transit in the brain have been 
established using both MRI and non-MRI methodologies 
(Kuo et al., 2007; Silva and Bock, 2008; Teeguarden et al., 
2007). There are differences in Mn2+ uptake in different 
organs with a high degree of Mn2+ accumulation in the 
pancreas, kidney and liver; a moderate uptake in the brain 
and spleen; and low levels in adipose tissue and skeletal 
muscle, regardless of the exogenous dose (Chauncey et al., 
1977; Sotogaku et al., 2000; Spiller et al., 1988; Takeda et 
al., 1998). However, despite sufficient levels of manganese 
reaching non-brain tissues, imaging these regions is often 
technically demanding with motion artifacts arising from 
the heart, respiration and bowel peristalsis, degrading the 
image quality and producing suboptimal diagnostic 
accuracy (McRobbie, 2007). To overcome these technical 
challenges magnetization-prepared rapid gradient echo 
(MP-RAGE) sequences are particularly well suited; 
providing detailed anatomical structures with high tissue 
contrast and short acquisition times (McRobbie, 2007; 
Mugler and Brookeman, 1991). MP-RAGE is less prone to 
detrimental motion artifacts in comparison with spin echo 
methods due to the nature and order of data acquisition 
relative to the timing of various motions such as peristalsis 
and respiration (Mugler and Brookeman, 1990b). 
 
 247
In this study, we determined the time-course effects of 
dose-dependent Mn2+ administration in non-CNS organs to 
aid implementation of MEMRI-based techniques for 
imaging non-CNS Ca2+-mediated cellular activity. We 
developed and applied in vivo 3D MP-RAGE MRI, 
obtaining SI profiles prior to, during and after intravenous 
(i.v.) infusion of manganese chloride (MnCl2). 
Conventionally, T1 is measured by spin echo-inversion 
recovery (IR-SE) but often such data is susceptible to 
motion artifacts when abdominal organs are imaged (see 
above), and hence our use of MP-RAGE MRI in these 
studies. Although the calculation of T1 from 
MP-RAGE-based methods can be complex (Deichmann et 
al., 2000; Jivan et al., 1997; Wright et al., 2008) the 
equation relating SI to T1 at varying inversion times (TI) 
can be approximated by the IR equation when low flip 
angles are used and the overall image repetition time (TR0) 
is large relative to T1 (Jivan et al., 1997). We have 
employed a similar method to assess T1 values, which we 
have termed T1-effective (T1-eff), in recognition of the 
approximations made when using the standard IR equation 
to calculate T1 values from MP-RAGE data. Correlation 
between MRI data and absolute tissue manganese (Mn) 
content is currently only available in the brain (Chuang et 
al., 2008) and heart (Waghorn et al., 2008), and even less is 
known about the systemic distribution of Mn2+ in vivo. Here 
we record T1-eff measurements in the plateau phase of the 
SI profile following Mn2+ administration and correlate this 
data with absolute tissue Mn, obtained by inductively 
coupled plasma atomic emission spectrometry (ICP-AES).  
 
Materials and Methods 
Sample (Dosing solution) Preparation  
A stock solution of manganese chloride tetrahydrate (1M 
MnCl2·4H2O, Sigma-Aldrich Co, UK) was diluted with 
distilled water to concentrations ranging from 0.04-40mM. 
 
Animal Preparation and Treatments 
All experiments were performed in accordance with the 
Animals (Scientific Procedures) Act 1986. Adult male 
C57BL/6 mice (Harlan, UK) were housed in individually 
ventilated cages and maintained on a 12:12 hour light-dark 
cycle (light on at 7am and off at 7pm). Animals of similar 
body weights were used within experiments to minimize 
inter-group variation. Animals were allowed ad libitum 
access to food and water. Prior to scanning, mice were 
fasted overnight from 5pm but allowed ad libitum access to 
water. All MRI scans were performed in the early light 
cycle of the day. Mice were weighed prior to scanning and 
then anaesthesia induced using a mixture of 4-5 % 
isoflurane, 2 L/min oxygen. Anaesthesia was maintained 
with 1.5-2 % isoflurane, 1 L/min oxygen via a nose cone. 
During scanning, respiration and rectal temperature were 
monitored continuously. Animal core temperature was 
maintained by a warm air heating system (SA instruments, 
NY, USA) with automated feedback control system at a set 
point of 37°C. As MnCl2 infusion causes an initial 
stimulation followed by depression of respiration (more 
pronounced at higher Mn2+ concentrations) (Silva et al., 
2004), anaesthetic levels were adjusted during the imaging 
to maintain steady state respiration.  
 
Experiment 1: Measurement of in vitro T1 (and R1) values 
by IR-SE and MP-RAGE 
To compare T1 and T1-eff values IR-SE and MP-RAGE 
were performed on 14 different concentrations of 
manganese (0.04-1.00mM), covering the range of T1 values 
in the subsequent in vivo study (experiment 2). Tubes 
containing 14 increasing concentrations of MnCl2 were 
positioned in a sample holder prior to scanning. The 
samples were placed within a quadrature volume coil 
(35mm internal diameter, Magnetic Resonance 
Laboratories, Oxford, UK) on a 4.7T VMRIS scanner 
(Varian Inc., Palo Alto, USA). T1 measurements were first 
made using IR-SE with the following parameters: TI = 20, 
40, 60, 80, 100, 140, 200, 300, 400, 500, 700, 900, 1200, 
1500, 2000, 2500, 3000 and 4500ms; TR (repetition time) = 
15s; TE (echo time) = 11.97ms; matrix size = 256 x 128; 
FOV (field of view) = 90 x 45mm; number of repetitions = 
2; and a single slice, 2mm thick.  
 
T1 is typically measured by spin echo-inversion recovery 
(IR-SE) but such data is susceptible to motion artifacts 
when abdominal organs are imaged. We have overcome 
these issues by using an MP-RAGE sequence. The equation 
relating SI to T1 at varying inversion times (TI) can be 
approximated by the IR equation when a low flip angle is 
used (< 8°) and the overall image repetition time (TR0) is 
large relative to T1 (greater than 5 times the T1) (Jivan et al., 
1997). We have employed a similar method to assess T1 
values which we have termed “T1-effective” (T1-eff) in 
acknowledgment of the limitations of the rapid imaging 
approach. A 3D MP-RAGE sequence was used to measure 
T1-eff using the following parameters: TI = 100, 200, 500, 
1000 and 2400ms; TR = 10ms; TE = 2.4ms; TD = 2s; 
matrix size = 256 x 128 x 64; FOV = 80 x 40 x 20mm; 
number of repetitions = 1 and a flip angle = 10°. (From 
previous unpublished data, tissue T1 values are in the range 
500–1000ms; 550ms and 800ms from pancreata and 
skeletal muscle, respectively, in dead mice using IR-SE). 
Overall image repetition time (TR0) = TD + TI + (phase 
encoding steps x TR), therefore TR0 = 2000ms + TI + (128 
x 10ms) and TR0 is therefore > 3380ms. A long TR0 was 
chosen to allow sufficient magnetization recovery, but low 
enough to keep the overall scan time manageable. T1 and 
T1-eff values were calculated from the IR-SE and 
MP-RAGE MRI data obtained from the various MnCl2 
solutions, respectively, using the following equation: SITI = 
M + B × (exp(-TI/T1)), where SITI is the SI at inversion time 
TI, and M is the magnetization at time t = 0. R1 (and R1-eff) 
values were calculated by taking the reciprocal value of T1 
(and T1-eff). To compare R1 and R1-eff, the percentage 
estimation error was calculated as follows: percentage 
estimation error = (R1-eff – R1) / R1 × 100 %.  
 
Experiment 2: Correlation of MP-RAGE and ICP-AES data 
following Mn2+ infusion  
Male C57BL/6 mice (n = 15, 22.1 ± 0.2g after overnight 
fasting) were prepared as above. Animals were divided into 
5 groups of 3 animals and given different doses of MnCl2. 
There were no significant differences in body weight 
between the groups (data not shown). Prior to MRI, a 27 
gauge butterfly cannulae was inserted i.v. into the tail vein 
for a 30min infusion of aqueous MnCl2 solutions (2, 5, 10, 
20 or 40mM) by a syringe pump (0.2ml/h, 0.1ml final 
volume). The highest dose of MnCl2 employed (40mM) is 
the LD50 for C57BL/6 mice (Silva et al., 2004). A further 6 
animals (21.7 ± 0.4g after overnight fasting) were also 
imaged without MnCl2 infusion. Employing such high 
MnCl2 doses provides greater signal in MEMRI 
experiments, however, due to possible toxicity, 
administration of as low a dose as possible (2mM) is 
preferred, especially when considering its use in 
longitudinal experiments. 
3D MP-RAGE MRI 
MRI scans were performed using a 4.7T VMRIS scanner at 
6min after the cessation of Mn2+ infusion. MP-RAGE 
parameters employed were as in experiment 1, with a total 
scan time of 22.5min. SI of regions of interest (ROIs, see 
below) at different TI(s) were measured and T1-eff values 
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calculated. After the T1-eff measurements, animals were 
euthanized and tissues: pancreas, spleen, kidney, liver, fat, 
skeletal muscle and heart collected (corresponding to 
36min after MnCl2 infusion). Tissues were frozen on dry 
ice and kept at -80°C prior to assessment of Mn by 
ICP-AES (see below). Of the 6 control mice that did not 
receive an infusion of MnCl2, three of them were 
euthanized following MRI scanning (22.5min) and organs 
collected for ICP-AES analysis. T1-eff values were 
calculated as in experiment 1.  
 
ICP-AES Analysis 
Frozen tissue samples were weighed, and dried (110ºC, 
48h) to a constant weight, prior to acid digestion. Samples 
were digested using a mixture of concentrated Aristar nitric 
acid (3ml) and concentrated Aristar perchloric acid (0.5ml) 
in a heating block, initially at 150ºC then progressively 
ramped up to a temperature of 200ºC over a period of 2h. 
The resultant clear solutions were quantitatively transferred 
to a 15ml graduated plastic tube and made up to a volume of 
10ml with 1 % nitric acid. The resultant solution was then 
analyzed using a SPECTRO VISION (CIROS) ICP 
spectrometer. Data is presented as µg/g dry mass. 
 
Experiment 3: Dose-dependent tissue SI time-course 
following MnCl2 infusion 
Male C57BL/6 mice were fasted overnight (n = 15, 19.7 ± 
0.4g after overnight fasting) and prepared as detailed above. 
In order to obtain a dose-dependent, time-course profile of 
Mn2+ entry into various tissues, different doses of MnCl2 (2, 
5, 10, 20 or 40mM, 0.2ml/h, 30min, final volume = 0.1ml, n 
= 3/group) were infused i.v. via the tail vein (as in 
experiment 2). MP-RAGE scans were performed, with the 
same parameters as in experiment 1, except TI = 740ms, 
FOV = 100 × 50 × 32mm with a total acquisition time of 
4min. The TI value of 740 ms was chosen to be as close to 
the TInull of unenhanced tissues such that the sequence 
provides heavily weighted images so as to be sensitive to 
manganese uptake.  Three consecutive datasets were 
collected prior to Mn2+ infusion to provide baseline data. 
The tail vein Mn2+ infusion was then started and a series of 
24 consecutive datasets collected: data was collected during 
the 30min MnCl2 infusion (0.2ml/h, 0.1ml) and then for a 
further ~66min after the end of infusion. The time-course 
data is presented as the % change in SI from baseline: % SI 
change = (SIt – SI0) / SI0 × 100 %. SI0 is the average SI of 
three MRI datasets acquired before the start of MnCl2 
infusion and SIt the SI at time t.  
 
The choice of flip angle value was based on preliminary 
experiments.  A C57BL/6 mouse was scanned as detailed 
above without administration of MnCl2 and the value of the 
flip angle for the MP-RAGE sequence varied: 5, 10, 15, 20, 
25, 30, 35, 40, 45 or 50°.  
 
Image analysis 
MRI images were analysed using Image J software (Image 
J 1.3.1, NIH, USA). SI from ROI was selected from each 
tube in the in vitro experiments. For in vivo tissue analysis, 
SI readings were obtained from ROIs drawn in the 
gastrosplenic portion of pancreas, left kidney cortex, liver, 
left thigh (skeletal muscle), spleen, epididymal fat and heart 
aided by reference to a standard mouse atlas (Iwaki and 
Hayakawa, 2005). ROIs (Supplementary Figure 2) were 
selected centrally within the organs to minimize partial 
volume effects, and the same ROIs used for images 
collected at the different TI values and at different time 
points. It was possible to apply the same ROIs in the 
pancreas, kidney, liver, hear, spleen and muscle for all 5 
acquisitions for T1-eff measurement in experiment 2 due to 
the lack of motion artefacts in the image.  Likewise, the 
same ROIs could be applied for all of the 27 serial 
acquisitions in experiment 3 except those for the heart and 
epididymal fat due to significant blurring of these areas in 
the images and this data was not analyzed.   
 
Statistical Analysis 
All values are expressed as mean ± standard error of the 
mean (sem). A probability p value < 0.05 was considered 
significant to reject the null hypothesis. Body weights 
between scanning groups were tested using the Student’s 
T-test. Linear regression analysis was performed (Prism 4) 
between R1 relaxation values derived from MEMRI and 
tissue Mn concentration calculated by ICP-AES, and also 
dose-dependence of R1 values in various organs. 
Percentage SI profiles in glucose challenge experiments 
were tested for significant differences using generalized 
estimating equations (GEE) using Stata 10 (Statacorp, 
Texas, USA).  
 
Results 
Experiment 1: Measurement of in vitro T1 (and R1) values 
by IR-SE and MP-RAGE  
In this study, we have used the standard IR equation to fit SI 
data from MP-RAGE MRI to generate a surrogate measure 
of T1, T1-effective (T1-eff). The data is well described by 
the equation with a goodness of fit > 0.9958 
(Supplementary Table 1) for the individual signal recovery 
curves at the various Mn2+ concentrations. T1-eff values 
were generally greater than the T1 values at all Mn2+ 
concentrations (Figure 1A). Linear relationships were 
observed between both relaxivities measured by IR-SE and 
MP-RAGE and different MnCl2 solutions (Figure 1B). In 
general, we observed an underestimation of relaxivities by 
MP-RAGE of 17.87 ± 0.56 %, compared to by IR-SE.  
 
Experiment 2: In vivo correlation between MP-RAGE and 
ICP-AES data following dose-dependent Mn2+ infusion in 
non-CNS organs. 
Manganese administration led to general decreases in T1-eff 
values in the pancreas, kidney, liver, spleen and heart 
(Figure 2). Whilst in muscle and fat, T1-eff values remained 
unaffected even after infusion of high concentrations of 
MnCl2 (Figure 2). This is consistent with the increased 
tissue Mn concentration as measured by ICP-AES (Figure 
3). However, although a decrease in T1-eff was observed in 
the spleen, ICP-AES measurement of Mn was generally 
unchanged. The strong positive linear correlation between 
tissue Mn (as measured by ICP-IES) in the pancreas (r2 = 
0.971), kidney (r2 = 0978), liver (r2 = 0.923) and heart (r2 = 
0.960) and infused MnCl2, indicates dose-dependent Mn 
uptake (Figure 3). In addition, infusion of MnCl2 results in 
greater Mn accumulation in the liver, kidney and pancreas 
compared to the heart (Figure 3). In the muscle, spleen and 
fat, infusion of up to 40mM MnCl2 did not generally affect 
absolute concentrations of Mn as measured by ICP-AES (p 
= NS) (Figure 3). A linear correlation was observed 
between R1-eff values and Mn concentration in the 
pancreas (r2 = 0.7129), kidney (r2 = 0.856), liver (R2 = 
0.753) and heart (r2 = 0.807) (Figure 4). No such correlate 
was observed for skeletal muscle and fat. 
 
Experiment 3: The time-course effects of MnCl2 infusion on 
SI in non-CNS organs 
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Prior to measurement of SI enhancement profiles in various 
organs, preliminary experiments were performed to 
determine the appropriate choice of the value of the flip 
angle for the MP-RAGE sequence.  Data employing flip 
angles of 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50° is shown in 
supplementary Figure 1: significant image degradation was 
observed at the 50° flip angle and the data excluded. The 
differences in SI between pancreas and kidney, liver or 
spleen increased over the flip angle range 5-20° and then 
decreased for 20-40° (Supplementary Figure 1). SI of 
individual organs were compared with that of the pancreas 
as the latter is especially difficult to distinguish in the MR 
image. However, while differences in SI, as well as tissue 
SI were increased, image distortion was also increased with 
increasing flip angles, consistent with the work of 
Deichmann et al., (Deichmann et al., 2000).  Thus, a flip 
angle of 10° was chosen as a compromise between high SI 
differences and low image blurring. 
 
The tissue-specific, dose-response effects following i.v. 
infusion of MnCl2 is shown in Figure 5. Liver, pancreas and 
kidney showed a marked increase in SI reaching a plateau 
around 30min, which was sustained for the duration of the 
scan. Increasing the MnCl2 dose had a marked effect on the 
overall SI level, resulting in different saturation points for 
different tissues, e.g. 10mM in the liver (Figure 5C). In the 
skeletal muscle, low concentrations of MnCl2 did not elicit 
any significant changes in SI. However, a transient increase 
in SI was observed at 40mM which returned back to 
baseline by 60min after the start of infusion (Figure 5D). 
 
Discussions 
It is well established that an increase in cytoplasmic Ca2+ 
induced by external stimuli leads to a wide range of effects 
in electrically excitable cells, such as neurons, muscle cells 
and pancreatic ß-cells, as well as non-excitable cells such as 
lymphocytes, epithelial cells and endothelial cells (Knot et 
al., 2005; Miura et al., 1997). The absolute increase in 
cytoplasmic Ca2+ is a composite of both intracellular release 
from Ca2+ stores and Ca2+ entry from the extracellular 
space. Importantly, it is the entry of Ca2+ into the cell that 
drives most Ca2+-dependent responses (Parekh, 2006). In 
this respect, paramagnetic Mn2+ is an appropriate surrogate 
ion for assessment of Ca2+ influx during Ca2+ signaling 
processes by T1-weighted MR imaging paradigms. Indeed, 
extracellular Mn2+ is taken up by a variety of different cell 
types which employ Ca2+-related processes, in a 
concentration- and time-dependent manner (Aoki et al., 
2006; Gimi et al., 2006; Lee et al., 2005; Rorsman et al., 
1982; Weed and Rothstein, 1960). 
 
Mn2+ can be administered as either inorganic salts such as 
MnCl2, or chelates such as manganese 
dipyridoxyldiphosphate (MnDPDP). MnCl2 is often used as 
the MRI contrast agent in preclinical studies due to its rapid 
kinetics and low cost (Zheng et al., 2000) whilst the 
chelated form of Mn2+ being less toxic, is more suitable for 
clinical practice. Plasma concentrations of Mn2+ return to 
baseline levels 1h after a single 100mM MnCl2 i.v. injection 
(unpublished observations), compared to several hours 
following administration of the chelate (Krombach et al., 
2004; Sotogaku et al., 2000). In our MEMRI studies, the 
use of controlled MnCl2 infusion was chosen to avoid high 
peak serum levels of Mn2+ that can occur following bolus 
delivery (Silva et al., 2004). Consequently, this limits the 
potentially adverse effects of this contrast agent on animal 
physiology and maximizes the duration of Mn2+ in the 
circulation for optimal cellular uptake. Moreover, previous 
studies have demonstrated MEMRI using a continuous 
MnCl2 infusion for ~ 30 min can be successfully used to 
detect neuronal activity (Kuo et al., 2007; Parkinson et al., 
2009). 
 
We have employed the standard T1/R1-measuring technique, 
IR-SE, demonstrating a linear correlation between R1 and 
increasing MnCl2 concentrations in vitro. Our data suggests 
that R1 measurements can be used to accurately estimate 
Mn2+ concentration in vitro. A similar, positive correlation 
between R1-eff values and Mn2+ concentration was also 
observed using MP-RAGE in vitro. Deviations in R1-eff 
from the IR-SE linear model were observed by MP-RAGE 
assessment at very high Mn2+ concentrations in experiment 
1 (see below). However, the R1-eff values measured in vivo 
correlate strongly with absolute tissue Mn concentration in 
the pancreas, kidney, liver and heart as indicated by the 
ICP-AES data. This is of particular interest given that there 
is no histological staining protocol readily available for 
detection of Mn2+ in tissues in vitro (Bock et al., 2008), let 
alone for in vivo assessment of tissue Mn2+ concentration. 
Our results suggest tissue Mn2+ concentration can be 
estimated in vivo according to its R1-eff value. Therefore, 
whilst MP-RAGE may not provide an absolute measure of 
T1, T1-eff appears to serve adequately as a surrogate for 
both T1 and tissue manganese concentration in 
experimental comparisons. 
 
The equation describing the dependency of the MP-RAGE 
signal on T1 is complex (24, 25). Jivan and colleagues 
simplified this equation to the IR equation based on certain 
criteria, including the employment of a low flip angle (< 8°) 
and an overall TR0 of > 5T1 (26). Here we have employed a 
flip angle of 10°, a compromise between minimizing image 
blurring and sufficient signal intensity and contrast. In 
order to compensate for this slightly higher flip angle, we 
employed centric rather than linear k-space filling; such 
that the MP-RAGE image contrast was weighted to the start 
of the acquisition window prior to possible perturbation of 
the longitudinal magnetization recovery by a subsequent 
RF pulse (20). In our in vivo studies the TR0 (>3380ms) was 
selected as a compromise between having as long a TR0 as 
possible while minimizing scan times. The TR0 we selected 
is not greater than 5 times the T1 in certain tissues as 
recommended by Jivan et al. (26). Further, we can address 
another source of the inaccuracy of MP-RAGE 
measurements by varying TR in order to account for the 
differencet TI values in measuring T1. However, whilst we 
acknowledge these parameter values may be a source of 
error in our T1 measurement by MP-RAGE, signal recovery 
in our studies is greater than 90 %; and indeed greater still 
when manganese is present.  
 
The MP-RAGE data from experiment 3 shows significant 
increases in SI in most ROIs as the concentration of infused 
MnCl2 increases, reflecting enhanced Mn2+ uptake within 
these tissues. An increase in SI occurred within the muscle 
at the highest MnCl2 dose with no apparent effects on 
T1-eff. This probably reflects the transient nature of the 
Mn2+ uptake in muscle relative to the T1-measurement 
window. In tissues exhibiting positive enhancement, the 
percentage change in SI tended to reach a maximum 30min 
from the start of Mn2+ infusion which was then sustained for 
the duration of the scan. With regard to application of 
MP-RAGE MEMRI to the measurement of calcium 
channel activation, it should be noted that at the time of T1 
measurement, post a 30min infusion, there is likely to be 
Mn2+ present in the plasma, interstitial tissue and 
intracellular space. This is an issue for the majority of all 
MEMRI techniques, where intracellular constituents are 
responsible for changes in SI. This possible confounder to 
accurate quantification of Ca2+ channel activity using may 
be addressed by additional non-MRI studies examining the 
time-dependent nature of Mn2+ uptake.  
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It should be noted that the highest dose of MnCl2 we have 
used does not appear to have reached a threshold saturation 
point for Mn2+ uptake in the pancreas, kidney, liver or heart 
(Figure 3A) suggesting these organs have a greater capacity 
for Mn2+ uptake. In agreement with previous work (Kuo et 
al., 2005), we have observed dose-dependent SI increases in 
the pancreas, kidney and liver. Given the importance of 
balancing MRI signal optimization and minimizing toxicity 
(Kuo et al., 2007; Silva et al., 2004), this data provides a 
practical MnCl2 dosing regimen for use in tissue-specific 
activation studies. Furthermore, tissues with similar Mn2+ 
accumulation patterns may reflect similar physiological 
properties, such as arterial input function, and could also act 
as a preferable internal reference in subsequent MEMRI 
scans. 
 
There are however, inherent limitations to the MEMRI 
technique that should be addressed. Firstly, current MRI 
methodologies are not capable of operating at sub-cellular 
resolutions and therefore, the process of redistribution of 
intracellular Ca2+ stores cannot be detected by MEMRI. 
Mn2+ is also toxic and tissue Mn2+ levels need to generate 
adequate SI for MRI but not significantly affect cell 
viability or function (Silva et al., 2004). Whilst MEMRI 
analysis is capable of generating a quantitative measure of a 
response to a stimulus, it is unable to discriminate between 
differences in activity of different cellular populations 
within the same ROI.  
 
In conclusion, we have shown that MP-RAGE MRI is an 
effective means of determining the distribution of Mn2+ in 
non-brain organs following i.v. infusion, and the estimated 
T1 values aid determination of optimal MRI parameters to 
be employed at 4.7T. The dose-dependent Mn2+ distribution 
in the major non-brain organs in mice provides a practical 
MnCl2 dosing regimen for use in tissue-specific activation 
studies. More work will be required to further the 
application of MEMRI to measure activation in electrically 
non-excitable cells in which Mn2+ has been proven to act as 
an indicator for Ca2+ fluxes, such as platelets (Hallam and 
Rink, 1985; Rink and Sage, 1990), lymphocytes 
(Balasubramanyam et al., 1993), endothelial cells (Hallam 
et al., 1988), neutrophils (Merritt et al., 1989), parotid 
acinar cells (Mertz et al., 1990), adrenal chromaffin cells 
(Powis et al., 1996) and mast cells (Fasolato et al., 1993). 
This study provides a potential 3D MRI technique for in 
vivo imaging of Ca2+ entry during Ca2+-dependent processes 
in a wide range of tissues, not just in the brain. 
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Figure 1. (A) Comparison of T1 and T1-eff values obtained 
by IR-SE and MP-RAGE, respectively, (a line of 
equivalence is also displayed). (B) Linear correlation 
analysis between Mn2+ concentrations and R1 or R1-eff 
relaxivities. Data analysed using Prism 4, (GraphPad, 
USA).  
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Figure 2. Changes in T1-eff values of various non-CNS 
tissues following i.v. infusion of 0.1ml of MnCl2 (2, 5, 10, 
20 or 40mM) (n = 3/group). T1-eff values were recorded 
following a 30min MnCl2 infusion. The control group 
received no infusion (n = 6). Data are presented as mean ± 
sem.  
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Figure 3. Tissue-specific relationship between infused 
MnCl2 (0.1ml of 2, 5, 10, 20 or 40mM dose) and manganese 
content as determined by ICP-AES in various mouse 
organs. Animals were euthanized following a 30min i.v. 
infusion of MnCl2 and 22.5min of MP-RAGE based MRI 
scanning. First order linear regression analysis was 
performed using Prism 4 (GraphPad, USA). Data are 
presented as mean ± sem. 
 
 
Figure 4 Tissue-specific relationship between R1-eff values 
and manganese content as determined by ICP-AES in 
various non-CNS organs; (A) pancreas, (B) kidney, (C) 
liver, (D) heart, (E) spleen, (F) muscle and (G) fat. First 
order linear regression analysis was performed using Prism 
4 (GraphPad, USA). Data are presented as mean ± sem. 
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Figure 5. The percentage change in SI from baseline in (A) 
pancreas, (B) kidney, (C) liver and (D) muscle, following 
i.v. infusion of various doses of MnCl2 (2, 5, 10, 20 or 
40mM, 0.2 ml/h); the grey box indicates the duration of 
manganese infusion. n = 3/group. Data are presented as 
mean ± sem. 
